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ABSTRACT
The purpose of this thesis was to  investigate the value in clinical situations of 
the well known in vitro anti-adrenergic effects of magnesium. Research interest 
in magnesium has been growing rapidly over the last twenty years. However, 
most of this interest has focused on the clinical consequences of magnesium 
de fic iency states and lit t le  a tten tion  has been given to  magnesium as a 
therapeutic agent. Despite the wide use of infusions of magnesium sulphate in 
obstetric practice, there is a dearth of knowledge regarding the actions of 
magnesium on a cardiovascular system. In laboratory studies, magnesium was 
shown to inhibit the release of catecholamines from adrenergic nerve terminals, 
an action which might have great clinical implications.
The effects of increasing dosages of magnesium on the cardiovascular system 
of the intact baboon were investigated. It was found that magnesium produced 
a consistent vasodilator effect which correlated well with the serum magnesium 
levels but the hypotensive effects at serum levels below 5mmol/l were minimal 
due to a concomitant increase cardiac output which was primarily mediated 
through an increase stroke volume. There was no evidence of negative
ii
in o tro p ic  e ffe c ts . The a c tio n s  o f m agnesium  on a d ren a lin e -in d u ce d  
cardiovascular disturbances were investigated. Magnesium sulphate infusions 
exerted vasodilator and anti-arrhythmic effects of a magnitude likely to be of 
clinical benefit w ithout producing negative inotropic effects. To demonstrate 
the safety of magnesium infusions in the presence of alpha and beta blockade, 
the interactions of magnesium in the presence of adrenaline with phentolomine 
and propranolol were investigated. No deleterious interactions were noted and 
it appeared that magnesium/propranolol combinations did not potentiate the 
negative inotropic effects of beta blockade.
In the c lin ic a l s tu d ies , the a b il i ty  o f m agnesium  in fu s io n s  to  in h ib it 
catecholamine release in response to the stress of endotracheal intubation was 
dem onstra ted. C ond itions in which catecholam ine excess cons is ten tly  
produces major d ifficulties include tetanus and phaeochromocytoma. These 
two conditions are relatively uncommon and this fact precluded controlled 
trials. Nevertheless, when suitable patients presented studies on the use of 
magnesium in these cond itions were conducted. In tetanus magnesium 
in fus ions  im proved ca rd iovascu la r con tro l and reduced catecholam ine 
production. In phaeochromocytomas magnesium enhanced intra-operative 
contro l of card iovascular disturbances and apart from periods of tumour 
handling reduced catecholamine production. It is concluded that magnesium 
infusions may be a valuable adjunct to the anaesthetic management of patients 
with high catecholamine output states.
I declare tha t th is  d isse rta tion  is my own, unaided work, except fo r the 
assistance acknowledged in the preface. It is being submitted for the degree 
of Doctor of Philosophy in Medicine, Johannesburg. It has not been submitted 
before fo r any degree or examination in any other University.
Michael Frank Mansel James
23rd August, 1988
To my family for all their support over the years.
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PREFACE
My in te re s t in m agnesium  as a th e ra p e u tic  agent in the  p resence of 
catecholam ine excess was o rig ina lly  aroused by the problem s posed by 
patients suffering from tetanus in Zimbabwe. The neuromuscular effects of 
magnesium and their potential benefit in reducing the muscle spasms of tetanus 
was orig inally suggested to me as a possible therapeutic modality by Dr. E.D.M. 
Manson whose key role in arousing my interest in this substance I gratefully 
acknowledge. It was originally hoped that magnesium might provide a cheap 
and simple method of management of tetanus on a conservative base which 
would enable the treatment of this life-threatening condition to be conducted 
in areas where intensive care therapy was impracticable. However, it rapidly 
became apparent tha t in th is  cond ition  magnesium produced profound 
neuromuscular blockade which required the use of positive pressure ventilation 
and this line of research was abandoned. However, it was noticed in passing 
that patients given magnesium appeared rpore cardiovascularly stable than 
those treated conventionally. This raised the possibility that magnesium might 
be exerting anti-adrenergic effects and a literature search revealed that such 
effects had been well established in laboratory conditions but had never been 
put to any clinical use. Consequently the animal work detailed in this thesis
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was undertaken to investigate this possibility and the results of using the agent 
in the management of tetanus were encouraging. The investigations culminated 
in the firs t use of this agent in a patient severely cardiovascularly unstable due 
to a phaeochrom ocytom a. The remarkable results achieved in th is case 
confirmed the theoretical concept that this drug ought to have a valuable place 
in a n aes the tic  m anagem ent. The s tud ies reported  in th is  thes is  were 
undertaken with the approval of the animal and human ethics committees of the 
University of Rhodesia (later Zimbabwe), with the exception of the study on 
endotracheal intubation which was approved by the human ethics committtee 
of the University of the Witwatersrand (clearance certificate No. 18/2/88).
As both tetanus and phaeochromocytomas are relatively uncommon conditions 
it has taken several years to compile the clinical material necessary for this 
thesis. It has also involved the co-operation of a number of my colleagues to 
whom I wish to express my thanks. Firstly, I would like to thank Dr. Randall C. 
Cork of Tucson, Arizona, whose statistical advice on the animal studies section 
of the thesis was invaluable. Secondly, I would like to thank my clin ica l 
colleagues whose co-operation enabled me to co llect the c lin ica l material 
reported. In particular I would like to thank Mr. R. Dent, Dr. K.R.L. Huddle, Dr. 
A. Manell and Dr. M. Plant, whose interest and enthusiasm helped me to gather 
large series of patients w ith phaeochromocytomas. Mr. J.F. White, Sr. J. 
Dennett, and Sr. G.M. Harlen of the Department of Anaesthesia, University of 
Zimbabwe, assisted with all of the animal studies, and much of the clinical work
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and their help is gratefully acknowledged. I am also grateful to Professor G. 
Harrison and Professor C. Rosendorf for their advice and suggestions. Finally 
I would like to thank a number of people whose enthusiastic assistance enabled 
me to produce this document. In particular I would like to thank Mrs. Rita 
Mendelson who helped with much of the transcribing of original publications 
into the thesis. In addition I wish to record my gratitude to Mrs. S. King who 
assisted with the production of several of the computer generated illustrations 
and Mrs. S. Green whose secretarial assistance has proved invaluable. As a 
concluding note I would like to comment that this thesis has been produced 
using a desk-top publishing package and I would like to thank Mr. N. Dennett 
of the Department of Anaesthetics of the University of the Witwatersrand for his 
assistance in running the programme. The entire processing of this document 
was my own work.
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management of very severe tetanus. Intensive Care Medicine 1985 11: 5-12
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1. Introduction
Magnesium has been an important substance in biologic evolution since the 
process firs t began. Present in large quantities in the primordial seas, the ion 
appears to have acquired a central role early in the evolutionary process since 
almost all reactions involved in fundamental cell processes such as protein 
b iosynthesis and anaerobic energy production are magnesium dependent 
(Aikawa, 1981). The ion is also known to catalyze many crucial prebiotic 
condensation reactions. Despite the central importance of these processes, 
magnesium has an even more fundamental role than this in the genesis of life 
on this planet. Central to all forms of life is the mechanism whereby the energy 
of the sun is captured and converted into chemical energy in the process of 
photosynthesis. Some three billion years ago, the porphyrin ring, the basic 
structure of such vital substances such as haemoglobin and the cytochromes, 
had been synthesized. The incorporation of magnesium in the centre of this 
molecule, resulted in the green pigment chlorophyll. This structure, which 
produces carbohydrate by the reduction of carbon dioxide with the liberation 
of oxygen using solar energy, is responsible fo r the large quantities of oxygen 
that has made life in its present form possible on this planet. Whilst other 
metals can be incorporated into the porphyrin ring, magnesium appears to offer
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the best combination of photochemical activity and molecular stability. In a 
study of the reasons why various metals play their highly selective roles in 
biochemical processes, Fuhrhop and Mauzerall (1969) concluded "if the aim of 
the b io log ica l system is minimum redox potential combined with maximal 
stab ility in a protonic solvent, then magnesium is a good mini-max solution to 
these requirements".
1.1 The Metabolic Significance of Magnesium
The emergence of compounds with high energy bonds from which energy could 
be readily released such as adenosine triphosphate completed the chain of 
energy utilization from the sun to the intracellular spaces of cells. The process 
of oxidative phosphorylation in which energy stored in carbon compounds is 
released and bound to ATP is the essential step which enables the aerobic cell 
to harness the energy of oxidation. Magnesium is the main catalyst involved in 
oxidative phosphorylation and is the essential cofactor w ithout which ATP 
cannot function. Wherever ATP exists, there is an o b liga to ry  need fo r  
magnesium (Aikawa,1981). In fact, v irtually all enzymatic reactions in which 
p h o sp h a te -co n ta in in g  com pounds p lay a ro le , and thus a ll b io lo g ica l 
energy-producing processes, are dependent on magnesium for activation (Ebel 
& G unther, 1980). Over 300 o ther enzyme system s are dependent on 
magnesium fo r ac tiva tion  inc lud ing  those involved in pro te in  synthesis,
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ca rbohydra te  m etabolism , DNA and RNA m etabolism  and regu la tion  of 
intracellular electrolyte content (Wacker & Paris), 1968; Ebel & Gunther, 1980; 
Olhaberry et al, 1983 a & b). So extensive is the involvement of magnesium in 
cellular physiology that it has been suggested that the ion be given serious 
consideration as a pervasive regulator of intracellular responses (Vidair & 
Rubin, 1981). In his extensive review of the biochemical role of magnesium 
Wacker (1980) concluded that "all cells require it for the completion of major 
m e tabo lic  fu n c tio n s , in c lu d in g , fo r  exam ple, photosynthes is , ox ida tive  
phosphorylation, nerve conduction, muscle contraction, membrane transport, 
and nucleic acid and protein synthesis".
1.2 Assessment of Magnesium Status
Despite this vital role in biochemical processes, magnesium has received scant 
attention, and it is only relatively recently that its importance in human biology 
has become apparent. Part of the explanation for this is that magnesium is 
d ifficu lt to measure accurately, and it is only since the development of atomic 
absorption spectrophotometry (Walsh, 1955; Wacker and Vallee 1964, Wacker, 
1980) that simple and accurate methods of measurement of the ion have been 
available. Durlach has recently reviewed the application of this technique to 
the measurement of magnesium levels in various tissues (Durlach, 1988). There 
is considerable controversy as to the lower level at which hypomagnesaemia
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can be said to exist, with quoted laboratory lower lim its ranging from 0.65 to 
0.9 mmol/l. The general consensus appears to centre around a value of 0.75 
mmol/l, with an upper lim it of 1.1 - 1.3 mmol/l, and a mean of 0.88 mmol/l 
although there is much debate as to whether serum levels are of any value in 
predicting total body magnesium states (See Durlach, 1988 for a review). It is 
generally fe lt that serum magnesium values are a relatively poor guide to the 
overall magnesium status in the body and that significant deficits can exist in 
company with a relatively normal serum value. However, there is no clear cut 
agreement as to which measurement can be said to be superior, with various 
claims being made for red cell magnesium, leukocyte magnesium and muscle 
biopsy as the best guides (Lim et al, 1969), with magnesium load testing being 
regarded as the only absolute method of detecting whole body magnesium 
deficits (Seelig, 1980). However, as magnesium penetrates cells with difficulty, 
it is generally accepted that serum magnesium levels are a satisfactory index 
of the therapeutic level, and thus these levels will be used throughout this study.
The homeostatic mechanisms which control total body magnesium are beyond 
the scope of this review, but the interested reader is referred to Wacker (1969), 
Seelig (1980), Ebel & Gunther (1980), Durlach & Durlach (1984) and Durlach 
(1988). It is, however, worth noting that a number of factors of relevance to 
anaesthetists may deplete body stores of magnesium. These include surgery 
(Heaton, 1964; Sawyer et al, 1970; Henzel et al, 1967), possibly on the basis of 
aldosterone release (Horton & Biglieri, 1962), catecholamine excess (Whyte et 
al, 1987; Joburn et al, 1985; Rayssiguer, 1977), d iure tics (vide infra) and
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emotional stress (Henrotte, 1986). Anaesthetists ought, therefore, to be aware 
of this problem, and the hazards which it may provoke (see Whang, 1984; 
Aldrete, 1987; Gambling et al, 1988; James, 1988 for reviews).
1.3 Interactions with Calcium and Potassium
Calcium exerts a nearly universal role in stimulus-response coupling (Gevers, 
1981; Rasmussen, 1986 a & b), and particularly in the communication between 
excitable cells through the release of neurotransmitter substances (Carafoli & 
Penniston, 1985). It has been known since the beginning of this century that 
magnesium can antagonize many of the actions of calcium (Meltzer & Auer, 
1908) and it does so by competing with calcium at various sites. Magnesium 
inhibits the release of calcium from endoplasmic reticular storage sites, notably 
the sarcoplasmic reticulum in skeletal and cardiac muscle (Dunnett & Naylor, 
1978; Vierling et al, 1978; Meissner & Henderson, 1987). The ion also regulates 
cytosolic calcium levels by enhancing calcium uptake by the sarcoplasmic 
reticulum (Stephenson & Podolsky, 1977) and activating ATPase-dependent 
pumps which extrude calcium  from the in trace llu la r space. In addition, 
magnesium com petes w ith  calcium  fo r b inding sites on tropon in  C and 
c a lm o d u lin  (P o d o lsky  & C o n s ta n tin , 1964; P o tte r et a l, 1976, 1981). 
Furthermore, and perhaps most importantly from the anaesthetic viewpoint, 
magnesium competes with calcium for membrane channels (Jenkinson,1957)
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and consequently can regulate the ease of ingress of calcium to the intracellular 
space. As a result of this m ultip lic ity  of actions, magnesium has been described 
as the physiological calcium antagonist (Iseri & French, 1984; Levine & Coburn, 
1984) which can, and does, modify many calcium-mediated responses. This 
ab ility  of magnesium to regulate calcium dependent processes has important 
physiological and pharmacological consequences.
Magnesium is a vital regulator of intracellu lar potassium stores, inhibiting efflux 
and stimulating active transport of potassium into the cell (Bara & Guiet-Bara, 
1984). Depletion of intracellular magnesium decreases the activ ity of N a+/K + - 
ATPase and increases potassium efflux from the intracellular space (Shine & 
Douglas, 1974; Dorderick et al, 1976; Shine, 1979; Whang & Welt, 1963). Low 
serum potassium levels accom panied by magnesium de fic its  can only be 
corrected with prior replacement of magnesium (Dyckner & Wester, 1984) and 
skeletal potassium is sim ilarly magnesium dependent (Dyckner & Wester, 1978; 
Whang & Welt, 1963). Muscle potassium  content correlates d irec tly  with 
muscle magnesium levels and intracellular magnesium/potassium deficiency 
results in down-regulation of the sodium-potassium pumps (Derup et al, 1988).
1.4 Magnesium in the Central Nervous System
In the central nervous system (CNS), the magnesium level of the cerebrospinal 
fluid (CSF) is tigh tly  controlled by an active transport mechanism which not only
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maintains the CSF above normal plasma levels, but also appears to prevent 
significant rises in CSF magnesium in the face of hypermagnesaemia (Pritchard, 
1955; Chutkow, 1981). Whilst the exact roles of calcium and magnesium in the 
exocytosis of potential CNS neurotransm itter substances have not been well 
worked out, there is some data to indicate that com petition between calcium 
and magnesium regulates the release of certain putative neurotransmitters such 
as acetylcholine, glutamate, aspartate and gamma aminobutyrate (Blioch et al, 
1968; Chutkow, 1981). Clark and Roman (1980) showed that magnesium can 
inhibit the sodium-mediated release of calcium from brain m itochondria, and 
this may provide a mechanism whereby magnesium may contribute to the 
control of neuronal function. A central role for magnesium in the regulation of 
adenosine receptors has also been suggested (Cooper et al, 1984), and 
magnesium may affect central opiate receptor binding (Sadee et al, 1982). In 
the face of sustained hypomagnesaemia the active transport mechanisms for 
magnesium fail, and a fall in CSF magnesium results. Magnesium deficiency is 
associa ted w ith  a va rie ty  of CNS d iso rde rs  inc lud ing  apathy, anorexia , 
nystagmus, vertigo and psychiatric abnormalities (Vallee et al, 1960; Fishman 
1965; Hanna 1961; Hanna et al, 1960), and ultimately coma and convulsions 
(Paunier et al, 1968; Berkelham m er & Bear, 1985; Matthey et al, 1986; 
Ravindran & Correlli, 1987). Alcohol depletes the body of magnesium and 
hypomagnesaemia has been suggested as a factor which may contribute to the 
aetiology of delirium tremens (Milner & Johnson, 1965).
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1.5 Magnesium and the Peripheral Nervous System
Peripherally, the role of magnesium in nervous system function is more clearly 
established. Magnesium is necessary for axonal stability, and can substitute 
for calcium in this role (Frankenhause & Meves, 1958). Hypomagnesaemia is 
associated with tetany even in the face of normal calcium levels and normal 
acid-base states (Wacker et al, 1962; Wilkinson et al, 1986; James & Wright, 
1986). W h ils t m agnesium  can p roduce  d ire c t suppress ion  of axonal 
transmission, the levels of magnesium required to do this are so great as to 
have no clinical significance (Mordes & Wacker, 1978), and this action will not 
be further considered. It has been known since the end of the last century that 
calcium was essential for the contraction of skeletal muscle in response to 
afferent nerve stimulation and later investigators have shown that the role of 
calcium was to trigger the release of acetylcholine in response to pre-synaptic 
denervation (Llinas, 1982; Rubin, 1970; Landau, 1969; Boullin, 1967). The 
release of acetylcholine at the motor end-plate is not only calcium dependent 
but can be antagonized by magnesium, and there is a d irect competition 
between extracellular calcium and magnesium for the facilita tion or inhibition 
of acetylcholine release at both the motor end plate and in autonomic ganglia 
(Wacker, 1980; Del Castillo & Engbaek, 1954; Del Castillo & Katz, 1954; Hutter 
& Kostial, 1954; Hubbard et al, 1968; Livingston & Wacker, 1971 & 1976; Mordes 
& Wacker, 1978). Intracellular magnesium does not appear to exert this effect, 
presumably because the competition between calcium and magnesium is for 
transm em brane transfer (Kharash et al, 1981). S im ilarly, the release of
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adrenaline and noradrenaline from the adrenal gland and at adrenergic nerve 
terminals is also calcium dependent (Rubin, 1970; Rasmussen, 1986 a & b; 
Knight & Baker, 1982). Low magnesium concentrations augment catecholamine 
release from adrenergic granules in response to direct stimulation (Baker & 
Rink, 1975; Douglas & Rubin, 1963) and hypermagnesaemia inh ib its  this 
function at levels readily obtained in clinical practice (Birmingham et al, 1960; 
Boullin, 1967; Kirpekar & Misu, 1967; Chutkow, 1981; Burn & Gibbons, 1964). 
Surprisingly, although this action of magnesium has been known for over 25 
years, no clinical use has been made of this potentially valuable phenomenon.
1.6 Magnesium and the Cardiovascular System
The role of magnesium in regulating the cardiovascular system has been a 
major focus for study.
1.6.1 Myocardium: On the myocardium magnesium appears to play a calcium 
antagonistic role both at a membrane level and within the myocardial cell 
(Kerrick & Donaldson, 1975; Guillain, 1982). Myocardial cells have a 
high magnesium content which is tig h tly  regulated into subcellular 
compartments resulting in a free cytosolic magnesium of approximately 
1mmol/l (Ebel & Gunther, 1980; Polimeni & Page, 1973). Within the 
myocardium, magnesium plays a vital role in energy metabolism and in 
the regulation of calcium release from, and re-uptake by, sarcotubular 
stores (Hasselbach et al, 1981; Ford & Podolsky, 1972; Polimeni & Page, 
1973). In the  presence o f m agnesium  d e p le tio n , ATP becomes
Introduction 10
inactivated and oxidative phosphorylation is inhibited (Krasner, 1979). 
There is much current interest in the role of hypomagnesaemia and the 
susceptib ility of the myocardium to ischaemic injury. Calcium has been 
suggested as an important component of the so-called reperfusion injury 
(McCord, 1985) and increases in free cytosolic myocardial calcium have 
been shown to occur following ischaemic damage (Bers, 1985; Nayler et 
al, 1979). There is an association between magnesium deficiency and 
an increased risk of sudden death due to  coronary artery disease 
(Anderson et al, 1975; Johnson et al, 1979; Karppanen, 1981; Leary & 
Reyes, 1983 a & b; Chipperfield & Chipperfield, 1977; Leary, 1986). 
Myocardial losses of magnesium follow ing ischaemic events have been 
widely reported (Boddy et al, 1978; Leary & Reyes, 1983 a & b; Page & 
Polimeni, 1972; Sheehan & Seelig, 1984; Abraham et al, 1977; Ebel & 
Gunther, 1983; C hipperfie ld  & C hipperfie ld , 1973; Dyckner, 1980; 
Schroeder, 1960; Shen & Ennings, 1972; Johnson et al, 1979) and 
hypom agnesaem ia is assoc ia ted  w ith  an increased inc idence  of 
post-ischaem ic arrhythm ias, and a decreased to lerance of hypoxia 
(Chang et al, 1985; Borchgrevink et al, 1987; Solomon, 1984; Bloom, 
1986). Magnesium appears to exert an important role in the genesis, 
severity and outcome of ischaemic heart disease (Seelig & Heggtveit, 
1974). Hypomagnesaem ia has also been described as a common 
causative factor in arrhythmias of many other types (Loeb et al, 1968; 
Krasner et al, 1981; Laban & Charbon, 1986; E isenberg, 1986), 
particularly in association with the use of diuretics and digoxin (Iseri & 
French, 1984; Chadda et al, 1968 & 1972; Burch & Giles, 1977; Fisher & 
Abrams, 1977; Rude & Singer, 1981; Hollifield, 1984; DeCarli et ai, 1986; 
Schipperheyn, 1984). These arrhythmias may prove refractory to any 
therapy other than replacement of magnesium. Magnesium is a crucial 
regulator of potassium exchange across the myocardial sarcolemma, 
opposing efflux (Hearse et al, 1978; Sheehan & Seelig, 1984; Dyckner &
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Wester, 1982) and Increasing uptake of potassium into the cytosol 
(Vincent 1982; Dyckner & Wester, 1978 & 1979). A possible basis for this 
association between magnesium, potassium and dig ita lis sensitivity has 
been provided recently by the dem onstration tha t magnesium and 
potassium deficiency in skeletal muscle results in down-regulation of 
sodium-potassium pumps, thus preventing the muscle from retaining 
potassium adequately (Dorup et al, 1988).
Magnesium has also been described as being a major regulator of 
coronary artery tone and hypomagnesaemia may worsen myocardial 
ischaemia by provoking coronary artery spasm (Vide infra). Magnesium 
defic iency may also worsen myocardial ischaemia by allow ing ATP 
depletion (Borchgrevink et al, 1987). Stress is a major factor provoking 
magnesium loss (Sheehan & Seelig, 1984), probably at least partly due 
to the actions of catecholamines on lipolysis (Rayssiguier, 1977), and 
th is  may w orsen the  ou tcom e fo llo w in g  m yo ca rd ia l in fa rc tio n . 
Magnesium deficiency can, of its own, aggravate the cardiovascular 
damage associated with stress and dietary magnesium supplementation 
may protect against this (Iseri et al, 1975; Classen, 1986). Magnesium 
deficiency has also been implicated in the arrhythmias associated with 
mitral valve prolapse (Galland et al, 1986; Frances et al, 1986) and those 
of the torsades de pointes type (Ramee, 1985).
The role of magnesium in myocardial contractility is unclear. There is 
some evidence that reducing magnesium levels may produce a loss of 
myocardial ATP and consequently a reduction in myocardial contractility 
(Skou et al, 1971), and that this may add to the cardiac failure following 
ischaemic in jury (Borchgrevink et al, 1987). Magnesium levels were 
noted to be low in association with cardiac failure (Wilkins & Cullen,
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1933; Iseri et al, 1952). H istological damage associated with magnesium 
defic iency has been described by many authors. Hypomagnesaemia 
renders the myocardium more susceptible to catecholamine-induced 
in ju ry  (Vorm ann et al, 1983), and has been associa ted  w ith  the 
development of cardiomyopathy (Kurnik et al, 1988; Bloom, 1986; Altura 
& Altura, 1986; see Seelig, 1980 for a review). Magnesium is essential 
for the inotropic action of the catecholamines, and even high levels of 
extracellular magnesium do not block myocardial contractile responses 
to adrenaline (Paddle & Haugaard, 1971; Levin et al, 1976).
1.6.2 Blood Vessels: There is a wealth of evidence associating alterations in 
magnesium homeostasis with disordered vascular contractile states. It 
has been extensively shown that magnesium functions as a calcium 
antagonist on blood vessels and that magnesium d irectly alters baseline 
vascular tone (Haddy, 1960; Haddy et al, 1973; Haddy & Scott 1973; 
Frohlich et al, 1962; Altura & Altura, 1974; 1978 a & b; 1979; 1980; 1981
a, b & c; 1982 a, b, & c; 1984 a, b & c; 1985 a & b; Altura et al., 1983). 
Magnesium is also known to alter vascular responsiveness to a wide 
range of vasoconstrictor substances including noradrenaline, serotonin, 
v a s o p re s s in , a n g io te n s in  I I ,p ro s ta g la n d in s  and p o ta ss iu m , 
hypermagnesaemia reducing and hypomagnesaemia increasing vascular 
responsiveness to these agents (Altura & Altura, 1976 a & b; 1978 b, 1981
b, 1982 a, 1984 a, b & c; Altura et al, 1976; Overbeck et al, 1969; Frohlich 
et al 1962; Viveros & Somjen, 1968; Carrier et al, 1976; Fujiwara et al, 
1978; Turlapaty, 1981; Turlapaty & Altura, 1982 a & b; Nishio et al, 1985). 
In addition, magnesium appears to be essential for the vasodilatory 
action of a number of substances including beta-adrenergic agonists, 
sodium  n itro p ru ss id e , ca lc ium  a n ta g on is ts , p ro s ta g la n d in s  and
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adenosine, and elevations in extracellular magnesium levels potentiate 
the actions of these vasodilators (Altura & Altura, 1971, 1976 a & b, 1981 
b, 1984 a & c, 1985 b; Altura, 1985; Askar & Mustafa, 1983; Foley, 1983; 
Turlapaty, 1981; Turlapaty & Altura, 1982 a & b; Arnold & Tackett, 1985; 
Thomas & Randall, 1985). Despite th is  c lea r-cu t evidence of the 
importance of magnesium in regulating vascular tone, the relationship 
between magnesium and hypertension is less clear-cut than might be 
imagined. Hypomagnesaemia has been implicated as a causative factor 
in the genesis of atherosclerosis (Rayssiguier, 1984; Ryan & Brady, 
1984) and in the development of hypertension (Resnick et al, 1983; 
Emerson et al, 1970) but the role of magnesium in the management of 
hypertension is uncertain. Lau & Oasa (1984) concluded that the role of 
disturbances in magnesium homeostasis, if any, has not been sufficiently 
defined in the pathogenesis and/or maintenance of hypertension to allow 
logical therapeutic decisions to be made. On the other hand Dyckner & 
Wester (1983) claimed that magnesium supplementation improved the 
response to antihypertensive medication, and Karppanen (1985) stated 
that increased dietary intakes of magnesium and potassium are safe and 
p o te n t ia l ly  b e n e fic ia l in p re v e n tio n  and tre a tm e n t o f a r te r ia l 
hypertension. In an extensive d ie ta ry  study, Jo ffres  et al (1987) 
suggested that magnesium may have a role to play in hypertension, but 
his results were inconclusive.
1.7 Magnesium and the Respiratory System
The role of magnesium in respiratory function has not been extensively studied. 
At a peripheral level, magnesium is essential for oxidative phosphorylation (vide
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supra) but little  is known about the role of magnesium in lung mechanics, ft 
has, however, been shown that pulmonary vessels demonstrate a sim ilar 
response to magnesium to that shown by vessels in other parts of the body 
(Altura & Altura, 1981c). It has also been shown that bronchial smooth muscle 
reacts in a s im ila r fash ion  to  vascu la r sm ooth muscle to  va ria tions  in 
magnesium levels (Haury, 1938). It was suggested by Haury (1940) that 
magnesium sulphate infusions may be beneficial in asthmatic patients and this 
e ffect has recently  been confirm ed (Okayama, 1987; Rolla et al, 1987). 
Magnesium defic iency decreases the s tab ility  of mast cells and increases 
histam ine production , which may provide an explanation fo r th is  role in 
bronchial asthma (Bois, 1963). There is no evidence of a central ventilatory 
depressant action  of magnesium and the on ly ac tion  of magnesium on 
ventilation appears to be as a result of its neuromuscular blocking properties.
1.8 Magnesium in Pregnancy
M agnesium  p lays a v ita l ro le  in the p hys io logy  o f norm al pregnancy. 
Magnesium levels have been shown to decline during pregnancy reaching their 
lowest point at the end of the first trimester (De Jorge et al, 1965), and in her 
extensive review of magnesium deficiency, Seelig (1980) stated that magnesium 
intake during pregnancy was likely to be suboptimal. There is a growing body 
of evidence that magnesium defic iency is common in pregnancy and may
Introduction 15
c o n tr ib u te  tow a rds  p lacen ta l in su ffic ie n cy  and to  the deve lopm ent of 
pre-eclamptic toxaemia and to frank eclampsia (Flowers, 1965; McGanity, 1965; 
S e e iig , 1980; W eaver, 1986). T h is  a p p a re n t a s s o c ia t io n  be tw een 
hypomagnesaemia and toxaemia of pregnancy has been strengthened by recent 
work which has suggested that the essential regulatory role of magnesium in 
prostaglandin synthesis may play a crucial role in the genesis of this syndrome 
when magnesium is deficient (Watson et al, 1986). It has also been shown that 
magnesium deficiency can produce umbilical artery spasm and that this may 
contribute to foetal growth retardation as well having a possible causative part 
to play in the development of pre-eclamptic toxaemia (Altura et al, 1983). A 
recent study has suggested that magnesium supplementation during pregnancy 
can reduce maternal morbidity and improve foetal outcome, but the study was 
too  small and non-specific  to ind icate any effect on the development of 
pre-eclampsia (Spatling & Spatling, 1988).
1.9 Magnesium and Other Organ Systems
Magnesium appears to play an important role in the functioning of various other 
organ systems. Magnesium is an important regulator of gastrointestinal smooth 
muscle and hypomagnesaemia has been associated with dysphagia (Hamed & 
Lindeman, 1978; Flink, 1978).
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Renal function is also c ritica lly  dependent on magnesium and magnesium 
deficiency has been associated with nephrocaicinosis and tubular damage 
(Leder, 1980; see Seelig, 1980 for an extensive review). Diuretics which result 
in potassium loss also produce magnesium depletion (Duarte, 1968; Dyckner & 
Wester, 1979; Reyes & Leary, 1982, 1984 a & b; Reyes et al, 1984; Leary, 1987). 
Magnesium has also been shown to be essential for normal bone development 
and may contribute to osteosclerosis and abnormal vitamin D metabolism. 
Magnesium appears to be necessary for normal functioning of vitamin D (see 
Seelig, 1980 for a review). Magnesium is necessary for normal carbohydrate 
metabolism and is an important coherent controller of glycolysis and the Krebs 
cycle (Garfinkel & Garfinkel, 1985). Magnesium deficiency inhibits insulin 
secretion and results in an impaired glucose tolerance curve (Durlach & Collery, 
1984; Legrand et al, 1987; Thomas, 1977). As diabetes itself may cause losses 
of magnesium, the ion may be of crucial importance in d iabetic patients. 
Magnesium may also be of importance in regulating thyro id  function and 
magnesium deficiency may accompany thyroid dysfunction (Rizek et al, 1965, 
1966).
It can thus be seen that magnesium plays a vast and crucial role in most of the 
biochemical processes essential to life. Consequently, magnesium deficiency 
is associated with an array of well defined syndromes, (see table 1.1) which are 
currently being extensively studied, and their importance quantified. Only 30 
years ago magnesium was regarded as merely a trace element. It is now being
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realized that this ion is one of the most important regulators of biochemical 
activity.
Table 1 . 1
Alterations in potassium, calcium and phosphate balance 
Hypokalemia 
Hypocalcemia 
Hypophosphatemia 
Neuropsychiatric manifestations
Personality changes (including apathy, depression, agitation, 
confusion, delirium)
Seizures
Vertigo, nystagmus, ataxia, coma, movement disorders (rarely) 
Neuromuscular manifestations
Chvostek’s and Trousseau’s signs 
Muscle twitching and tremor 
Spontaneous carpopedal spasms 
Muscle cramps
Muscle (including respiratory) weakness 
Paresthesia
Cardiac manifestations
Predisposition to digoxin-mediated arrhythmias 
Electrocardiographic changes (including prolonged (QT interval) 
Cardiac arrhythmias (including ventricular premature beats, ventricular 
tachycardia, torsades de pointes, ventricular fibrillation)
Alterations in vascular tone and blood pressure
Increased vascular smooth muscle tone and reactivity, leading to spasm 
Increased blood pressure
Table 1.1 Manifestations of magnesium deficiency
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2. C lin ical Consequences of Hypermagnesaemia
Raised serum magnesium levels are rare In clinical medicine as the ion is 
relatively poorly absorbed from the gastrointestinal tract (Agus, 1982; Aikawa, 
1980) and the renal elimination of any excess magnesium is extremely rapid 
(Barker et al, 1959; Chesley & Tepper, 1958; Pritchard, 1955, Aikawa et al, 1968; 
Quamme, 1986), excretion of a magnesium load by the kidney being complete 
within 4-8 hours (Smith et al, 1962). Hypermagnesaemia was firs t reported in 
association with renal failure by Salveson and Linder (1923), and it is now well 
recognized that impaired renal function is the most common prerequisite for the 
developm ent of hypermagnesaemia (Wacker & Parisi, 1968). In order to 
produce a s ign ificant increase in serum magnesium levels for therapeutic 
purposes in the presence of normal renal function, it is necessary to administer 
the agent intravenously or intramuscularly. Magnesium has a moderately large 
volume of d istribution which approximates to the volume of the extracellular 
space (Chesley, 1979) and this, coupled with the rapid renal elimination, means 
that large loading doses and continuous infusions or intramuscular injections 
are necessary to maintain serum magnesium levels in the generally accepted 
therapeutic range of 2-4 mmol/l. Despite the extensive therapeutic use to which
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magnesium has been put, there is a surprising amount of controversy regarding 
its precise mechanisms of action.
Hypermagnesaemia affects almost every organ system in the body.
2.1 Central Nervous System
Until recently it was widely assumed that magnesium is a powerful central 
sedative and may even have anaesthetic properties (Meltzer & Auer, 1905 a & 
b, 1906a; Peck & Meltzer, 1916; Engbaek, 1952b; Aldrete et al, 1968, Fishman, 
1965; Katzman, 1966; Crossland, 1971). Meltzer and Auer (1905 a & b, 1906a) 
described general anaesthesia, respiratory and cardiovascular depression, and 
re flex suppression which they ascribed to  centra l e ffects of peripheral 
in je c tio n s  of magnesium salts, in p a rticu la r depression of the medulla 
oblongata. When administered d irectly into the CSF by ventricular injection 
magnesium produces a sleep-like state (Feidberg, 1958; Feldberg & Sherwood, 
1957). It is now known that magnesium penetrates the blood brain barrier 
extremely poorly and that its level in the CSF is tightly controlled, probably by 
an active transport mechanism (Chutkow, 1981). Even in cases where high 
levels of serum magnesium have been maintained fo r several days CSF 
magnesium has been found to be only marginally above normal (Pritchard,
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1955). Therefore, since magnesium penetrates the brain with such difficulty, 
several authors have queried whether parenterally administered magnesium can 
produce significant sedative effects (Berns & Kollmeyer, 1976; Guthrie & Ryan, 
1910; Rubin et al, 1943). Somjen et al (1966) demonstrated in three subjects 
that fu ll consciousness was maintained at serum magnesium levels in excess of 
14 mEq/l provided that ventilation was artific ia lly  supported. Mordes & Wacker 
(1978) concluded that "magnesium is not an anaesthetic nor even a major 
central nervous system depressant". More recently, however, Thurneau et al 
(1987) described a small but highly statistically significant increase in CSF 
magnesium concentrations following magnesium treatment in pre-eclamptic 
patients. They suggested that this small increase might be sufficient to explain 
some of the anticonvulsant actions of the agent. Thompson et al (1988) 
described a reduction in minimum alveolar concentration of halothane in 
magnesium treated rats which they ascribed to a central effect of the ion.
2.2 Peripheral Nervous System
Magnesium prim arily affects the peripheral nerves by interfering with the 
release of neurotransmitter substances at all synaptic junctions.
2.2.1 Motor End Plate: It has been known since the middle of the 19th century 
that magnesium can exert a curare-like effect, and early this century it 
was shown that this action could be reversed by neostigmine (Joseph & 
Meltzer, 1910). It is now well documented that this effect is due to
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pre-synaptic inh ib ition  of acetylcholine release by com petition with 
calcium for membrane channels on the pre-synaptic terminal (Engbaek, 
1952 a & b; Del Castillo & Engbaek, 1954; Jenkinson & Engbaek, 1954; 
Hutter & Kostial, 1954; Jenkinson, 1957; Livingston & Wacker, 1971; 
Mordes & Wacker, 1978). As a result, magnesium will potentiate the 
action of the non-depolarising muscle relaxants (Ghonheim & Long, 
1970; Giesecke et al., 1968; Morris & Giesecke, 1968; Sinatra et al, 1985). 
The interaction of magnesium with the depolarizing muscle relaxants is 
less c lea r-cu t. A lthough it is genera lly assumed that magnesium 
prolongs the action of depolarizing relaxants as well as those of the 
non-depolarising group (Giesecke et al, 1968; Skaredoff et al, 1982), this 
is not invariable (Sinatra et al, 1985) and the in te raction  between 
magnesium and suxamethonium is much more complex than that with the 
competitive relaxants. Patients treated with magnesium sulphate do not 
demonstrate fasciculations (De Vore & Asrami, 1980). Whilst prolonged 
treatment with magnesium may prolong the duration of suxamethonium 
blockade, acute hypermagnesaemia does not (James et al, 1986). 
Baraka and Yazlgi (1987) found no prolongation of the action of a single 
dose of suxamethonium in magnesium-treated pre-eclamptic mothers. It 
is possib le  tha t Ghonheim ’s in v itro  study created an erroneous 
impression of pro longation of the action of suxamethonium due to 
w ashou t of p se ud o ch o lin es te rase  from  the p re pa ra tio n . Acute 
administration of magnesium sulphate prior to the use of suxamethonium 
appears to prevent the release of potassium provoked by the relaxant 
(Aldrete et al, 1970; James et al, 1986). To the present time, no clinical 
use has been made of these interactions, although the possibility exists 
th a t m agnes ium  may reduce  the  in c id e n c e  and s e v e r ity  of 
suxamethonium-induced muscle pains, and may make suxamethonium 
usable in those circumstance in which the risks of excessive potassium 
release currently make the relaxant contra-indicated.
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2.2.2 Autonomic Nerve Terminals: Magnesium exerts a similar, although less 
well known, e ffect on autonom ic ganglia  (H utter & Kostial, 1954; 
Stanbury, 1948) and on vagal nerve terminals (Kuriyama, 1964; Somjen 
& Baskerville, 1968) to that dem onstrated at the motor end plate. 
Magnesium sim ilarly inhib its the neurogenically mediated release of 
catecholam ines from the adrenal gland and from adrenergic nerve 
terminals (Kirpekar & Misu, 1967; Bouillin, 1967; Douglas & Rubin, 1963; 
Burn & Gibbons, 1964; George & Leach, 1971).
2.3 Cardiovascular System
The complex interrelationships between magnesium and cardiac and vascular 
contractility  have already been mentioned. Raised serum levels of magnesium 
ought to produce marked hypotension as a result of the negative inotropic 
action of the ion on the myocardium, the direct vasodilating properties of 
magnesium on blood vessels and the reduction in sympathetic drive which 
magnesium ought to produce. Clinically, however, evidence for magnesium 
induced hypotension  is varied and co n flic tin g . In early investiga tions, 
hypotension follow ing the infusion of magnesium was noted in several studies 
using animal models (Meltzer & Auer, 1905b, 1906a; Hoff et al, 1939; Rubin et 
al, 1943; Lee et al, 1984). More recently, Maxwell et al (1965), Aldrete et al 
(1968) and McCubbin et al (1981) have also supported this observation in 
various intact animal models, whereas Dandavino et al (1977) using pregnant 
sheep, found only transient hypotension.
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In hum ans, v e ry  c o n f l ic t in g  re s u lts  have been re p o rte d . W here 
hypermagnesaemia complicated renal failure, several authors have found that 
marked reductions in blood pressure occurred In association with raised serum 
magnesium levels (Blackfan & Hamilton, 1925; Randall et al, 1964; Alfrey et al, 
1970), and there have been a number of other case reports of significant 
hypotension in association with hypermagnesaemia w ithout renal failure (Boos, 
1910; Moore & W ingo, 1942; Grantham et al, 1960; Mordes et al, 1975; 
Bourgeois et al, 1986; Prestley, 1912). Most investigators studying human 
volunteers have found some evidence of a reduction in blood pressure as a 
result of magnesium infusions but these changes have been generally minimal 
and of short duration (Kelly et al, 1960; Somjen et al, 1966; Winkler et al, 1942; 
Mori, 1978; Mroczek et al, 1977; Young & Weinstein, 1977). However, some 
authors have reported little, if any, cardiovascular effect even at high infusion 
rates of magnesium (Flowers et al, 1962; Kelly et al, 1960), although in both 
o f these  re p o rts  bo lus  doses appeared to  p roduce  a g re a te r e ffe c t. 
Hypotension is not consistently produced by magnesium in the management of 
pregnancy-induced hypertension (Flowers et al, 1962; Pritchard et al, 1984; 
Pritchard & Pritchard, 1975), and consequently, magnesium has been described 
as a poor vasodilator (Scott et al, 1968; Morris & Assali, 1981).
2.3.1 Vascular Resistance: Clearly, magnesium can exert profound effects on 
vascu la r sm ooth muscle and has been shown to  be an im portant 
regulator of blood vessel tone in a wide variety of tissues. The evidence 
for this was reviewed in the previous chapter. There is also extensive 
evidence of increased peripheral blood flow, regional vasodilatation and 
increased m icrocirculatory perfusion as a result of magnesium infusions
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(Haury, 1939; Overbeck et al, 1969; Mroczek et al, 1977; Altura & Altura, 
1985 a, b & c; Dandavino et al, 1977). In addition to its direct effects on 
the vessel wall, raised serum magnesium levels may also reduce 
peripheral vascular tone by a number of other mechanisms:
a) Central Nervous System. Although there is some evidence that direct 
administration of magnesium into the ventricular system may produce a 
reduction in the output of the vasomotor centre (Leusen, 1949), available 
data tend to argue against a major central role for the hypotensive 
effects of hypermagnesaemia (Lau & Oasa, 1984). The levels of CSF 
magnesium required to inhibit vasomotor centre function are very high 
(10 mmol/l) and it is extremely unlikely that peripheral administration of 
magnesium salts could increase CSF magnesium levels sufficiently to 
cause a s ign ifican t a lte ration  in vasom otor output. As has been 
discussed in the previous chapter, CSF magnesium is tigh tly  controlled 
and little  affected by alterations in magnesium levels of the blood.
b) Sympathetic Ganglia. Sympathetic blockade has been shown to occur 
in heart-lung preparations (Hutter & Kostial, 1954; Stanbury, 1948) with 
elevations in the magnesium content of the perfusate, and it is possible 
tha t th is  e ffect may play a role in hypermagnesaemic hypotension 
(Mordes & Wacker, 1978). Against this is the fact that animals with a 
to ta lly  ablated central nervous system still produced a hypotensive 
response to magnesium injections (Hoppe & Emmerson, 1974; Haury, 
1939) indicating that other mechanisms than just sympathetic control 
must be involved.
c) Catecholamines. As has been reviewed above, there is no doubt that 
levels of hypermagnesaemia commonly used in clinical practice can 
inhibit the release of catecholamines from both the adrenal medulla and 
from peripheral nerve terminals. However, this effect had until now only
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been demonstrated on isolated tissue and there is currently no evidence 
to suggest that this action of magnesium plays a significant role in 
hyperm agnesaem ic hypo tens ion . U nder norm al c ircum stances, 
c ircu la ting  catecholam ines exert lit t le  regula tory e ffect on resting 
vascular tone (Cryer, 1980) and it seems unlikely that this mechanism 
p lays a m ajor ro le  in the reduc tion  o f vascu la r tone  caused by 
magnesium infusions under normal circumstances. However, as none of 
the studies on magnesium-induced hypotension has considered the 
p o ss ib le  e ffe c t th a t the  m agnesium  in fu s io n  may have had on 
c a te c h o la m in e  leve ls  in the  e xp e rim e n ta l m ode l, th is  rem ains 
speculative. Magnesium may also interfere with the peripheral action of 
catecholamines. Noradrenaline has been reported as being ineffective 
in severe human hyperm agnesaem ic shock (M ordes et al, 1975). 
Diminished responsiveness to vasoconstrictor catecholamines has been 
demonstrated on perfused rat mesentery (George & Leach, 1971; Suzuki 
et al, 1982), in the forelimb of dogs (Haddy, 1960) and on vessels in the 
ear of rabbits (Farmer & Campbell, 1967). In addition, several authors 
have shown the dependence of vasoconstrictor agents on normal serum 
magnesium levels (vide supra). All of these studies have looked at 
isolated tissue or limited areas, and there is no data available on the 
effect that magnesium may have on catecholamine-induced vascular 
responses in the intact subject. Magnesium ought to have useful 
anti-adrenergic properties, but this possibility awaits further study.
When all of these factors are considered, there can be little  doubt that 
magnesium produces peripheral vasodilatation despite the fact that the 
hypotensive effect of parenteral administration is inconsistent.
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2.3.1 Myocardium : Myocardial depression may or may not play a part in 
magnesium induced hypotension. Because magnesium is a calcium 
antagonist, increased levels of magnesium ought to produce a reduction 
in myocardial contractile force, and indeed, isolated skinned fibres of 
ventricular muscle do show a reduction in tension development in the 
presence of elevated magnesium levels (Donaldson & Kerrick, 1978; 
Fabiato & Fabiato, 1975). There is generally assumed to be little  change 
in the cardiac action potential produced by high levels of magnesium in 
isolated heart perfusates (Hoffman & Suckling, 1956). Recent work has, 
however, questioned this assumption (Katholi et al, 1979; Kraft et al, 
1980; Moe, 1984) and Altura (1985) believes that magnesium inhibits the 
ca lcium  dependent inward current, which may help to  explain its 
anti-arrhythmic effects particularly in the presence of ischaemia. Using 
an isolated heart/lung preparation, Stanbury and Farah (1950) found a 
decreased stroke volume and increased right and left atrial pressures 
proportionate to the extracellular magnesium level. On the isolated 
heart, increased co n cen tra tio n s  of e x tra ce llu la r m agnesium  ion 
produces marked depression of contractile force (Paddle & Haugaard, 
1971; Shine & Douglas, 1974 & 1975; Kovacs & O’Donnell, 1975; Levin 
et al, 1976). Wallis et al (1986) reported severe myocardial depression 
with combinations of magnesium and diitiazem, but not with magnesium 
alone. In all of the above studies, rather high levels of magnesium (10 - 
40 mmol/l) were used, and this makes it very d ifficu lt to extrapolate the 
data to the clinical setting in which serum magnesium levels are unlikely 
to exceed 4-6mmol/l. in the intact animal, the evidence for cardiac 
depression by clin ica lly useful levels of raised magnesium is less clear. 
Various studies in both animals and humans have shown some evidence 
of a negative ino trop ic  action, p rinc ipa lly  a raised central venous 
pressure (Szekely, 1945; Aldrete et al, 1968; Bristow et al, 1977 a & b; 
Critelli et al, 1977; Mori, 1978; Charbon 1983). However, other studies
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have fa iled to  demonstrate any myocardial depression and several 
authors have found an increase in cardiac output associated with raised 
serum magnesium levels (Cotton et al, 1984; Dandavino et al, 1977; 
Maxwell et al, 1965; Mroczek et al, 1977). Mordes & Wacker (1978) 
concluded that some form of myocardial compromise was probably 
necessary for the maintenance of hypermagnesaemic hypotension and 
expressed the op in ion  tha t more research on the haemodynamic 
consequences of hypermagnesaemia was necessary. As it appears that 
c l in ic a lly  em ployed leve ls  of serum m agnesium  do not produce 
significant myocardial depression, sustained, or even increased cardiac 
output may be the explanation for the minimal hypotensive effect of 
magnesium infusions despite significant vasodilatation.
The inherent e lectrica l rhythm ic ity  of the heart seems particu la rly  
resistant to the effects of magnesium, with cardiac arrest only occurring 
when the serum magnesium levels are extremely high - above 12.5 
mmol/l - levels not normally attainable in the clinical situation. It is 
generally accepted that excess magnesium in the range of 2.5 - 5 mmol/l 
produces prolongation of the PR and QT intervals (Wacker & Parisi, 
1968; Wacker, 1980) as a result of the reports of Miller and Van Dellen 
(1938 & 1941) and Smith et al (1939). However, other reports have failed 
to  show  s ig n if ic a n t c o n d u c tio n  d e fe c ts  fo llo w in g  m agnesium  
adm in istra tion, provided the calcium level is maintained (Young & 
Weinstein, 1977; Surawicz et al, 1961) or that there are no major changes 
in the serum potassium level (Watanabe & Dreyfus, 1972). DiCarlo et al 
(1986) studying human volunteers found an increase in the PR interval 
with rapid bolus injection of MgS04, but no change in the QT or QTc 
intervals. On the isolated heart, magnesium produces a bradycardia 
(Stanbury, 1948; Stanbury & Farah,1950; Haury, 1939), and there have 
been c l in ic a l re p o rts  o f b ra d y c a rd ia  in a s s o c ia t io n  w ith
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hypermagnesaemia and renal fa ilu re . Berns and Kollmeyer (1976) 
described a patient in whom the use of magnesium containing antacids 
was associated with junctional bradycardias at relatively low levels of 
serum magnesium (2.25 - 2.4 mmol/i). On the other hand, Enselberg et 
al (1950) found an initial increase followed by a slight slowing of heart 
rate with rapid intravenous injection of magnesium sulphate, and DiCarlo 
et al (1986), Winkler et al (1942) and Szekley (1946) found no change in 
heart rate following magnesium infusion. Cardiorespiratory arrest has 
been described follow ing magnesium infusion (Richards et al, 1985) but 
it is likely that respiratory arrest due to neuromuscular pararalysis was 
the precipitating event. In normal subjects, there may be an increase in 
heart rate w ith increased serum magnesium levels as a result of a 
reduction in vagal tone due to the inhibition of acetylcholine release 
which can result from increased magnesium (Somjen et al, 1966; Somjen 
& Baskerviile, 1968, Toda & West, 1967). Magnesium infusions increase 
both atrial and ventricular refractory periods, and this may account for 
its general anti-arrhythmic action.
2.4 Genitourinary System
The effects of hypermagnesaemia on renal function are unclear. Several 
authors have described a reduction in glomerular filtra tion rate in association 
with hypermagnesaemia (de Alvarez & Richards, 1952; Hammarsten et al, 1957; 
Heller et al, 1953), whereas Kelly et al (1960) found an increase in renal plasma 
flow. Altura & Altura (1985b) have described renal vasodilating effects of 
m agnesium  and va so con s tric tio n  resu lting  from  hypom agnesaem ia. A
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magnesium load is rapidly filtered through the kidneys, and this might be 
expected to exert a diuretic effect. There appears to be a tubular maximum for 
magnesium which is close to the upper lim it normal serum magnesium values, 
and therefore any excess magnesium filtered through the glomerulus is rapidly 
excreted, whereas, at normal serum magnesium values, 95-99% of the filtered 
load is reabsorbed (Aikawa, 1981). Duarte (1968) suggested the possibility of 
an active tubular excretory mechanism for magnesium but this has not been 
confirmed (Roy, 1985). Hypermagnesaemla reduces the tubular reabsorption 
of both water and sodium (DiBona & Sawin, 1971) which would also be likely to 
have a d iuretic effect. As a result of the renal vasodilatation, the reduced 
reabsorption of sodium and water, and the rapid excretion of magnesium itself, 
magnesium infusions ought to produce a brisk diuresis, but there is very little 
data on the action of infused magnesium on renal output. Calcium excretion is 
also increased by increased urinary excretion of magnesium (Kelly et al, 1960), 
but is unclear whether or not this is due to intra-renal effects or to the negative 
feed-back loop which exists between parathyroid hormone release and serum 
magnesium levels (Dawson 1984; Massry et al, 1970; Zumkley & Lehnert, 1984). 
Certainly, prolonged elevations in serum magnesium may produce a reduction 
in serum calcium  levels, but which mechanisms predom inate is not well 
established.
The use of magnesium In the management of pre-eclamptic toxaemia will be 
d is c u s s e d  in m ore d e ta il la te r , bu t th e re  are se ve ra l e ffe c ts  of
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hypermagnesaemia on the female reproductive system which are pertinent to 
the present d iscussion. A lthough it genera lly  assumed that magnesium 
in fus ions do not in te rfe re  w ith  normal labour (H utch inson et al, 1964), 
magnesium can reduce uterine tone (Miller et al, 1982; Reece et al, 1984). 
Magnesium also vasodilates the uterine blood vessels (Altura et al, 1983) and 
increases uterine blood flow  w ithout reducing system ic arteria l pressure 
(Dandavino et al, 1977). Although magnesium does cross the placenta readily, 
the  e ffe c ts  on the  neonate  are d if f ic u lt  to  d is tin g u is h  from  those of 
pre-eclampsia. Stone & Pritchard (1970) noted no III effects in a large series of 
infants born to toxaemic mothers who had been given magnesium, and Green 
et al (1983) were unable to demonstrate any re la tionship between serum 
magnesium levels in neonates and diminished neurobehavioural scores.
2.5 Endocrine Systems
N e g a tive  fe e d -b a c k  lo o p s  ap pe a r to  e x is t be tw een m agnesium  and 
catecholam ines, parathyro id  hormone, ca lc iton in  and insu lin  (Durlach & 
Durlach, 1984). It is well known that sustained hypermagnesaemia can result 
in inhibition of parathyroid hormone release (Buckle et al, 1968; Gitelman et al, 
1968; Massry et al, 1970; Sherwood et al, 1970) and possib ly in reduced 
hormone receptor sensitivity (Slatopolsky et al, 1976), with consequent falls in 
serum calcium. In view of the evidence that magnesium deficiency worsens
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diabetic control and reduces insulin sensitivity, it might be anticipated that 
hypermagnesaemia might increase insulin sensitivity and reduce blood sugar. 
T he re  is , h o w e ve r, no in fo rm a tio n  on th is  s u b je c t. D e lib e ra te  
h yp e rm agnesaem ia  has been used o c c a s io n a lly  in the  tre a tm e n t of 
thyro tox icos is , but it has been shown that magnesium infusions have no 
consistent influence on the peripheral actions of thyroid hormone (Wiswell, 
1961).
2.6 Coagulation of Blood
An increase in the m agnesium/calcium  ra tio  w ill increase c lo tting  times 
(Genville & Lehman, 1944) and reduce platelet adhesiveness (Davies et al, 1968; 
Hughes & Tonks, 1965; Rayssiguier, 1986). It has been suggested that 
magnesium may increase throm boresistance in vascular endothelium  by 
increasing the production of PGI2 (Watson et ai, 1986), but there is little  clinical 
evidence that hypermagnesaemia significantly alters coagulation. Such reports 
as there are relate to abnormalities of coagulation with hypermagnesaemia 
com pounding renal fa ilu re  where the action of magnesium is d ifficu lt to 
d e te rm in e  w ith  any p re c is io n . It seems s ig n if ic a n t th a t co a g u la tio n  
abnorm a lities  have not been reported in obs te tric  patients treated with 
m agnesium  in fu s io n s , desp ite , or pe rhaps because of, the  fa c t tha t
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d issem inated  in travascu la r coagu lopa thy  is frequen tly  associa ted w ith 
pre-eciampsia.
Hypermagnesaemia has a wide variety of actions, many of which have been 
imperfectly investigated (see table 2.1). Several aspects of the action of this 
agent are potentially of great clinical interest, particularly the unique capability 
of magnesium to inhibit the release of catecholamines, the anti-adrenergic 
effects of the agent, and its value as a vasodilator and anti-arrhythmic, in 
addition to its interaction with neuromuscular blocking drugs. If these actions 
could be confirmed in clinical circumstances, then magnesium would appear 
to offer a useful addition to the anaesthetic armamentarium.
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Table 2.1
Central Nervous System
Cerebral vasodilatation 
Minimal central sedation 
Peripheral Nervous System
Inhibition of transmitter release
Motor end plate - paralysis 
Autonomic Nerve terminals 
Cardiovascular System
Possible myocardial depression 
Possible alterations in electrical conduction 
General and regional vasodilatation 
Moderate hypotension 
Genitourinary System
Relaxes pregnant uterus 
Vasodilates uterine blood vessels 
Metabolism
Inhibits parathyroid hormone and lowers serum calcium 
May improve diabetic control 
Coagulation
Mild anticoagulant effect
Table 2.1 Effects of Hypermagnesaemia
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3. Therapeutic Use of Magnesium
Magnesium has been used as a therapeutic agent for centuries. The first 
medicinal use of this drug was described in Renaissance Italy when magnesium 
salts were employed for their aperient properties. The medicinal properties of 
the waters of the Epsom Spa were discovered in 1618 and accounted in large 
m easure fo r the p o p u la r ity  of Epsom as a re so rt. A cco rd in g  to  the 
Encyclopedia Brittanica  magnesium sulphate was isolated from Epsom water 
by Grew in 1695 and Sir Humphrey Davy firs t isolated the metal in 1808. In the 
early 19th Century oral administration of magnesium oxide was used to treat 
patients with urinary calculi and by the middle of that century it had been shown 
that intravenous magnesium sulphate given to animals m im icked curare 
(Wacker, 1980). With the possible exception of the treatment of urinary calculi, 
where the ob ject is to increase the urinary content of magnesium, orally 
administered magnesium is more properly regarded as a dietary supplement 
rather than as a therapeutic agent. This is because it is impossible in normal 
circumstances to achieve any significant increase in serum magnesium levels 
by oral administration of the agent because of the rapid renal elimination. 
Therefore, although oral administration of magnesium salts has been widely 
advocated in a variety of conditions in which magnesium deficiency is likely to
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occur, this review is confined to the parenteral administration of magnesium 
salts to achieve deliberate hypermagnesaemia.
3.1 History of Magnesium Therapy
At the beginning of this century, several attempts were made to use parenteral 
magnesium sulphate as a therapeutic agent. Blake (1906) described the effects 
of magnesium sulphate administered by the intrathecal route. His review noted 
that magnesium sulphate injections produced profound muscle relaxation in 
most patients with a variable sensory block. The unpredictable nature of the 
b lock led him to  doubt tha t in tra theca l magnesium in jections should be 
advocated for anaesthesia but the prolonged duration of effect prompted him 
to  use th is  techn ique in the management of te tanus. He adm in istered 
intrathecal magnesium sulphate to two patients suffering from the end stages 
of tetanus. In both cases the injections produced relief of symptoms for a 
variable period of time from four to twelve hours and one patient made a 
complete recovery. Blake also noted that if enough magnesium sulphate was 
given, and particularly if the patient was placed in a head down position, 
p ro fo un d  loss  of consc io u sn ess  cou ld  be p roduced  by th is  rou te  of 
administration. According to Meltzer (1916), a surgeon - Thedor Kocher - made 
a favourable report on the action of magnesium sulphate in tetanus and Meltzer 
himself reported the use of magnesium sulphate by intravenous, intraspinal and
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subcutaneous injections. He asserted that "no other remedy is capable of 
relieving the furious symptoms [of tetanus] to such a satisfactory degree as do 
the injections of magnesium sulphate" (Meltzer, 1916). He included in this 
paper a report of one patient who received a total of 131 gms of magnesium 
sulphate parenterally over a seventeen day period with complete recovery. 
Meltzer and Auer reported studies on animals and humans in which they claimed 
to  produce anaesthesia by intravenous and subcutaneous in jec tions  of 
magnesium sulphate (Meltzer & Auer, 1905 a & b, 1906 a & b). Peck and 
Meltzer (1916) described the performance of surgery on several patients in 
whom intravenous magnesium sulphate was the sole anaesthetic agent used. 
Meltzer also described the use of magnesium sulphate as an anticonvulsant 
when given by intrathecal injection (Meltzer & Auer, 1906b). Subsequently, 
there  have been several o ther reports  o f the use o f magnesium as an 
anticonvulsant (Blackfan & McKhann, 1931; Moore and Wingo, 1942; Winkler 
et al, 1942). However, this use of magnesium has now largely disappeared 
except for the use of magnesium sulphate in the treatment of pre-eclamptic 
toxaemia, probably because of the very poor levels of CSF magnesium that can 
be achieved by intravenous administration (vide supra). It seems most likely 
that the m ajority of the effects observed by early workers were due to  a 
com bination of peripheral neuromuscular inh ib ition  and cerebral hypoxia 
secondary to respiratory insufficiency. In their review of the effects of excess 
m agnes ium  M ordes and W acker (1978) com m ented  th a t the  ce n tra l 
anticonvulsant activity following peripheral administration of magnesium is
unproven.
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3.2 Pre-eclampsia and Eclampsia
Probably the most widely accepted use of magnesium sulphate has been the 
parenteral administration of this agent in the management of pre-eclamptic 
toxaemia. This form of therapy which was firs t introduced in the 1920’s was 
popularized by the extensive work of Pritchard and his colleagues (Pritchard, 
1955; Pritchard & Pritchard, 1975, Pritchard et ai, 1984). In the United States 
this form of therapy is now standard practice but its use is controversial. In 
Britain it is w idely assumed that magnesium has no anticonvulsant effect and 
produces purely peripheral control of convulsions (Crawford 1982), and even 
in centres where the use of magnesium is accepted there is a fierce debate over 
its mechanism of action. Sibai and others (1984) were unable to show any 
a lteration in pre-convulsant EEG patterns in pre-eclam ptic patients given 
magnesium infusions, and questioned the effectiveness of magnesium as an 
anticonvulsant. Donaldson (1986) has recently reviewed the evidence against 
magnesium exerting significant anticonvulsant actions and has queried its value 
in pre-eclampsia. Much of the controversy surrounding the role of magnesium 
in the management of p re -ec lam ptic  toxaem ia is due to  the incom plete 
information available as to the pathogenesis of eclamptic convulsions and the 
influence of magnesium on the disease process. The cerebral pathology has 
been attributed, at least in part, to severe cerebral vasoconstriction (Pritchard, 
1980). This theory neatly explains the probable role of magnesium in reversing 
the convulsions as magnesium is known to be a powerful cerebral vasodilator 
(Seelig et al, 1983; Altura & Altura, 1984) and would thus antagonize the
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regional vasoconstriction and improve cerebral oxygenation. On the other 
hand, Donaldson (1986) attributes the cerebral pathology to endothelial injury 
and vasodilatation leading to local cerebral oedema. The evidence for this 
arises from post-mortem studies and its exact relevance to the clin ical condition 
prior to  a convulsion is unclear. If however, this were the case, magnesium 
would be expected to worsen cerebral oedema. There is no evidence that this 
occurs. It is possible that the local vascular in jury allows penetration of 
magnesium into the damaged brain tissue, thus explaining the anticonvulsant 
e ffect (Borges & Gucer, 1978) There is clear evidence of the fa ilu re  of 
magnesium to  reduce blood pressure s ign ifican tly . The studies that are 
available tend to suggest that the failure of magnesium infusions to produce 
hypotension in pre-eclampsia is primarily due to a compensatory increase in 
cardiac output but this is by no means established. No dose response curves 
for magnesium infusions exist and there is considerable controversy over the 
precise actions of magnesium on the cardiovascular system (vide supra).
More recently other authors have suggested that magnesium may play a role in 
genesis and management of pre-eclampsia by altering the production and 
activ ity of vasoactive substances. It has been shown that hypermagnesaemia 
increases the production of the vasodilator prostaglandin PGE2 which may not 
only improve tissue perfusion in this condition but may also antagonize the 
hypercoagulability which is associated with pre-eclampsia (Watson et al, 1986). 
Fuentes and Goldkrand (1987) reported a reduction in the levels of angiotensin
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converting enzyme in pregnant women with pre-eclampsia following the use of 
magnesium sulphate. Surprisingly, there are no controlled tria ls comparing 
sedative/vasodilator regimes with the results of magnesium therapy. The role 
of magnesium in the management of this potentially life-threatening condition 
therefore remains controversial.
Magnesium possesses toco lytic properties which potentiate the uterine relaxant 
properties of the B-adrenergic stimulants (Osa & Ogasawara, 1979), and this 
has recen tly  prom pted investigation of the agent in the management of 
premature labour. Initial results have been promising (Miller et al, 1982; Reece 
et al, 1984) particularly in view of the fact that the use of magnesium appears 
to enhance foetal well-being (Reece et ai, 1984) possibly on the basis of uterine 
vasodilatation (Suresh & Nelson, 1987).
3.3 Magnesium and Arrhythmias
In the last few years, interest has revived in the therapeutic potential of 
magnesium infusions and has focused on its anti-arrhythmic properties and its 
role as a calcium antagonist. Magnesium has been used as an anti-arrhythmic 
agent since the 1930’s. In paroxysmal atrial tachycardia with ventricular 
extrasystoles magnesium appeared to have considerable beneficial effects
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(Boyd & Sherf, 1943; Szekely, 1945; O p’t Hof et al, 1980). The role of 
m agnesium  in d ig ita lis  in to x ica tio n  is well estab lished and the use of 
magnesium infusions for the management of digitalis-associated arrhythmias is 
widely accepted (Enseiberg et al, 1950; Rude & Singer, 1981; Seller, 1971; 
Seller et al, 1970; Szekely & Wynne, 1951; DeCarli et al, 1985; Neff et al, 1972). 
As many of these reports focused on patients who were magnesium deficient it 
was unclear whether or not the beneficial effects noted were due to magnesium 
and potassium replacement particularly in the intracellular space (Watanabe & 
Dreyfus, 1972; Whang, 1986; Wills, 1986; Sheehan & Seelig, 1984) or whether 
this was a pharmacological effect of magnesium itself. Podell (1985) regarded 
the case for magnesium in the pathogenesis and treatment of arrhythmias as 
interesting but unproven. Recently, deliberate hypermagnesaemia has been 
suggested as being anti-arrhythmic in its own right even in patients who have 
normal serum magnesium levels (Enseiberg et al, 1950; Ghani & Rabah, 1977; 
Iseri et al, 1983 & 1985; Iseri, 1986; Hayward & Zwerling, 1986; Zwerling 1987), 
and the mechanisms of action of magnesium on myocardial electrophysiology 
have been reviewed (DiCarlo et al, 1986; Dyckner & Wester, 1982; Ghani & 
Rabah, 1977; Shattock et al, 1987). Recent studies have shown that intravenous 
magnesium sulphate is extremely effective in terminating arrhythmias of the 
torsades de pointes type (Topol & Lerman, 1983; Tzivoni et al, 1984; Iseri, 
1986). The arrhythmias associated with mitral valve prolapse have also been 
shown to respond to magnesium therapy (Frances et al, 1986; Galland et al, 
1986). It has also been suggested that magnesium infusions may reverse
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ven tricu la r fib r illa t io n  due to  hypotherm ia, or increase the like lihood  of 
successful defibrillation (Buky, 1970).
3.4 Magnesium and Ischaemia
There has been much recent interest in the role of magnesium as a protective 
agent during periods of myocardial ischaemia. Harris et al (1953) showed that 
magnesium either as the sulphate or the chloride could suppress ventricular 
arrhythmias follow ing myocardial infarctions. In the mid 1970’s it was shown 
that the use of magnesium in cardioplegia infusates had a protective effect 
during ischaemic cardiac arrest (Hearse & Humphrey, 1975; Hearse et al, 1975, 
1978, 1981), and it is has been demonstrated that magnesium can inhibit
calcium influx into the sarcoplasmic reticulum (Koomen et al, 1983; Bers 1985). 
It was shown tha t the add ition  of 15mmol/l to  the ca rd iop leg ia  so lu tion 
prevented potassium and magnesium efflux from  and calcium  in flux into 
ischaemic cells resulting in fewer post-ischaemic arrhythmias and improved 
tension development. Doring & co-workers (1976) showed that magnesium- 
asparta te -proca ine  com binations provided both m etabolic and structura l 
protection during ischaemic arrests. Since then, other workers have confirmed 
the p ro tec tive  e ffects of hypermagnesaemia in the hypoxic myocardium 
(Shapiro, 1980; Bersohn et al, 1982; Kyosolo et al, 1985; Yano et al, 1985; Bers, 
1985; Woods & Chapman, 1985), although Engelman et al (1978) questioned the
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value of low levels of magnesium in the cardioplegia infusate. Ferrari et al 
(1986) com pared the benefic ia l e ffects of n ifed ip ine  w ith  those of high 
magnesium/low calcium infusates and found that the latter offered significantly 
better protection to  the arrested heart. Galloway et al (1986) reported a case 
in which infusion of magnesium reversed early ischaemic contracture in the 
myocardium follow ing cardiopulmonary bypass. As a result of these reports, 
the addition of magnesium to cardioplegic solutions remains popular, and 
Manners & Nielson (1981) noted that the return of the perfusate to the patient 
was harmless, and might offer the advantages of avoiding hypomagnesaemia to 
the post-bypass patient.
Several further studies have shown that patients dying from acute myocardial 
ischaemic events had a lowered myocardial magnesium (Abraham et al, 1977; 
Chipperfield & Chipperfield, 1973; Dyckner, 1980; Johnson et al, 1979; Leary 
and Reyes, 1983b; Schroeder, 1960; Shen & Ennings, 1972). Magnesium has 
been shown to  be an im portan t regu la to r o f co rona ry  a rte ry  tone and 
magnesium defic iency shown to  produce spasms of the coronary arteries 
(Turlapaty & Altura, 1980). Acute magnesium deficiency reduces myocardial 
tolerance to ischaemia (Borchgrevink et al, 1987) and magnesium deficiency 
extends the size of myocardial infarctions (Chang et al, 1985). Recently, there 
have been several studies suggesting that magnesium infusions resulting in 
deliberate hypermagnesaemia may produce an Improved outcome in patients 
suffering from myocardial ischaemic events by reducing infarct size (Weinstein
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et al, 1986; Morton et al, 1984; Hughes & Tonks, 1965; Rasmussen et al, 1986). 
W oodward and Zakaria (1983) reported tha t potassium  and magnesium 
in fus ions pro tected  rat hearts against reperfusion-induced arrhythm ias 
fo llow ing  coronary a rtery liga tion . C lin ica l studies have confirm ed that 
magnesium can reduce the incidence of post-infarction arrhythmias (Abraham 
et al, 1987; Rasmussen et al, 1987; Harris et al, 1953), thus improving patient 
outcome. Beneficial effects of infusions of magnesium have also been claimed 
in patients with angina and with peripheral vascular disease (Browne, 1969, 
1984). Magnesium thus appears to offer considerable myocardial protection to 
the ischaemic heart.
The direct vasodilator effect of magnesium on coronary vessels has been used 
in the termination and prevention of Prinzmetal’s variant angina (Cohen & 
Kitzes, 1984, 1986). It has also been suggested that the vasodilator and 
anticoagulant effects of magnesium may have beneficial effects on flap survival 
in patients undergoing microvascular surgery (Acland, 1972).
Realization that calcium may be the final common pathway mediating hypoxic 
cellular injury (Schanne et al, 1979) has led to suggestions that magnesium 
may be potentially beneficial in the protection of various other tissues from 
ischaemic events. The successful use of magnesium in resuscitation of the 
ischaemic brain was reported by White et al (1983) and this report was followed
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by further evidence of this action (Ames & Nesbett, 1983; Vacanti & Ames,1984). 
Keane et al (1988) have recently shown improved cerebral recovery from 
asphyxiation with enhanced cerebral blood flow  in post-asphyxic newborn 
lambs. On the other hand, Ruiz et al (1986) were unable to demonstrate any 
benefit in cerebral resuscitation from the use of magnesium or any of several 
other agents. Magnesium, in various concentrations, has been employed in 
flush solutions for the preservation of human cadaveric kidneys, with a value of 
5 mmol/l appearing to offer optimal benefit (Schweitzer & Sutphen, 1982; 
Collins et al, 1984).
Application of the concept of magnesium as a calcium antagonist to skeletal 
muscle has led some investigators to study the role of the ion in malignant 
hyperpyrexia. Sair et al (1970) reported improved preservation of porcine 
m uscle c rea tine  phosphate  du ring  hyperpyrex ia  when magnesium was 
a d m in is te re d , and som e im p ro ve m e n t in s u rv iv a l was re p o rte d  in 
hyperpyrex ia -suscep tib le  swine fo llow ing  in travenous adm in is tra tion  of 
magnesium sulphate (Flewellen & Nelson, 1980). Nevertheless, it seems 
unlikely that magnesium will have a major role to play in this intracellular 
disorder since it penetrates the intracellular space so poorly. Gordon (1976) 
noted that magnesium decreased the responsiveness of chronically denervated 
muscle to acetylcholine, and Clinton et ai (1985) made use of this effect to treat 
painful muscle spasms in a paraplegic patient.
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The fact that ATP exists only as a magnesium chelate has resulted in the 
investigation of the role of a combination of ATP-Mg in the management of 
low-perfusion states. Some success in ameliorating the effects of reperfusion 
on the kidney (Hirasawa et al, 1985) and the liver (Clemens et al, 1985) has been 
reported recently, and further work is needed in this field. The rationale for the 
use of this combination in ischaemia and shock has recently been reviewed 
(Chaudry et al, 1986).
Magnesium in company with alkali has been reported to be of benefit in the 
management of s ick le-ce ll anaemia in children (Hugh-Jones et al, 1964), 
probably on a multifactorial basis involving the vasodilator, anticoagulant and 
calcium antagonist properties of magnesium.
Magnesium, thus, has a wide variety of applications and potential benefits, 
some of which remain to be fu lly explored. Despite the well-known ability of 
magnesium to inhibit the release of catecholamines no attempt has been made, 
up till the present time, to use this potentially valuable action in the clinical
sphere.
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4. Aims and Scope of this Thesis
Magnesium appears to offer many actions that may be of benefit in a variety of 
c lin ica l s ituations which have not been previously studied. Of particular 
interest in anaesthesia and intensive care is the apparent ability of magnesium 
to antagonise adrenergically-mediated responses which may be harmful to the 
patient. It has been demonstrated in the laboratory that magnesium has 
alpha-adrenergic receptor blocking properties and in addition has the unique 
capacity to inhibit the release of catecholamines from the adrenal gland and 
from the peripheral adrenergic nerve endings. Although these properties of 
magnesium are well established they have never been investigated in a clinical 
situation. This thesis therefore aims to investigate the clin ical potential of 
magnesium in patients in whom catecholamine excess is anticipated and in 
whom such excess may be deleterious.
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4.1 Animal Studies
Before embarking on clinical studies of the use of magnesium, it appeared 
necessary to clarify and to extend the knowledge of the action of magnesium 
on the cardiovascular system and its interaction with catecholamines.
4.1.1 Cardiovascular Effects of Magnesium Infusions: To study the action of a
wide range of serum concentrations of magnesium in a situation as 
closely resembling the clinical environment as possible, infusions of 
magnesium were studied in intact lightly anaesthetised and minimally 
instrumented baboons and a dose-response relationships established 
for a range of cardiovascular variables.
4.1.2 Interactions of Adrenaline and Magnesium: It seemed necessary to extend
the knowledge regarding the interaction of magnesium with adrenergic 
agonists to studies in the intact animal. Using the same model, studies 
of the action of magnesium in baboons receiving high dose adrenaline 
infusions were conducted. The animal experimentation was completed 
by comparing the anti-adrenergic actions of magnesium with those of 
standard alpha- and beta-adrenergic receptor blocking agents and by 
investigating the interaction of magnesium with these agents.
4.2 Clinical Studies
Despite the w ide range of c lin ica l c ircum stances in which in fusions of 
magnesium salts have been employed, there have been no in vivo studies of the
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in teraction of magnesium with catecholamines in patients w ith adrenergic 
excess.
4.2.1 Endotracheal Intubation: In the clinical setting the commonest situation
in which surges of catecholamine release occur is during laryngoscopy 
and the Insertion of an endotracheal tube. The potential harm to patients 
as a result of these adrenergic surges is considerable and the role of 
magnesium in preventing the release of catecholamines in response to 
this stress stimulus was investigated.
4.2.2 Tetanus: Catecholamine excess is a common problem in the management
of very severe te tanus. The a b ility  of magnesium to con tro l the 
card iovascu la r consequences of catecholam ine excess during the 
management of 10 patients with very severe tetanus was investigated. A 
later case presented the opportunity for study of the effect of magnesium 
infusions on catecholamine levels in a patient with this condition.
4.2.3 Phaeochrom ocytom a: In the anaesthe tic  m anagem ent o f pa tien ts  
undergoing surgery fo r the removal of phaeochrom ocytom as, the 
prevention of the release of excess catecholamines and the control of 
cardiovascular disturbances that inevitably occur present one of the 
greatest challenges in modern anaesthesia. The final section of this 
thesis therefore included an investigation of the value of magnesium 
infusions in the inhibition of catecholamine release and the obtunding of 
the cardiovascular consequences of adrenergic excess where release of 
these agents was not preventable.
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5. Cardiovascular Effects of Magnesium
Despite the wide range of clinical conditions in which magnesium has been 
used, the mechanism of action of the agent remains controversial largely 
because of d iscrepancies between labora tory data and observed clin ica l 
effects. Magnesium has well established vasodilator effects in vitro and in vivo 
(Altura & Altura, 1981a), but the hypotensive effects appear to be transitory 
(Kirpekar & Misu, 1967; Winkler et al, 1942), and myocardial depression may be 
required for the maintenance of magnesium-induced hypotension (Mordes & 
Wacker, 1978). Although magnesium has been shown to inhibit contractile 
force in isolated, perfused hearts and in cardiac muscle strips (Kovacs & 
O’Donnell, 1975; Levin et al, 1976; Paddle & Haugaard, 1971; Shine & Douglas, 
1974), studies in in tact animals and humans have been less conclusive, 
negative inotropic effects being demonstrated in some studies (Cotton et al, 
1984; Dandavino et al, 1977; Maxwell et al, 1965; Mroczek et al, 1977), but not 
in others (Aldrete et al, 1968; Critelli et al, 1977; Mori, 1978; Szekely, 1946; 
Altura & Altura, 1985 a & b; Friedman et al, 1987).
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There have been surprisingly few detailed studies of the effects of magnesium 
on cardiovascular function in intact animals, and dose-response relationships 
have not been well described. This study was undertaken in order to define 
more accurately the effects of a wide range of serum magnesium concentrations 
on the cardiovascular system. In order to approximate as closely as possible 
to the clin ical situation, ligh tly  anaesthetized, intact and minimally instrumented 
baboons were chosen as the experimental model.
5.1 METHODS
Seven adult male chacma baboons were studied with the approval of the animal 
experimentation ethics committee. The animals were in itia lly sedated with 
ketamine 10 mg/kg i.m. and then transferred to a heated operating table. 
Anaesthesia was induced w ith th iopentone 4 mg/kg i.v., and the trachea 
intubated under muscle relaxation induced with suxamethonium 1 mg/kg. The 
lungs were ventilated with 25% oxygen in nitrous oxide. End-expired carbon 
dioxide was monitored using a Datex CD300 infra-red capnograph with nitrous 
oxide compensation, and minute ventilation adjusted to keep the CO2 w ithin a 
range of 32-36 mmHg. The capnograph was calibrated against a mixture of 
oxygen and carbon d iox ide  con ta in ing  a known partia l pressure o f CO2 
(approximately 40mmHg), prior to each experiment. The use of a known partial 
pressure rather than percentage of CO2 to calibrate the capnograph prevents
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errors in measurement due to alterations in barometric pressure, and is the 
most accurate way to use this instrument at altitude (James & White, 1984). 
Blood gas analysis was not available for animal samples in Zimbabwe at this 
time, as facilities were lim ited and restricted to human specimens only. Urine 
was collected by bladder expression, and plasmalyte B infused to replace 
excreted volume so as to maintain flu id balance. E lectrocardiographic leads 
were attached to each limb, and lead li monitored throughout the experiment. 
A 21-gauge cannula was inserted into the femoral artery, and an Edwards 
7-french gauge triple-lumen thermodilution pulmonary artery catheter (Edwards 
93A-131-7F) inserted via the femoral vein into the pulmonary artery. All lines 
were placed by percutaneous push-in in order to leave minimal residual pain 
from catheter insertion sites during the experimental period and follow ing the 
experiment as these were survival experiments. Systemic arterial, pulmonary 
arterial, and central venous pressures pressures were monitored using Hewlett 
Packard strain gauge transducers (HP 1280C), pressure module (HP 8805D). A 
continuous written record was made of the transducer output and of the ECG 
on a Hewlett Packard 4-channel pen recorder (HP 7754A) at a chart speed of 
25mm/sec. The transducers were electronically zeroed using the zero fac ility  
built into the equipment, and the calibration of the transducers was checked 
aga ins t a m ercu ry  co lum n p r io r  to and a fte r each experim ent. Core 
temperatures were monitored throughout using the therm istor probe on the 
pu lm onary a rte ry  ca the te r. Pulm onary cap illa ry  wedge pressures were 
measured interm ittently. Muscular relaxation was maintained with alcuronium 
0.3 mg/kg. Stable conditions such that heart rate, arterial blood pressure and
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cardiac output remained within a range of 10% on either side of preceding 
readings were maintained for 1h before any recordings were taken.
Baseline recordings of heart rate, pulmonary and systemic arterial pressures, 
central venous pressure, pulmonary capillary wedge pressure and cardiac 
output were then made. Cardiac output (CO) was estimated by thermodilution 
(see Appendix A) using 5 ml of cold 5% dextrose using a Hewlett Packard 
cardiac output computer (HP 78231C). Systemic and pulmonary vascular 
resistances, stroke volume and stroke work were calculated. Arterial blood 
samples for serum calcium and magnesium levels were taken, and the samples 
analysed by the methods detailed in appendix A. The firs t baboon was used to 
validate the methods used and to ensure that stable experimental conditions 
could be maintained and that appropriate cardiovascular measurements could 
be achieved. In the remaining six animals, a loading dose of 60 mg/kg 
magnesium sulphate (MgS04) as a 50% solution in water was administered over 
one minute and all the measurements repeated. A continuous infusion of 50% 
MgS04 was com m enced at a ra te  of 12.5 m g/m in and con tinu e d  un til 
cardiovascular stability, judged by variation in successive measurements of 
less than 10%, had been maintained for at least 5 min. All measurements were 
again repeated. The infusion rate was increased to 25 mg/min and then by 25 
m g/m in increm ents up to  a maximum of 200 mg/m in, w ith re p e tit io n  of 
measurements at each infusion rate once cardiovascular stability had been 
achieved. Any ECG abnormalities were noted. At the end of each experiment, 
neuromuscular reversal was performed using neostigmine and atropine and
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adequate reversal checked using a nerve stim ula tor before return ing the 
animals to the animal house. Calcium was added if necessary. This latter 
precaution was necessary as two fata lities had occured in earlier experiments 
as a result of inadequate recovery from neuromuscular blockade follow ing 
withdrawal of ventilatory support.
Data from  all 6 baboons was pooled fo r each variable and rank ordered 
according to the serum magnesium. The data for each variable was then divided 
in to  groups as fo llow s: group 1 inc luded  all data co llected  at a serum 
magnesium of 1 mmol/l or less. Subsequent groups represented data collected 
within a group width of 1 mmol/l above the previous group. The individual 
groups were then analyzed by analysis of variance for differences from baseline 
values and from other groups. Where analysis of variance indicated that 
s ig n ifica n t d iffe rences existed between groups, the groups which were 
s ign ifica n tly  d iffe rent at the 5% level were determined using the Duncan 
multiple-range procedure.
U sing ungrouped  poo led  data, c a rd io v a s c u la r param eters and serum 
magnesium levels were analyzed fo r associa tion by regression analysis. 
Finally, data obtained with serum magnesium levels between 1 and 5 mmol/l 
were com pared w ith  baseline va lues and w ith  data ob ta ined at serum 
magnesium levels g reater than 5 m m ol/l using S tudent's t-tes t w ith the 
Bonferroni modification for multiple comparisons. Significance was defined as 
p < 0.05. Data analysis was performed using the Statistical Package for Social 
Sciences (SPSS) statistical package on a mainframe computer.
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5.2 RESULTS
Satisfactory anaesthesia was established readily, and no additional doses of 
muscle relaxants were necessary after the one hour stabilization period. As no 
painful procedures were performed during the experimental period, the light 
levels of anaesthesia used appeared adequate at all times. Results are 
presented as means 1 Standard error of the mean (SEM).
5.2.1 Serum Magnesium: The mean baseline serum magnesium was 0.617 _±_ 
0.015 mmol/l. Bolus injection always produced higher serum magnesium 
levels than subsequent infusions of less than 50 mg/min (3 g/h). The 
maximum serum magnesium level attained was 9.4 mmol/l and values
greater than 8 mmol/l were achieved on only three occasions. Values of 
greater than 7 mmol/l were therefore grouped together giving eight 
groups covering a range of serum magnesium from <1 to 7+  mmol/l. 
The number of data points obtained in each group is shown in table 1.
Table 5.1
Group SeMg Number
1 < 1 9
2 1-2 13
3 2-3 12
4 3-4 10
5 4-5 3
6 5-6 6
7 6-7 7
8 7 + 6
Table 5.1. Data groups determined by serum magnesium levels. 
SeMg - serum magnesium in mmol/l
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5.2.2 Serum Calcium: Serum calcium was unchanged throughout.
5.2.3 Arteria l Blood Pressure: A scattergram plot of systolic blood pressure 
changes against serum magnesium levels showed a moderate negative 
correlation (r = -0.555), and a significant slope to the line fitted to the 
data points (p<0.001, Figure 5.1).
SBP (mmHg)
Figure 5.1 Scattergram of changes in systolic blood pressure against serum magnesium levels.
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In the grouped data analysis, the only group of those with serum magnesium 
mmol/l to show a significant reduction in SBP was the 2-3 mmol/l group (-20.1 
±_ 7.3 mmHg, p<0.05). The mean reduction in SBP for all the groups with 
serum magnesium levels below 5 mmol/l was 15.6 ± _ 3.5 (p<0.01). At higher 
serum magnesium levels SBP fell to 47.8 ±_ 12.8 mmHg below baseline values 
in the 5-6 mmol/l group (p < 0.05), and declined steadily to a mean value of 60.2 
.±.14.5 mmHg below baseline in the 7+  mmol/l group (p<0.05). These changes 
are summarized in figure 5.3. There was a small but significant reduction in 
systolic pressure in the group with serum magnesium levels <5m m ol/l of 15.67 
mmHg (p < 0.01). The mean reduction in SBP from baseline at serum magnesium 
levels of >5 mmol/l was 54.23 .±.7.46 mmHg which was significantly different 
from the reduction obtained in the <5mmol/l group (p<0.001).
D iasto lic  a rte ria l pressure (DBP) corre la ted  well w ith  changes in serum 
magnesium levels (r = -0.72, p<0.001), but the changes were small (Figure 5.2), 
and in the grouped data only reached significance at levels of serum magnesium 
greater than 5 mmol/l (Figure 5.3). In the 5-6 mmol/l group, the mean decrease 
in DBP was 27.4 ± .5 .4  mmHg and in the 7+  mmol/l group was 44.5 ±_ 11.5 
mmHg (p<0.05). The mean reduction in diastolic blood pressure with serum 
magnesium levels <5m m ol/l was 4.09 ± .3 .5 8  mmHg which did not reach 
statistical significance. There was a highly significant reduction in diastolic 
pressure at serum magnesium levels > 5m m o l/l of 54.23 ± 7 . 4 6  mmHg 
(p< 0.001) and this group was significantly different from the <5m m ol/l group
(p<0.0001).
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DBP (mmHg)
Figure 5.2 Scattergram of changes in diastolic blood pressure against serum magnesium
Figure 5.3 Systolic and Diastolic Blood Pressure and Heart Rate for grouped data 
* - p < 0.05
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5.2.4 Heart Rate: Changes In HR correlated poorly with magnesium levels on 
the scattergram  p lo t (r = -0.391), a lthough a line w ith a s ign ificant 
negative slope could be fitted to the data points (p<0.01, Figure 5.4). In 
the grouped data (Figure 5.1), the only significant change at magnesium 
levels of mmol/l was a small decline in HR of 9.8 ±_2.7  bpm (p <0.05) 
in the 1-2 mmol/l group (Figure 5.3). In the 5-6 mmol/l group, HR fell 
sharp ly to 23.5 _±_ 7.1 bpm below baseline (p< 0 .0 5 ), and declined 
slightly thereafter. The overall change in HR for magnesium levels of 
<5m m ol/l was -9.8 ±_ 1.9 bpm (p<0.01), whereas fo r the higher group 
the mean was -24.5 jfc.4.6 bpm (p<0.01). The difference between these 
two groups was highly significant ( p < 0.001).
HR (beats/min)
Figure 5.4 Scattergram of changes in heart rate against serum magnesium levels
5.2.5 Rhythm and C onduction : A rrhythm ias were uncommon. At serum 
m agnesium  leve ls  above 6.5 m m ol/l, three an im als showed b rie f
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episodes of nodal rhythm, always of less than 30 seconds duration, 
which resolved spontaneously as the experiment proceeded, despite 
increasing serum magnesium levels. PR intervals were not significantly 
altered at any time except for the periods of nodal rhythm. QTc intervals 
and QRS complexes were not altered at any stage, and there was no 
evidence of intraventricular conduction defects.
5.2.6 Systemic Vascular Resistance: There was a steady decline in SVR 
which correlated well with serum magnesium levels (r = -0.67, p<  0.001) 
on the scattergram  p lo t (F igure 5.5). The reduction  in SVR was 
significant in all groups with magnesium levels above 1 mmol/l. In the 
overall group with a serum magnesium value <5m m ol/l the mean 
reduction in SVR was 357 j^ 4 9  dyne.sec.cm '5 (p<0.001). The reduction 
in SVR in the > 5mmol/l group was also highly statistically significant and 
the mean value in this group was 1008.51 ±_ 152.36 dyne.sec.cm '5 below 
base line  (p < 0 .0 0 1 ). The d iffe rence  between these groups was 
significant at the 0.001 level.
Figure 5.5 Scattergram of systemic vascular resistance against serum magnesium levels.
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were not significantly altered at any time except for the periods of nodal 
rhythm. QTc intervals and QRS complexes were not altered at any stage, 
and there was no evidence of intraventricular conduction defects.
5.2.6 Systemic Vascular Resistance: There was a steady decline in SVR 
which correlated well with serum magnesium levels (r = -0.67, pcO.001) 
on the sca tte rgram  p lo t (F igure 5.5). The reduction  in SVR was 
significant in all groups with magnesium levels above 1 mmol/l. In the 
overall group w ith a serum magnesium value <5m m ol/l the mean 
reduction in SVR was 357 .±.49 dyne.sec.cm"5 (p<0.001). The reduction 
in SVR in the > 5mmol/l group was also highly statistically significant and 
the mean value in this group was 1008.51 ±_ 152.36 dyne.sec.cm"5 below 
base line  (p < 0 .0 0 1 ). The d iffe rence  between these groups was 
significant at the 0.001 level.
SVR (dyne.sec.cm'^
Figure 5.5 Scattergram of systemic vascular resistance against serum magnesium levels.
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5.2.7 Cardiac Output: There was no correlation (r = -0.160, n.s.) between 
cardiac output and serum magnesium levels on the scattergram plot 
(Figure 5.6). When the grouped data was considered (Figure 5.7), the 
change in CO was seen to be biphasic with CO significantly increasing 
at all levels of serum magnesium between 1 mmol/l and 5 mmol/l, the 
mean increase for the group being 286.5 _±_60 ml/min (p<0.001). Above 
5 mmol/l, CO returned towards the baseline, and the mean change in the 
5mm ol/l group was a decrease of 38 ±_ 149 m l/m in which was not 
s ig n ifica n tly  d iffe ren t from  baseline. The d iffe rence  between the 
<5m m ol/l and the 5mmol/i group was statistically significant (p<0.05).
0 2 4 6 8 10
Serum Magnesium (mmol/l)
Figure 5.6 Scattergram of changes in cardiac output against serum magnesium levels.
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Figure 5.7 Cardiac Output v. Serum Magnesium for grouped data.
* - p<0.05
5.2.8 Stroke Volume: Although there was a significant slope to the regression 
line  fo r s troke  vo lum e aga ins t serum m agnesium  (p < 0 .0 1 ), the 
correlation was poor (r = 0.256, Figure 5.8). S lightly better correlation 
could be demonstrated between SV and serum magnesium values below 
5mmol/l (r = 0.367, p<0.01). Changes in SV for the grouped data are 
shown in Figure 5.9. SV was elevated above baseline at all levels of 
increased magnesium. There was a 15% increase above baseline in the 
1-2 m m ol/l group (5.28 ±_ 1.13 m l/beat, p < 0 .05 ) which rose to  a 
maximum of 34.6% above baseline (11,0 ± 2 .6  ml/beat) in the 6-7 mmol/l 
group (p<0.05).
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SV (ml/beat)
Figure 5.8 Scattergram of changes in stroke volume against serum magnesium levels.
Figure 5.9 Stroke Volume v. Serum Magnesium for grouped data. 
* - 0.05
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SW (gm.m/beat)
Figure 5.10 Scattergram of changes in stroke work against serum magnesium levels.
Figure 5.11 Stroke Work v. Serum Magnesium for grouped data. 
*-p<0.05
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5.2.9 Stroke Work : A lthough there was a significant negative corrleation 
between serum magnesium concentrations and SW (Figure 5.10), the 
response was b iphasic . SW increased in all g roups w ith  serum 
magnesium values of less than 5 mmol/l (Figure 5.11), giving a mean 
increase from baseline of 4.1 ±_ 1.2 gm.m/beat in the <5 mmol/l group 
(p < 0.001). In all groups with magnesium levels above 5 mmol/l, SW fell 
significantly below baseline (p<0.001), the overall change in this group 
being -10.2 ^l 1.9 gm.m/beat
5.2.10 Pulmonary Arteria l Pressure: PAP was not significantly altered at any 
stage of the experiment and there was no correlation between PAP and 
serum magnesium levels.
5.2.11 Pulmonary Vascular Resistance: PVR did not change significantly during 
the experiment.
5.2.12 Pulmonary C ap illa ry  Wedge Pressure: There were no s ign ifican t 
changes in PCWP demonstrable in the grouped data analysis, and on the 
scattergram there was no correlation between changes in PCWP and 
serum magnesium levels.
5.2.13 Central Venous Pressure: CVP also showed a biphasic response, but 
the changes were extremely small (Figure 5.12). There was a weak 
p o s itive  co rre la tio n  betw een serum m agnesium  leve ls  and CVP 
(r = 0.338, p<0.01) but in the grouped data, no single data point was 
sign ificantly  d ifferent from baseline. The only detectable significant 
change was a small decrease in the <5 mmol/l group (-0.97 ±_ 0.287 
mmHg), and a small increase in the >5 mmol/l group (1.23 ±_ 0.65 
mmHg). The groups were s ig n ific a n tly  d iffe re n t from  each other 
(p <0.01) but not from baseline.
Cardiovascular Effects 65
CVP (mmHg)
Figure 5.12 Scattergram of changes in central venous pressure against serum magnesium levels
5.2.14 Bolus Injection: Following bolus injection, two of the animals reached 
serum magnesium levels in the 1-2 mmol/l range, two in the 2-3 mmol/l 
range and two in the 3-4 mmol/l range. All of the results produced by 
bolus injection were within one standard deviation of the mean of the 
appropriate group.
5.3 DISCUSSION
The dose-related reduction in system ic vascular resistance shown in the 
present study confirms the vasodilator properties of magnesium previously 
demonstrated in a variety of tissues in various species (Altura & Altura, 1981 a, 
b & c; Altura & Altura, 1978 a & b; Turlapaty & Altura, 1978; Turlapaty et al,
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1980), and also in Intact animals and humans (Haddy, 1960; Haury, 1939; 
Overbeck et al, 1969). This effect is due to the direct action on vascular smooth 
muscle (Altura & Altura, 1981b; Altura & Altura, 1984c), to interference with the 
action of various vasoconstrictor agents (Altura & Altura, 1981 b & c; Altura & 
A ltura, 1977; Levin et al, 1976; Turlapaty & A ltura, 1980), and possibly 
blockade of sympathetic ganglia (Hutter & Kostial, 1954; Stanbury, 1948). The 
hypotensive effect of magnesium has been ascribed to a combination of all of 
these effects (Engbaek, 1952). The absence of effect on venous pressure 
suggests that the major role of magnesium in intact animals is on resistance 
ra th e r than c a p a c ita n ce  vesse ls , a lth ou g h  some re ce n t w o rk  on the 
m icrocirculation questions this notion (Altura & Altura, 1985b).
In the face of this clear-cut evidence of the vasodilator action of magnesium, 
the conflicting evidence regarding hypermagnesaemic hypotension requires 
explanation. Although a hypotensive response to acute hypermagnesaemia has 
been well described both in animals and humans (Alfrey et al, 1970; Altura & 
Altura, 1985a; Blackfan & Hamilton, 1925; Hoff et al, 1939; Matthews & Brooks, 
1910; Meltzer & Auer, 1906b; Moore & Wingo, 1942; Mordes et al, 1975; 
Mroczek et al, 1977; Pritchard et al, 1984; Randall et al, 1959; Scott et al, 1968; 
Young & Weinstein, 1977), the effect appears to be inconsistent. In humans, 
some au tho rs  have reported  lit t le  ca rd iovascu la r e ffec t at high serum 
magnesium levels (Flowers et al, 1962; Kelly et al, 1960), whilst others have 
found marked but transient hypotension (Mroczek et al, 1977). In animals, both
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trans ien t (Dandavino et a l, 1977) and susta ined (M cCubbin et al, 1981) 
hypotension has been reported. Hypotension is not consistently produced by 
magnesium in the management of pregnancy-induced hypertension (Flowers et 
al, 1962; Pritchard et al, 1984; Pritchard & Pritchard, 1975), and consequently, 
magnesium has been described as a poor vasodilator (Scott et al, 1968). Part 
of the exp lanation for th is  inconsis ten t hypotension may lie in the rapid 
clearance of magnesium from the plasma. This study illustrates the difficu lties 
of maintaining high serum magnesium levels in the presence of normal renal 
function as even massive infusion rates produced a maximum serum magnesium 
level of only 9.4 mmol/l. In this study, as in others (Maxwell et al, 1965; 
Mroczek et al, 1977), the fall in blood pressure correlated moderately with 
changes in serum magnesium. As many of the papers describing the transitory 
hypotensive effect of magnesium did not include serum magnesium estimations, 
and inadequate serum magnesium levels are common in obstetric patients 
(Herbert et al, 1968; Sibai et al, 1981), probably due to underlying magnesium 
d e fic ie n cy  (Cadell et a l, 1975), inadequa te  m agnesium  leve ls must be 
considered as part of the explanation of this phenomenon. The frequently 
repeated observation that a bolus of MgSC>4 produces a greater effect than does 
a continuous infusion may also reflect poorly maintained magnesium levels. 
There was no indication in the present study that the magnesium levels obtained 
following the loading dose produced a different effect to that of sim ilar serum 
magnesium levels maintained by constant infusion.
Cardiovascular Effects 68
However, poorly  maintained magnesium levels cannot provide a complete 
answer to the problem of magnesium-induced hypotension, and the effects of 
magnesium on CO must also play a part. The present study has shown that 
although there was a significant reduction in systemic vascular resistance, 
relatively little  hypotension was produced by levels of serum magnesium below 
5 m m ol/l, a find ing  in agreement w ith  o ther stud ies (Cohen et al, 1984; 
Dandavino et al,1977; Mroczek et al, 1977). This can only be explained by a 
concomitant increase in CO which largely compensated for the fall in SVR. In 
the present study, significant falls in blood pressure only occurred once CO had 
returned to near-baseline values. Magnesium administration has been shown 
to increase CO and stroke volume (Mroczek et al, 1977; Stanbury & Farah, 
1950), but an increase in SW has not been demonstrated before. In the present 
study, SW increased up to levels of serum magnesium of 5 mmol/l. This 
increased SW, along with an increased CO suggests improved myocardial 
contractility.
Magnesium is generally regarded as having a negative ino trop ic  action. 
Magnesium inhibits the contractile force of isolated heart muscle (Langer, 1968; 
Shine & Douglas, 1974; Solaro & Shiner, 1975; Stanbury & Farah, 1950), 
although the effect is small as long as the calcium levels remain within normal 
lim its (Kovacs & O’Donnell, 1975; Levin et al, 1976; Shine, 1979). A reduction 
in m yocardia l perform ance in humans has been claimed in some studies 
(Aldrete et al, 1968; C ritelli et al, 1977; Mori, 1978), but the increased CO
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dem onstrated in o thers (M roczek et al, 1977) argues against s ign ifican t 
myocardial depression. In the present study, there was no clear evidence that 
even high levels of serum magnesium exerted a significant negative inotropic 
effect. Although CVP was significantly higher at levels of serum magnesium 
above 5 mmol/l when compared to the lower magnesium group, this difference 
was small (1.26 j t0 .6 5  mmHg) and PCWP was unaffected. The return of CO to 
baseline levels in the higher range of serum magnesium was the result of a 
reduction of HR alone as SV was always above baseline values. The reduction 
in SW at higher magnesium levels may be construed as indicating impaired 
con trac tility , but, since stroke volume was not reduced, this reduction is 
entirely accounted for by changes in mean arterial and wedge pressures (see 
equation in Appendix A). As arterial pressure is the product of peripheral 
resistance and cardiac output, and cardiac output was not significantly different 
from baseline at the higher magnesium levels, it must be concluded that the 
reduction in stroke work was mainly the result of the reduction in peripheral 
resistance and thus unlikely to be due to impaired contractility. In a non-steady 
state model such as that used in these experiments, in which all the factors that 
may a lte r c o n tra c t il i ty  (p re load , a fte rlo ad  and heart rate) are va ry ing  
independen tly , d ire c t m easurem ents of c o n tra c t il i ty  such as dp/dtmax 
themselves vary, and are no longer true reflections of con tractility . It is 
there fore  d if f ic u lt to make absolute statem ents regarding the effects of 
magnesium on con tractility  but it is reasonable to conclude that myocardial 
performance was not depressed in this study, and the possibility that moderate 
e levations in serum magnesium im proved function  remains. A possib le
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explanation is that p-receptor agonist binding in the myocardium may have 
been enhanced. Magnesium does augment p-agonist receptor binding in 
certain tissues (Bird & Maguire, 1978; Morton & James, 1985; Vincent, 1982; 
Williams et al, 1978), although this effect has not been studied in myocardial 
tissue. Both the use of ketamine, and the very light level of anaesthesia used 
could have increased catecholamine levels, as could the adrenergic response 
to reductions in arte ria l pressure. H igher levels of magnesium may have 
inhibited the release of catecholamines (Douglas & Rubin, 1963; Kirpekar & 
Misu, 1967; Lishajko, 1970; Von Euler & Lishajko, 1973) thus reducing the 
circulating level and producing a decline in SW. Estimations of catecholamine 
levels were not available at the time of these experiments, and this possibility 
needs further study. The other anaesthetic agents used are unlikely to have 
influenced these results significantly as nitrous oxide has minimal cardiac 
effects, and suxamethonium should not affect contractility. Alcuronium may 
produce mild hypotension, but this was not seen at the start of the experiments, 
and as no alcuronium was given within 1 hour of starting measurements this 
effect should not have influenced the results. Acid-base disturbances are 
extremely unlikely to have influenced these results as the CO2 levels were kept 
constant and perfusion was always good. Although arterial blood gas analysis 
was not available, end-expiratory CO2 estimation represents a reasonable 
approximation in the absence of lung disease or gross reduction in cardiac 
output, and is particularly useful in detecting changes (Nunn, 1987). There is 
no evidence that MgS04 infusion of itse lf provokes an acidosis e ither in 
obstetrics (Pritchard, 1975) or in the later parts of this thesis when large
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infusions of the salt were used in the management of patients with tetanus and 
phaeochromocytoma.
Magnesium is generally thought to produce prolongation of the PR and QT 
intervals (M iller & Van Dellen, 1941; Smith et al, 1939; Van Dellen & Miller, 
1939; Von Euler & Lishajko, 1973), although other reports have not shown 
sign ificant conduction defects provided the serum calcium and potassium 
levels are maintained (McCubbin et al, 1981; Surawicz et al, 1961; Watanabe & 
Dreyfus, 1972; Young & Weinstein, 1977). The ECG changes found in this study 
were minimal, but may this be the result of species variation. It is possible that 
the use of suxamethonium for intubation contributed to the slowing of heart rate 
in the initia l groups, but highly unlikely that this effect would have persisted, 
and the change at magnesium levels above 5 mmol/l is most likely to be a pure 
magnesium effect. The levels of magnesium used in clinical practice seem 
u n like ly  to  p roduce  se rious ECG a b n o rm a litie s  o the r than a poss ib le  
prolongation of atrial conduction time.
The apparen t absence of e ffec t of magnesium on pulm onary vessels is 
surprising in view of other reports of pulmonary vasculature behaving in the 
same manner as the systemic vascular tree to magnesium loads (Altura & Altura, 
1981c; Howell & Carrier, 1986). This experiment does not shed any light on the 
reason for this observation, but species peculiarity may account for it.
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Magnesium competes with calcium at the cell membrane, and may be regarded 
in many circumstances as a physiological calcium antagonist (Altura & Altura, 
1981 a & b; Altura & Altura, 1985 a, b & c; Iseri & French, 1984). The present 
study lends support to this concept. It has been shown that magnesium exerts 
a c o n s is te n t, dose -re la te d  v a s o d ila to r e ffec t, and the re la tive ly  weak 
hypotensive action of this substance is probably the result of compensatory 
increases in CO. The absence of a major negative inotropic effect has been 
demonstrated, and even relatively large elevations of serum magnesium did not 
produce serious arrhythmias or conduction defects.
From this study, it may be concluded that magnesium increases peripheral 
perfusion, but is unlike ly to depress m yocardial con trac tility  or produce 
serious hypotensive consequences. It is thus likely to prove a safe agent in 
c lin ica l c ircum stances where a reduction  in a fterload or an increase in 
peripheral perfusion is required. The potential benefit of these observations in 
conditions of catecholamine excess are investigated in later sections of this
thesis.
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6. INTERACTIONS WITH ADRENALINE AND ITS 
ANTAGONISTS
As a result of the Investigations described in the previous chapter, it may be 
concluded that magnesium can exert significant vasodilator effects which may, 
in part, be due to interactions between magnesium and adrenergic agonists. It 
has been shown in vitro that magnesium interferes with the peripheral action of 
catecholamines, and that it may regulate the release of catecholamines from 
both the adrenal gland and peripheral nerve terminals (Altura & Altura, 1977; 
Hutter & Kostial, 1954; Levin et al., 1976; Stanbury, 1948; Turlapaty & Altura, 
1982). However, these effects have not been demonstrated in the intact animal, 
and no attempt has been made to quantify the extent of the interaction between 
magnesium and catecholamines in vivo. Before clinical consideration could be 
given to the use of magnesium in conditions of catecholamine excess, it would 
be necessary to establish a number of facts. Firstly, it would need to be 
established whether or not the degree of magnesium inhibition of adrenergic 
receptors was sufficient to be of clinical use. Secondly, it would be important 
to know whether or not the interaction was potentially hazardous in terms of 
massive vasodilatation or severe disturbances of heart rhythm. Finally, it is 
known that some other alpha-adrenergic antagonists, such as phentolamine,
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have anti-arrhythmic properties, and it would be interesting to find out whether 
or not the well-known anti-arrhythmic properties of magnesium extended to 
situations of catecholamine overactivity. This study was designed to investigate 
the in teraction between magnesium and adrenaline on the cardiovascular 
system of the intact baboon. Adrenaline was chosen as the adrenergic agonist 
since the combined alpha- and beta-adrenergic stimulant effect of high doses 
of th is  agent would most c lose ly  approxim ate to  the c lin ica l s itua tion . 
Furthermore, if, as seemed like ly  prio r to the study, magnesium exerted 
prim arily  a-antagonist properties, the use of adrenaline would allow  the 
unmasking of po ten tia lly  dangerous interactions between (3-agonists and 
magnesium such as severe tachyarrhythmias.
6.1 METHODS
Twelve adult male Chacma baboons were studied with the approval of the 
animal experimentation ethics committee, and the experimental procedure was 
essentially sim ilar to that used in the previous study. The animals were initia lly 
sedated with ketamine 10 mg/kg i.m. and then transferred to the operating 
room and placed on a heated operating table. Anaesthesia was induced with 
thiopentone 4 mg/kg i.v. and the trachea intubated under muscle relaxation 
induced with suxamethonium 1 mg/kg. The lungs were ventilated with 25% 
oxygen in nitrous oxide and minute ventilation adjusted to keep the end-expired
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carbon dioxide level within the normal range. Electrocardiographic leads were 
attached to each limb and lead II monitored throughout the experiment. An 
arterial cannula was inserted into the left femoral artery and an Edwards 7FG 
trip le lumen thermodilution pulmonary artery catheter inserted via the right 
femoral vein, and a written record of the transduced pressures and the ECG 
made as in the previous experiment. Muscular relaxation was maintained with 
intermittent doses of suxamethonium as required to prevent movement. This 
relaxant was chosen as the previous study had shown that sustained muscle 
relaxation seemed unnecessary once all lines had been established. This 
techn ique  a lso removed any risk of problem s pe rta in ing  to  reversal of 
non-depolaris ing relaxants. Stable conditions as previously defined were 
maintained for one hour before any readings were made. Baseline recordings 
of heart rate, pulmonary and systemic systolic, diastolic and mean arterial 
pressures, central venous pressure, pulmonary artery wedge pressure and 
cardiac output were made at th is time. Cardiac output was estimated by 
thermodilution using 5 ml of 5% dextrose held between 0-5° Centigrade as the 
injectate. The mean of three consistent readings was taken on each occasion. 
From these values systemic and pulmonary vascular resistances, stroke volume 
and stroke work were calculated. Arterial blood samples fo r calcium and 
magnesium levels were taken.
An infusion of adrenaline 1 ^.g/kg/min. was then commenced and continued 
throughout the experiment. Once stable conditions had been present for at 
least 5 minutes of adrenaline administration, all measurements were repeated.
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Stable conditions were defined on this occasion as a difference of less than 10% 
between successive measurements 5 m inutes apart. Where arrhythm ias 
occurred, all measurements were recorded during periods of sinus rhythm. At 
this point, animals were allocated at random to a control group, or to an 
experimental group. Animals in the experimental group then received a bolus 
o f m agnesium  60 m g/kg by in travenous in je c tio n , and ca rd iovascu la r 
parameters again measured, along with serum calcium and serum magnesium 
levels. Once the values had been recorded, a further bolus of magnesium was 
injected and all measurements again repeated. Bolus injection, rather than an 
infusion, of magnesium was used in order to achieve a rapid increase in serum 
magnesium levels, the previous experiment having shown infusions to produce 
slow and unpredictable changes in serum magnesium. Control animals were 
given two identical volume injections of saline instead of the magnesium.
The results within the treatment groups were analyzed by analysis of variance 
and significantly different results identified using Duncan’s multiple range test. 
Between group comparisons were made using Student’s t-test. Statistical tests 
were performed using the SPSS package. Significance was defined as p<0.05.
6.2 RESULTS
As in the previous study, anaesthesia was m aintained w ithout d ifficu lty  
throughout the experiment.
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Results are presented as means _±_ 1 S.E.M., and the principal features are 
illustrated in table 1. Cardiovascular measurements in treatment and control 
groups were not significantly different either at baseline or after the infusion of 
adrenaline, and therefore measurements in the treatm ent group only are 
reported In the text for the sake of clarity. Saline injections produced no 
significant alterations in the adrenaline-induced changes and control group 
data is therefore presented only where there were significant differences from 
the treatment group.
6.2.1 Serum Magnesium: Baseline serum magnesium values were similar in all
animals (0.617 _ t0.01 mmol/l). Initial bolus injection produced serum 
magnesium levels of 3.4 _±_ 0.31 m m ol/l, and the second in jection 
resulted in similar levels of 3.33 .±.0.29 mmol/l. Serum magnesium was 
unaltered from baseline in control animals.
6.2.2 Serum Calcium: Serum calcium levels were not significantly changed at 
any stage of the experiments.
6.2.3 Arteria l B lood Pressure : Adrenaline produced a significant increase in
systo lic  blood pressure (SBP) in both groups (p<0 .05). Within 60 
seconds of the firs t injection of magnesium SBP decreased to a mean 
value 167.5 .±.20.1 mmHg, and after the second injection, the mean value 
was 166.8 ± .  9.0 mmHg. The post-adrenaline SBP was significantly 
greater than baseline and this elevation persisted in the control animals. 
Both post-magnesium blood pressures were significantly lower than in 
saline-treated contro ls (p<0 .05). Post-magnesium values were not 
significantly different from baseline. These changes are summarized in 
figure 6.1.
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Figure 6.1. Changes in systolic arterial pressure.
* - p < 0.05 for differences between MgSO4 and saline
+ - p < 0.05 for differences from baseline.
Diastolic pressures were sim ilarly affected, increasing significantly from 
a baseline value of 94.0 ±_ 6.5 mmHg to 125.2 ± .  13.6 mmHg with the 
adrenaline infusion (p<0.05), and decreasing to 96.7 ±_8.2 mmHg and
84.2 ± .4 .2  mmHg with the two doses of magnesium. Controls remained 
significantly above the treatment group (p<0.05).
6.2.4 Heart Rate: HR initia lly increased as the adrenaline infusion commenced, 
but rapidly slowed, presumably from vagal reflexes as a result of the 
raised arterial pressure, and multifocal ventricular and supra-ventricular 
arrhythmias were seen in all animals. At steady-state conditions during 
the adrenaline infusion, the mean HR was 89.8 _±_ 13.4 beats/min. which 
was not significantly different from the baseline value of 101.0 ± . 3.2
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beats/min. The firs t bolus injection of magnesium immediately abolished 
the arrhythm ias and increased the HR to  a mean of 130.33 ±_ 9.3 
beats/min. with the second dose producing a further increase to 145.8 
±_ 4.9 b e a ts /m in ., bo th  o f these post-m agnes ium  va lues being 
significantly above baseline and post-adrenaline values (p<0.05). The 
HR a fte r  each m agnesium  dose was s ig n if ic a n t ly  g re a te r than 
saline-treated controls (p<0.05), and saline had no effect on either the 
heart rate or the arrhythmias induced by the adrenaline infusion. The 
difference between the two MgSC>4 doses was not significant. These 
changes are summarized in figure 6.2.
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Figure 6.2. Changes in Heart Rate.
*-p<0.05 for differences between MgSO4 and saline
+ -p <  0.05 for differences from baseline
6.2.5 Cardiac Output: The adrenaline infusion caused a s ligh t, but not 
significant reduction in CO in both groups. The firs t bolus of magnesium 
caused an increase in CO to 5.59 ±_ 0.83 l/min. and the second bolus
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caused a further increase to 6.18 i.0 .7 2  l/min. The treatment group was 
significantly different from controls and from baseline after each bolus 
(p < 0.005 for both magnesium doses). The within-group difference in 
CO after each of the two doses of magnesium was not significant (figure 
6.3).
CO (litres/min)
8 i-------------------
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Magnesium vmm Control
Figure 6.3. Changes in Cardiac Output.
* -p <  0.005 for differences between MgSOA and saline
+ -p<0.05 for differences from baseline
6.2.6 Stroke Volume: Baseline mean SV was 34.73 ±_ 2.60 ml/beat. Adrenaline 
infusion reduced SV slightly in both groups but this change was not 
s ign ifican t. Follow ing the in jec tions  of magnesium, SV increased 
significantly from post-adrenaline levels to 42.26 _±_ 4.38 ml/beat and 
42.38 _±_ 4.29 ml/beat (p<0.05). The two post-magnesium levels of SV 
were s ign ifica n tly  higher than those in the saline-treated contro ls 
(p<0.05). These results are illustrated in figure 6.4.
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Figure 6.4. Changes in Stroke Volume.
* -p <  0.05 for differences between MgSO4 and saline
6.2.7 Systemic Vascular Resistance: In the treatment group, the adrenaline 
in fu s io n  in c re a se d  SVR from  a b a se lin e  mean o f 2506 ±_ 207 
dyne.sec.cm '5 to a mean of 4378 jL 497 dyne.sec.cm'5 (p<0.05), with a 
similar significant increase occurring in the control group. The first 
magnesium injection reduced SVR to 1809 _±_303 dyne.sec.cm '5 and the 
second produced a fu rthe r reduction in SVR to  1451 ±_ 135 dyne, 
sec.cm '5. This second value was s ign ifican tly  below baseline SVR 
( p < 0 .0 5 ). SVR in con tro l an im als rem ained unchanged from  the 
post-adrenaline levels, and the difference between the controls and 
magnesium-treated animals was significant at the 0.005 level for each of 
the post-magnesium values (figure 6.5).
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Figure 6.5. Changes in systemic vascular resistance.
* - p < 0.05 for differences from baseline
+ - p < 0.005 for differences between MgS04 end saline
6.2.8 Pulmonary Artery Pressure: Following adrenaline, pulmonary systolic 
pressure increased from a mean baseline value of 18.7 .±.3.8 mmHg to 
36.33 jL 15.4 mmHg (p<0.05). The injections of magnesium produced 
a small but non-significant reduction in pressure to means of 32.3 _±_4.3 
mmHg and 30.7 j^ 4 .7  mmHg respectively.
Pulmonary diastolic pressures showed a similar pattern, but none of the 
changes reached statistical significance.
6.2.9 Pulmonary Vascular Resistance: PVR was increased by adrenaline from
109.8 ±_ 14.7 to 182 jL  47.4. Magnesium reduced PVR to 108.7 ±_ 24.5 
and 114 ±_ 19.2 but neither of these changes reached s ta tis tica l 
significance due to the large variability in the samples.
(dyne.sec.cm'5)
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6.2.10 Central Venous Pressure: CVP increased significantly from a baseline 
value of 4.67 _±_ 0.76 mmHg to 9.33 ±_ 1.31 mmHg following adrenaline. 
Following the first magnesium injection, CVP fell to 6.50 jL1.54 mmHg 
and after the second injection to 5.33 _±_ 1.36 mmHg. Neither of the 
post-magnesium values was significantly different from baseline. The 
difference between saline-treated controls and the magnesium group 
was not significant after the first dose of magnesium, but CVP was 
s ign ifican tly  lower in the magnesium group after the second dose 
(p < 0.02). When the change in CVP from baseline was considered, the 
post adrenaline increase of 4.67 ±_ 1.02 mmHg was significantly different 
from baseline and from both post-magnesium values.
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Figure 6.6. Changes in central venous pressure
* -p <  0.05 for differences between MgS04 and saline
+ -p<0.05 for differences from baseline
Interactions with Adrenergic Agents 84
6.2.11 Pulmonary Capillary Wedge Pressure: Adrenaline significantly raised 
PCWP from baseline by a mean of 10.8 ± .3 .4  mmHg (p<0.05). Following 
the firs t magnesium in jection, PCWP was 6.0 ± .2 .7  mmHg above 
baseline, and after the second injection PCWP was 2.83 2.91 mmHg
above baseline. The changes in PCWP following magnesium injections 
were not s ig n if ic a n t ly  d if fe re n t from  e ith e r base line  va lues, or 
post-adrenaline levels. There was no significant difference between 
treatment and control groups.
TABLE 6.1
EVENT BASELINE ADRENALINE MAGNESIUM1 MAGNESIUM2 SALINE
SBP 147.3±_8.2 214.7±_16.5* 167.5±20.1 + 166.8±_9.0 + 207.5_±_14.3
DBP 94.0±.6.5 125.2±_13.6* 96.7±_8.2 + 84.2±_4.2+ 121.2_±.1lV
HR 101.0±.3.2 89.8±_13.4 130.3±_9.3* + 145.8±_4.9* + 94.9±_10.4
CO 3.54±_0.35 2.83±_0.36 5.59±.0.83*'1h 6.19±_0.72* + 2.79±_0.42
SV 34.7±.2.6 28.5±_3.8 42.3±_4.4* + 42 .4±4 .3*+ 30.4±.4.8
SVR 2505±207 4378±_497* 1809±.303 + 1451±_135*+ 4298±_387*
Table 6.1. Significant changes in cardiovascular parameters with infusion of 
adrenaline and subsequent injections of magnesium or saline. As the values 
after each injection of saline were virtually identical, a single value for controls 
is shown.
SBP - systolic blood pressure in mmHg
DBP - d iastolic blood pressure in mmHg
HR - heart rate in beats per minute
CO - cardiac output in litres per minute
SV - stroke volume in ml per beat
SVR - systemic vascular resistance in dyne.sec.cm'5
* - significant difference from baseline values p<0.05
+ - significant difference from control values p<0.05
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6.3 DISCUSSION
Magnesium is necessary for normal smooth muscle physiology (Altura & Altura, 
1981 b) and variations in serum magnesium can profoundly affect vascular tone. 
Hyperm agnesaem ia reduces vascu la r tone by a number of mechanisms 
including direct action on vascular smooth muscle (Altura & Altura, 1981c; 
A ltu ra  & A ltu ra , 1984 a & b), in te rfe re n ce  w ith  the  a c tio n  o f va rious  
vasoconstrictor agents (Altura & Altura, 1977; Levin et al., 1976; Turlapaty & 
Altura, 1980), and possibly blockade of sympathetic ganglia (Hutter & Kostial, 
1954; Stanbury, 1948). The hypotensive effect of magnesium has been ascribed 
to a combination of all of these effects (Engbaek, 1952). The reduction in 
vascular resistance demonstrated in this study could be explained by any of 
these mechanisms. However, in this study SVR was reduced to one third of the 
pre-magnesium level which is far in excess of the reduction demonstrated in the 
same baboons without adrenaline in whom sim ilar levels of serum magnesium 
reduced the SVR by 20% (vide supra). As both ganglionic blockade and direct 
vasodilatation should have been operative to the same extent in this and the 
previous study, it seems reasonable to conclude that the large reduction in 
periphe ra l res istance shown in the present study was p rim a rily  due to 
alpha-adrenergic blockade as a result of the increased serum magnesium. 
Alpha-adrenergic blockade produced by hypermagnesaemia has been well 
described in isolated vessels in various organs from different species (Altura & 
Altura, 1981; Burn & Gibbons, 1964; Farmer & Campbell, 1967; Turlapaty & 
Altura, 1982) but has not previously been shown to have a clin ica lly useful
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action in an intact animal. Since blood pressure was restored to baseline by 
the infusion of magnesium it is highly likely that this effect will be of clinical 
value.
Magnesium is well known as an anti-arrhythm ic agent in various circumstances, 
notably in the presence of d ig ita lis  (Boyd & Sherf, 1943; Chadda et al., 1968; 
E nse lbe rg  et a l., 1950; Is e r i et a l., 1975; S zeke ly , 1946). H ow ever, 
anti-arrhythm ic properties of magnesium in the face of high levels of adrenaline 
have not been previously shown, and this adds to the usefulness of magnesium 
in patients who may have raised circulating catecholamine levels. Interestingly, 
part of the ab ility  of magnesium to counteract cardiac g lycoside-induced 
arrhythmias has recently been ascribed to a reduction in sympathetic tone 
produced by magnesium (Tackett, 1986). The failure of adrenaline to increase 
heart rate in this experiment was almost certainly due to two factors. The first 
of these would have been reflex vagal inhibition of the heart in response to 
baroreceptor stimulation by the elevated blood pressure; the fact that a brief 
tachycardia was seen in itia lly  prior to the rise on blood pressure supports this 
hypothesis. The multifocal arrhythmias which occurred frequently resulted in 
com pensatory pauses w hich would a lso have contributed to  the overall 
decrease in rate. The increase in heart rate seen after the injection of MgS04 
was probably due to the unopposed p-adrenergic effect of adrenaline in the 
absence of arrhythmias. However, alterations in vagal tone probably also 
played a part. The reduction in arterial blood pressure alone would have 
reduced the level of vagal inhibition, but in addition, magnesium has been
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shown to inhibit the release of acetylcholine from vagal nerve terminals (Somjen 
& Baskerville, 1968; Toda & West, 1967). The relative importance of this action 
is d ifficu lt to assess in view of the direct inhibitory action of magnesium on the 
SA node.
The marked increase in ca rd iac  ou tpu t and stroke volum e seen in th is 
experiment fo llow ing the adm inistration of MgS04 was probably due to  a 
combination of the reduction in afterload produced by the fall in SVR, and the 
unopposed p-adrenergic action of adrenaline. It is unlikely that magnesium 
produced any increase in contractility  in its own right. However, an increase in 
p-agonist binding in the presence of elevated magnesium levels has been shown 
in some tissues (Bird & Maguire, 1978; Morton & James, 1985; Vincent, 1982; 
Williams et al, 1978), although this effect has not been studied in myocardial 
tissue. If th is  increase in agonist b inding occurs in the myocardium, the 
increase in cardiac output and stroke volume could, in part, have been due to 
increased adrenerg ic s tim u la tion . W hether or not magnesium enhances 
p-agonist binding, its use in situations of catecholamine excess may be of value 
to the myocardium on other grounds. It has been shown that magnesium does 
not in te rfe re  w ith  the in o tro p ic  e ffe c t of ad renerg ic  s tim u la tion  o f the 
myocardium, but that high levels of magnesium reduce lactate production by 
the myocardium, thus presumably protecting the myocardium against some of 
the adverse metabolic consequences of adrenaline (Paddle & Haugaard, 1971). 
It is clear from this study that the relatively normal blood pressure obtained 
after the magnesium injections was due in large part to the increased cardiac
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output, as peripheral resistance was significantly lower than baseline at this 
time.
It is interesting to note that despite the use of large doses of MgS04, serum 
magnesium levels were similar after each bolus dose. The explanation for this 
is likely to lie in very rapid clearance of the substance from the blood, but this 
result does seem remarkable in view of the rather longer half-life of magnesium 
shown in other studies. It is probable that at least part of the explanation for 
th is  rem arkably rapid removal of magnesium lies in the enhancement of 
m agnesium  c le a ra n ce  by ca te ch o la m in e  s t im u la t io n . An inc reased  
disappearance of magnesium from the blood stream during catecholamine 
stimulation has been shown although whether this indicates increased renal 
losses of magnesium or increased intracellular uptake of the ion is at present 
unclear. Whilst Whyte et al (1987) believe that catecholamine stimulation 
causes magnesium to move into the in trace llu la r space, o ther evidence 
suggests that catecholamines cause intracellular losses of magnesium resulting 
in in itia lly raised serum magnesium concentrations, but ultimately magnesium 
deficiency (see Durlach, 1988 for a review). One thing is clear, however, and 
that is that if effective serum levels of magnesium are to be achieved in patients 
with catecholamine excess, quite large doses of MgS04 of at least the upper 
dosage range recommended in obstetrics (Sibai et al, 1981; Pritchard et al, 
1984) will have to be administered. An appropriate initial dosage schedule 
might therefore be to start with a loading dose of 60mg/kg MgS04 followed by 
an infusion of 30mg/kg/hour.
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In conclusion, this study has shown that magnesium may be a useful, rapid 
acting a-adrenergic blocker, as well as a useful anti-arrhythmic in the presence 
of high levels of circulating catecholamines, in addition, it is possible that 
magnesium may inhibit the release of catecholamines from the adrenal gland. 
There is thus a sound basis fo r the use of magnesium in fusions in the 
management of conditions of catecholamine excess.
6.4 Interactions with Alpha-Adrenergic Blocking Drugs
The above described study demonstrated that magnesium has useful adrenergic 
antagonist properties, which may be of use in certain clinical circumstances. 
However, patients with conditions of catecholamine excess are likely to be 
tre a te d  w ith  o th e r a d re n e rg ic  b lo ck in g  d rugs, p a r tic u la r ly  a-blockers. 
Therefore, before the hypothesis that magnesium may be useful in such 
conditions could be tested in humans, the extent of its interaction with other 
adrenergic blockers had to be investigated. In particular, it was essential to 
determine whether or not a combination of magnesium and a-blockade was 
likely to produce catastrophic hypotension. The purpose of this study was to 
compare the cardiovascular effects of magnesium in the presence of adrenaline 
with those of a standard a-adrenergic antagonist, phentolamine.
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6.5 METHODS
In order to derive maximum information from this study, the same six animals 
who had served as the magnesium group in the previous experiment were used 
for this study, and the results obtained compared with those from the previous 
investigation. The anaesthetic protocol was identical to that already described 
in previous experiments, and identical instrumentation was used. As before, 
stable conditions were maintained for one hour before any readings were taken. 
Baseline recordings of heart rate, pulmonary and systemic systolic, diastolic 
and mean arterial pressures, central venous pressure, pulmonary artery wedge 
pressure and cardiac output were then made.
An infusion of adrenaline 1 ^.g/kg/min was then commenced and continued 
throughout the experiment. Once stable conditions had been present for at 
least 5 minutes, all measurements were repeated. Where arrhythmias occurred, 
measurements were recorded during periods of sinus rhythm. All six animals 
then received 0.2mg/kg phentolamine intravenously, followed by a bolus of 
MgS04 60mg/kg iv. After each drug, all cardiovascular parameters were again 
measured, along with serum calcium and serum magnesium levels.
The results within the treatment groups were analyzed by analysis of variance 
and significantly different results identified using Duncan’s multiple range test.
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Between group com parisons w ith  the resu lts  obta ined from  the use of 
magnesium alone were made using Student’s t-test. Significance was defined 
as p < 0.05.
6.6 RESULTS
Results are presented as means ±_ 1 S.E.M.
6.6.1 Serum magnesium: Baseline serum magnesium values were similar in all
anim als w ith  a mean of 0.617 ±_ 0.01 mMol/l. The MgS04 bolus 
increased serum magnesium levels to  3.15 ±  0.31 m m ol/l. This 
compared well with the previous study in which the initial bolus injection 
produced serum magnesium levels of 3.4 _t0.31 mMol/l, and the second 
injection resulted in similar levels of 3.33 _±0.29 mMol/l.
6.6.2 Serum Calcium: Serum calcium levels were not significantly changed at
any stage of the experiments.
6.6.3 Arteria l B lood Pressure : Adrenaline produced a significant increase in
sys to lic  blood pressure (SBP) from a mean of 154.8 _±_ 7.9 mmHg 
(p <0.05) to a mean of 227.3 _±_ 11.3 mmHg. Phentolamlne significantly 
reduced SBP to 110.0 ± .9 .5  mmHg (p<0.05) and following the injection 
of MgS04 SBP was 130.8 _±_ 16.4 mmHg, which was not significantly 
d iffe rent from the post-phentolam ine level. This was a s ign ificantly 
greater reduction than that produced by the firs t injection of magnesium 
alone (p<0.05), but after the second magnesium injection, values were 
not significantly different. In both studies, the SBP following either
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phentolamine or magnesium was not significantly different from baseline 
(figure 6.7).
SBP (mmHg) 
250 -----------------
Figure 6.7. Changes In systolic arterial pressure during adrenaline infusion with either 
phentolamine-magnesium sequence or magnesium alone.
+ - Significant changes from baseline
* - Significant differences between groups
Phent-Mag - phentolamine-magnesium sequence
Phent/Mag - administration of either phentolamine or MgSOA
Diastolic pressures were sim ilarly affected, increasing significantly from 
a baseline value of 92.5 _±_ 6.4 to  128.2 ±_ 6.1 mmHg (p < 0 .05 ). 
Phentolamine significantly reduced DBP to 49.8 ±_ 6.9 (p<0.05), and 
follow ing MgS04 the DBP was 65.8 ,±_9.2 mmHg. Again, the reduction 
in DBP was significantly greater after phentolamine than after the first 
dose of magnesium alone (p<0.01), although after the second dose of 
MgS04 there were no significant differences.
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6.6.4 Heart Rate: As in the previous experiment, HR in itia lly  increased as the 
adrenaline in fusion commenced, but rap id ly  fe ll and became very 
irregular, with multifocal ventricular and supra-ventricular arrhythmias 
seen in all animals. At steady-state conditions during the adrenaline 
in fu s io n , the mean HR was 95.7 _±_ 7.5 beats/m in  w hich was not 
significantly different from the baseline value of 116.2 _±_3.4 beats/min. 
Phentolamine immediately abolished the arrhythmias and significantly 
increased HR to  a mean of 188.3 ±_ 5.8 beats/min. Phentolamine 
produced a significantly greater increase in HR than that seen after 
magnesium alone (p<0.01). In jection of MgS04 after phentolamine 
produced a slight drop in heart rate to 174.0 .±.5.2 beats/min (figure 6.8).
HR (beats/min)
Baseline Adrenaline Phent/Mag Magnesium
■ I  Magnesium H H  Phent-Mag
Figure 6.8. Changes in heart rate during adrenaline infusion with either 
phentolamine-magnesium sequence or magnesium alone.
+ - Significant changes from baseline
* - Significant differences between groups
Phent-Mag - phentolamine-magnesium sequence
Phent/Mag - administration of either phentolamine or MgSOA
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6.6.5 Cardiac O utput: The adrenaline in fus ion caused a s ligh t, but not 
significant reduction in CO from a mean of 3.51 jt0 .2 7 l/m in  to a mean 
of 3.17 ±_ 3.0 l/min. Phentolamine caused a marked increase in CO to 
5.98 .± .0 .361.min and after magnesium the CO was 6.7 ±_0.49 l/min; both 
of these values were significantly different from both baseline and post 
adrenaline values, but not from each other, or from the values obtained 
using magnesium alone (figure 6.9).
CO (litres/min)
Baseline Adrenaline Phent/Mag Magnesium
Magnesium iH !  Phent-Mag
Figure 6.9. Changes in cardiac output during adrenaline infusion with either phentoiamine- 
magnesium sequence or magnesium alone.
+ - Significant differences from baseline
Phent-Mag - phentoiamine-magnesium sequence
Phent/Mag - administration of either phentolamine or MgSO4
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6.6.6 Stroke Volume: Baseline mean SV was 30.11 _±_ 1.97 ml/beat. After the 
adrenaline infusion SV was 33.02 ±_ 1.4 ml/beat but this difference was 
not significant. After phentolamine SV was 34.75 ± .  3.35 ml/beat, and 
after the addition of magnesium the SV was 38.91 .±.2.53 ml/beat, the SV 
after magnesium being significantly higher than baseline (p<0.05), but 
not significantly different from other values (figure 6.10).
SV (ml/beat)
Figure 6.10. Changes in stroke volume with either phentolamine-magnesium sequence or 
magnesium alone.
+ - Significant differences from baseline 
Phent-Mag - phentolamine-magnesium sequence 
Phent/Mag - administration of either phentolamine or MgS04
6.6.7 Systemic Vascular Resistance: The adrenaline infusion increased SVR 
from a baseline mean of 2502 .±.91 dyne.sec.cm'5 to a mean of 3938 ,±_ 
240 dyne.sec.cm '5 (p<0.05). Phentolamine significantly reduced SVR to
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801 ±_ 54 dyne.sec.cm*5 (p<0.05) and after magnesium the value was 
904 jfc. 88 dyne.sec.cm'5.
SVR (dyne.sec.cm*5) 
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H H  Magnesium i M i  Phent/Mag
Figure 6.11. Changes in systemic vascular resistance, after the administration of adrenaline, with 
either phentolamine-magnesium sequence or magnesium alone.
+ - Significant changes from post-adrenaline values
* - Significant diferences between groups
Phent-Mag - phentolamine-magnesium sequence
Phent/Mag - administration of either phentolamine or MgSC>4
The reduction in SVR produced by phentolamine was significantly greater than 
that produced by the first dose of MgSC>4 in the initial study, but there was no 
sign ificant d ifference between the groups after the final magnesium dose. 
When the post-adrenaline value for SVR was taken as the base point for between 
group comparisons, there was a significant, but small, difference between the 
reduction in SVR produced by phentolamine after adrenaline and that produced
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by the firs t magnesium dose, but the reduction in SVR after the final magnesium 
dose was virtually identical in the two study groups (figure 6.11).
6.6.8 Pulmonary Artery Pressure: Following adrenaline, pulmonary systolic 
pressure increased from a mean baseline value of 21.5 _±_ 1.6 mmHg to 
36.0 4.0 mmHg (p<0.05) which compared well with similar changes
found in the previous study. Neither phentolamine nor MgS04 produced 
a significant reduction in PAP, and there were no differences between 
the results in the two studies. Diastolic pressures showed a similar 
pattern, but none of the changes reached statistical significance.
6.6.9 Central Venous Pressure: Adrenaline produced an significant increase 
in CVP of 4.7 .±.1.0 mmHg from baseline in both groups (p<0.05). In 
both groups, the CVP returned to baseline after the administration of the 
vasodilator drugs.
6.6.10 Pulmonary Capillary Wedge Pressure: Adrenaline significantly raised 
PCWP from baseline by a mean of 12.2 mmHg (p<0.05). Phentolamine 
returned PCWP to baseline, and the levels of PCWP after phentolamine 
were sign ificantly  lower than those after adrenaline (p<0.05). This 
result compared well with that obtained In the previous study in which 
there was a similar trend, but the changes did not reach statistical 
significance. There were no significant differences between the groups.
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At the level of serum magnesium attained in these experiments, magnesium 
appeared to  exert s im ila r ca rd iovascu la r e ffects  to  those produced by 
phentolamine. Phentolamine produced a significantly greater increase in heart 
rate than that produced by magnesium alone, but this was probably simply due 
to  a re flex response to  the greater hypotensive e ffect of phentolam ine 
compared to that produced by magnesium alone. It could be argued that the 
tendency of magnesium to reduce heart rate might have contributed to the 
lesser increase in heart rate, particularly in view of the tendency for heart rate 
to  decrease in the phento lam ine group fo llow ing  the adm in is tra tion  of 
magnesium. The results of these experiments, however, do not permit the 
draw ing of tha t conc lus ion , and tha t must remain a pure ly  specula tive  
possibility. Cardiac output changes in the two groups were similar, although 
magnesium produced an increase in stroke volume, whereas stroke volume 
follow ing phentolamine was unchanged. This is probably because the slower 
heart rate after magnesium allowed more time for ventricular filling, although it 
should be noted that in the magnesium group the increased stroke volume was 
achieved against a significantly higher vascular resistance than that pertaining 
follow ing phentolamine.
6.7  D ISCUSSIO N
Phentolamine produced a greater reduction in SVR than that produced by 
magnesium, but the d ifference was small. The addition  of magnesium to
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phentolamine produced no significant changes in any of the cardiovascular 
variables measured, and it seems likely, therefore, that the two drugs were 
acting through sim ilar mechanisms, and that this large dose of phentolamine 
produced near-maximal a-adrenergic blockade. Although magnesium is well 
known to  be a direct vasodilator, in the presence of adrenaline, its a -  blocking 
properties appear to predominate.
Although it is d ifficu lt to draw any concrete conclusions regarding contractility 
from a study of this nature in which preload and afterload are continuously 
varying, there were no obvious signs of negative inotropic effects of magnesium 
in this study. On the contrary, following the infusion of magnesium, stroke 
volume was significantly increased above baseline despite the fact that preload 
and afterload were at similar level as those prior to adrenaline infusion. The 
only significant increase in stroke volume in the phentolamine group occurred 
after the addition of magnesium. This might be taken to imply that magnesium 
might have exerted a positive inotropic effect in the presence of adrenaline as 
no such increase in stroke volume was seen in the phentolamine group despite 
a lower afterload. There is no evidence that magnesium exerts a positive 
inotropic effect in its own right, and the only likely explanation for this is that 
magnesium could have enhanced p-agonist b inding to  the myocardium. 
Magnesium does augment p-agonist receptor binding in certain tissues (vide 
supra), although this effect has not been studied in myocardial tissue.
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This study has confirmed that magnesium has useful a-adrenergic blocking 
properties, similar to those possessed by phentolamine although of lesser 
magnitude at the dosages used. It seems unlikely to produce dangerous 
additional effects in patients already treated with other a-adrenergic blocking 
drugs. In add ition  it has been shown tha t magnesium can exert useful 
anti-arrhythmic effects in the presence of catecholamines and it is unlikely to 
produce any m yocard ia l depression under the c ircum stances of raised 
adrenaline levels. There is a possibility that magnesium may have a protective 
effect on the adrenergically-stimulated heart.
6.8 Interactions with Beta-Adrenergic Blocking Drugs
The final piece of information required to indicate that magnesium sulphate 
would be safe to use in conditions of catecholamine excess was the extent of 
possible interaction with ^-b locking agents. In the management of these 
patients, a-adrenergic blockade is almost invariably the firs t-line  choice. 
Administration of a p-adrenergic blocker to a patient with catecholamine excess 
Is likely to be extremely hazardous as the unopposed alpha effects could 
produce severe hypertension and cardiac failure (Hull, 1987; Edmondson & 
Flowers, 1979; Buchanan et al., 1978). The only circumstances in which 
p-adrenergic blockers should be used to treat adrenergic overload should be
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in conjunction with the use of a-blockade. Therefore, in order to investigate 
the potential for interaction between magnesium and p-blockers it was decided 
to  use the same experim enta l model as tha t em ployed in the previous 
experiments described in this chapter, but in addition to administer p-blockade 
subsequent to the a-blockade in order to restore near-normal cardiovascular 
status to the animal despite the continuing adrenaline infusion. Subsequent 
administration of magnesium should thus unmask any potentially dangerous 
interaction, in particular the danger of myocardial depression, as is known to 
occur with other calcium antagonist drugs in the presence of 0-blockade.
6.9 METHODS
Six chacma baboons were studied using the same experimental design as has 
been previously described, with the same monitoring devices, and the same 
anaesthe tic  techn ique . As in the previous experim ents, an in fusion of 
adrenaline was administered at a rate of 1n.g/kg/min. and continued throughout 
the experiment. Phentolamine was then administered intravenously, with 
re p e titio n  of a ll m easurem ents, fo llow ed  by the adm in is tra tion  of 1mg 
p rop rano lo l in travenously, at which po in t a ll measurements were again 
repeated. MgS04 at a dose of 60mg/kg was then administered and a final set
of measurements made.
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Results are presented as means ±_ 1 S.E.M. The main points from the results
are summarized in table 6.2.
6.10.1 Serum Magnesium: Serum magnesium levels were increased from a
baseline value of 0.68 0.045 mmol/l to 3.26 _±_ 0.12 mmol/l by the
magnesium infusion.
6.10.2 Heart Rate: As in the previous experiment, adrenaline produced an initial 
tachyca rd ia  fo llow ed by a return of heart rate to  baseline values 
accompanied by multifocal arrhythmias. Phentolamine again abolished 
the arrhythmias and produced a rapid increase in heart rate to  a mean 
of 187.17 ±_ 6.76 beats per min. Propranolol reduced the heart rate to 
a mean of 122.67 j^ 8 .2 7  which was not significantly different from the 
baseline value of 116.83 ± .7 .8 7  beats per min. The administration of 
MgS04 was accompanied by a further slight, not significant decline in 
heart rate to 109.83 i 2 . 5 5  beats per min.
6.10.3 Systemic B lood Pressure: As in the previous experiment, the infusion of 
adrenaline increased blood pressure s ign ificantly  to 235.17 _±_ 19.4 
mmHg and the use of phentolamine reduced the blood pressure to 100.80 
±_ 11.04 mmHg, which was not significantly different from the baseline 
value of 123.17 _±_ 8.27 mmHg. Neither propranolol nor magnesium 
caused any further significant change in blood pressure.
Diastolic blood pressure was sim ilarly affected with adrenaline causing 
a significant increase above and phentolamine causing a significant 
reduction below baseline. Propranolol restored DBP to baseline levels 
and magnesium produced no further significant change.
6 .10  RESULTS
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6.10.4 Cardiac Output: As in the previous experim ents, at steady state 
cond itions during the adrenaline infusion CO was not s ign ificantly  
different from baseline. Phentolamine produced a significant increase 
in h e a rt ra te  and th is  was re s to re d  to  b a se line  leve ls  by the 
adm in is tra tion  of the beta-b locker. Magnesium produced a small 
increase in cardiac output, but this did not reach statistical significance.
6.10.5 Stroke Volume: There were no significant differences for the values of 
stroke volume at the various stages of the experiment. However, when 
the  changes in s tro ke  vo lum e from  base line  w ere co n s id e re d , 
magnesium produced a significant increase in stroke volume (figure 
6 . 12) .
SV (ml/beat)
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Figure 6.12 Changes in stroke volume from baseline at each stage of the experiment.
* - p <  0.05 for differences from baseline.
*
____________ |_______________________________________________ |_______________________________________________ l____________________________________________ ________________
Adrenaline Phentolamine Propranolol Magnesium
I  + S.E.M.
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6.10.6 Pulmonary Arteria l Pressure: As in the previous studies adrenaline 
caused a significant increase in both systolic and diastolic pressures and 
phentolamine restored these values to their baseline levels. Neither 
propranolol nor magnesium produced any further significant changes.
6.10.7 Central Venous Pressure: CVP was s ign ificantly  increased by the 
adrenaline infusion and this was restored to baseline by phentolamine. 
Neither proprano lo l nor magnesium caused any fu rther s ign ificant 
changes in CVP.
6.10.8 Pulmonary Capillary Wedge Pressure: The changes in PCWP were 
identical to those in CVP with adrenaline producing a significant increase 
in wedge pressure, but no other result being significantly different from 
baseline
Table 6.21 over
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TABLE 6.2
Base Adren Phent Prop Magnesium
HR 116.83 107.00 187.17* 122.67 109.83
b.p.m. (7.87) (14.01) (6.76) (3.56) (2.55)
SBP 123.17 235.17* 100.80 114.67 116.63
mmHg (8.27) (19.40) (11.04) (8.41) (6.95)
DBP 76.17 128.17* 38.33* 71.83 65.67
mmHg (7.14) (10.63) (2.24) (5.84) (4.07)
CO 3.63 3.41 6.27* 3.81 4.33
l/min (0.27) (0.21) (0.42) (0.41) (0.38)
SV 32.18 35.56 33.84 31.63 39.72
ml/beat (3.21) (5.15) (2.76) (4.04) (3.92)
Table 6.2. Principle cardiovascular changes found with magnesium injection in 
adrenaline treated a- and p-blocked baboons. Figures in parentheses indicate 
one standard error of the mean.
Base - baseline values
Adren - results follow ing adrenaline infusion
Phent - results following phentolamine administration
Prop - results follow ing propranolol administration
HR - heart rate
SBP - systolic arterial blood pressure 
DBP - d iastolic arterial blood pressure 
CO - cardiac output 
SV - stroke volume
* - p<0.05 for differences from baseline.
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As in the previous experim ent, phentolam ine reversed the hypertensive, 
vasoconstrictor and arrhythmic effects of adrenaline, allowing the unopposed 
beta effects to produce significant increases in cardiac output and heart rate, 
but not stroke volume. The marked decrease in systemic vascular resistance 
was probably in part due to p-mediated vasodilatation as well as to a-blockade. 
The administration of propranolol reversed these p-adrenergically mediated 
changes and restored all of the measured cardiovascular variables to baseline 
values. It is reasonable to assume, therefore, that a- and p-adrenergic 
blockade, at the doses used, had totally reversed the effects of adrenaline in 
these animals. The further addition of magnesium to the preparation produced 
very little  further change in cardiovascular parameters, the only significant 
change being the increase in stroke volume from baseline values.
6.11 D ISC USSIO N
On the basis of these results it would seem reasonable to conclude that 
magnesium is not likely to exhibit additive effects with those of the p-blockers 
in patients with catecholamine excess. In particular, there was no evidence at 
a ll tha t magnesium was like ly to  produce po ten tia lly  hazardous negative 
inotropic actions in combination with p-antagonists in such patients. On the 
contrary, the increase in stroke volume might be interpreted as an increased 
p-agonist effect, although this interpretation must be regarded with caution as 
the complex interrelationships between preload and afterload in this model
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make hard conclusions about contractility very d ifficu lt to draw. By far the most 
reasonable conclusion is that magnesium is unlikely to be dangerous in the 
presence of p-blockade in patients with adrenergic excess.
6.12 CONCLUSIONS
These experiments have demonstrated for the first time in the intact animal a 
num ber of in te re s tin g , and p o te n tia lly  va luab le , in te ra c tio n s  between 
magnesium and adrenergically active agents. In the first experiment it was 
shown that magnesium can exert anti-adrenergic effects of a magnitude that 
would be likely to be useful in the clinical situation. The second experiment 
showed that these actions of magnesium were qualitatively sim ilar to those of 
phen to lam ine , and th a t the re  were no obv ious  p o te n tia lly  hazardous 
interactions between magnesium and this alpha-adrenergic blocker. Finally, it 
was shown that magnesium did not appear to have any apparently hazardous 
in te rac tions  w ith  be ta-b lockers. In pa rticu la r, the th eo re tica lly  possible 
potentiation of the negative inotropic effects of beta-adrenergic blockade did 
not appear to  occu r. C om b ina tions  of a lpha- and be ta -b lockade  w ith  
magnesium seem, there fore , un like ly  to  be dangerous in a pa tien t w ith
catecholamine excess.
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Magnesium does, therefore, appear to have a considerable number of potential 
a p p lic a t io n s  in c o n d it io n s  o f c a te c h o la m in e  o v e r lo a d . The use fu l 
alpha-adrenergic antagonistic effects of this agent combined with its capacity 
for inhibiting the release of catecholamines could make magnesium uniquely 
beneficial in such clinical situations. There is also the interesting possibility 
that magnesium may protect the myocardium from the adverse metabolic 
consequences of catecholamine drive. Demonstration of the fact that the 
theoretical possibility that magnesium can inhibit the release of catecholamines 
is, in fact, borne out in the clinical situation is the theme of the final chapters 
of this thesis.
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7. Catecholam ine Release at Endotracheal 
Intubation
It has been shown in preceding chapters that magnesium has anti-adrenergic 
properties which may be clin ica lly useful in conditions of adrenergic excess. 
The u n ique  a d d it io n a l a b il i ty  o f th is  agen t to  in h ib it  the  re lease  of 
catecholamines from adrenergic nerve terminals and from the adrenal gland in 
v itro  (D ouglas & Rubin, 1963; L isha jko, 1970), may have many c lin ica l 
applications, but this action has never been investigated in intact animals or 
humans.
The commonest situation in which an anaesthetist faces a predictable stress 
response in his patients is at the time of endotracheal intubation. It is well 
known that laryngoscopy and intubation produce marked increases in heart rate 
and blood pressure (Siedlecki, 1975), which carries with it a risk of myocardial 
stra in . The problem  has been extensively reviewed by Ng (1985). This 
response is associated with the release of catecholamines in large amounts 
(Russell et al., 1981; Derbyshire et al., 1983). There are various techniques by 
which this intubation-related stress response can be attenuated, all of which
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depend on reduction in input stimuli by local anaesthetics or centrally-acting 
analgesics, or the peripheral b lockade of adrenerg ic responses. These 
methods include the use of lignocaine both top ica lly  and by intravenous 
in je c tio n  (S to e ltin g , 1978); the a d m in is tra tio n  of be ta -b lo ck ing  drugs 
(Siedlecki, 1975); the use of direct-acting vasodilators (Stoelting, 1979); and 
the use of large doses of opiates, notably fentanyl and alfentanil (Stanley et at., 
1980, Crawford & Fell, 1987). All of these techniques have disadvantages 
related to either cardiovascular or respiratory depression, and none of them 
directly inhibits the release of catecholamines.
As has been demonstrated in previous chapters, magnesium seems to have 
relatively minor cardiovascular side effects at moderate blood levels, despite 
its apparently useful anti-adrenergic properties. Such cardiovascular effects 
as do occur are likely to be beneficial to a stressed myocardium - reduction in 
afterload and a decrease in heart rate. The only respiratory depressant effect 
of this agent is related to its well-known ability to potentiate the action of the 
non-depolarising neuromuscular blocking drugs (Ghonheim & Long, 1970). The 
stress of endotracheal intubation therefore seemed an appropriate model in 
which to  investiga te  the a b ility  of magnesium to  con tro l card iovascu lar 
disturbances and to inhibit the release of catecholamines under repeatable and
controlled situations.
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7.2 METHODS
The study was approved by the Ethics Committee of Hillbrow Hospital and the 
University of Witwatersrand and all patients gave informed consent.
7.2.1 Patient selection: Participants in the trial were male ASA l- ll patients
booked fo r elective m axillo-facia l surgery in which the anaesthetic 
techn ique  would requ ire  endo trachea l in tu ba tio n . Patients were 
randomly allocated to one of two Groups, Group A or Group B, using 
tables of random numbers. There were 15 patients in each group.
7.2.2 Anaesthetic Technique. All patients were premedicated with diazepam 10
mg p.o. 1 hour preoperatively. Under local anaesthesia, an intravenous 
cannula was inserted into one forearm for infusion of drugs, and a central 
venous line was placed via an antecubita l vein fo r blood sampling. 
Anaesthesia was induced with a sleep dose of thiopentone, and Group A 
patients then received an infusion of MgS04 60mg/kg i.v. over 1 minute. 
Group B subjects received an equivalent volume of saline also over 1 
minute. During these infusions, 50% nitrous oxide in oxygen was 
inhaled. Subjects in both groups then received suxamethonium 1mg/kg 
intravenously. Tracheal intubation was performed 60 sec. after the 
administration of suxamethonium. Based on the rapidity of onset of the 
anti-adrenergic effect of magnesium (see chapter 6), this timing ought 
to have allowed for the magnesium to exert its full effect. The person 
p e rfo rm in g  the in tu b a tio n  and the  la b o ra to ry  s ta ff pe rfo rm in g  
catecholamine estimations were blind as to the group to which the 
patient belonged.
7.2.3 Catecholamine Estimations. Blood samples for estimation of catechol­
amines were taken by an assistant at the following times: immediately
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prior to induction, immediately prior to intubation, Immediately following 
intubation and at 2 and 5 minutes after intubation. Tubes with blood 
samples fo r plasma catecholam ine measurement were immediately 
placed on ice. Samples were centrifuged at 3 000 revolutions per minute 
for 10 min at 4° C. Aliquots of the serum were stored at -70°C for not 
longer than 1 week. Fractionated serum catecholamine concentrations 
were de te rm ined  using reversed-phase  h igh -pe rfo rm ance  liq u id  
chromatography with electrochemical detection and an internal standard 
(K rs tu lov ic , 1982; Causen & Carruthers, 1982). The lower lim it of 
sensitivity of this method is 10 pg/ml (see Appendix A).
Standard ECQ leads were monitored throughout the procedure and blood 
pressure was monitored non-invasively using an automatic oscillotonometric 
device which recorded the blood pressure every 60 sec. Heart rate was also 
recorded every 60 sec. Statistical analysis was performed using Student’s 
t-tes t to  detect differences if any between the groups. S ignificance was 
defined as (p <0.05).
7.3 RESULTS
Results are reported as means _±_ 1 S.E.M.
The mean thiopentone dose used in Group A was 304.6 ±_ 15.2 mg and 322 ±_ 
18.4 mg in Group B. There was no significant difference between the groups.
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7.3.1 Serum Magnesium: Baseline serum magnesium concentrations were 0.85
_±_ 0.24 mmol/l in Group A and 0.81 ± 0 .3 1  mmol/l in Group B. In Group 
A serum magnesium levels increased to 2.95 ±_ 0.56 mmol/l follow ing 
intubation and remained unchanged in Group B.
7.3.2 C ard iovascu lar System: Induction of anaesthesia produced minimal 
non-significant changes in heart rate and blood pressure in both groups. 
In the magnesium group the injection of magnesium produced a rise in 
heart rate of 13 ±_ 3.9 beats per minute from a pre-induction mean of
92.2 j±_ 2.9 b.p.m.; in the control group there was no significant change 
in heart rate from the baseline level of 90.4 ±_ 2.5 b.p.m. Following 
intubation heart rate increased to a maximum mean value of 120.9 +.5.8 
beats per minute at 2 minutes post-intubation in the control group and 
in the magnesium group heart rate remained virtually unchanged from 
post-magnesium values at 107.3 .±.3.9 beats per minute. The difference 
between groups at 2 min. post-intubation was significant at the 0.05 level 
(figure 7.1)
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Figure 7.1 The effect of either MgSOA or saline on heart rate at the time of endotracheal 
intubation.
* -p<0.05
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Neither magnesium nor saline produced significant changes in systolic 
or d iastolic arterial blood pressures. Systolic blood pressure prior to 
intubation was 108.4 _±_ 3.2 mmHg in the magnesium group and 105.5 ±_
3.3 mmHg in the control group. At 2 minutes after intubation systolic 
blood pressure had increased to 128.1 _±_ 5.3 mmHg in the magnesium 
group and to 143.9 j l  4.8 mmHg In the control group (p<0.05, figure 
7.2).
mmHg
Prs-lnductlon Post-induction Post-intubation 2 mins 5 mins
Control f t ®  Magnesium
Figure 7.2 The effect of either MgSOA or saline on systolic blood pressure at the time of 
endotracheal intubation.
* -p<0.05
Diasto lic blood pressure Increased in the magnesium group from a 
pre-intubation value of 69.9 ±_ 13.0 mmHg to a post-intubation value of 
82.5 ±_ 15.0 mmHg. In the contro l group d ias to lic  blood pressure 
increased from 68.8 +_ 10.5 mmHg to 96.4 +_ 14.4 mmHg following 
intubation. The difference between the groups was significant at the 
0.02 level.
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7.3.2 Catecholamines: Noradrenaline concentrations prior to induction were 
sim ilar in the two groups: Group A 297.3 _±. 27.9 pg/ml and Group B 
271.4 ±_ 35.5 pg/ml and were not significantly changed by induction of 
anaesthesia . Fo llow ing  in tu ba tio n , no radrena line  concen tra tions 
increased to 626.1 _±_ 59.4 pg/ml in Group B and to 469.4 j^3 1 .1  pg/ml 
in Group A (p < 0 .0 5 ). Two m inutes a fte r in tubation  noradrenaline 
concentrations in Group B increased to 944.6 ±_ 68.7 pg/ml whilst in 
Group A the noradrenaline value was 532.5 _±_30.1 pg/ml (p<0.01). Five 
minutes after intubation noradrenaline concentrations were 790.7 .±.68.7 
pg/ml in Group B and 462.7 40.0 pg/ml in Group A (p <0.01, figure
7.3).
Initia l adrenaline levels were m ildly elevated in both groups, probably as 
a result of the stress of impending surgery, despite the fact that the 
patients were apparently adequately premedicated. This effect has been 
described before (Derbyshire et al, 1983). Adrenaline values fell in both 
groups following induction of anaesthesia from 94.5 _±_16.9 pg/ml to 68.3 
_±_ 11.2 in Group A and from 113.9 ±_ 19.5 pg/ml to 74.9 .±.14.2 pg/ml in 
Group B. In group A adrenaline concentrations remained at baseline 
levels throughout the study. In Group B, adrenaline concentrations 
increased follow ing intubation to 158.9 ±_ 19.7 pg/ml (p<0.01) and to 
279.6 ±_ 92.3 pg/ml (p<0 .05) two minutes after intubation. At five 
m inutes after in tubation adrenaline concentra tions had returned to 
post-induction values and were not significantly different from Group A 
(Figure 7.4).
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Pre-induction Post-induction Post-Intubation 2 mins 5 mins
Control Watm. Magnesium
Figure 7.3 The effect of either MgS04 or saline on noradrenaline levels at the time of 
endotracheal intubation.
*-p<0.05  h— p<  0.01
pg/ml 
400 --------
Pre-induction Post-induction Post-intubation 2 mins 5mins
Control m  Magnesium
Figure 7.4 The effect of either MgSO4 or saline on adrenaline levels at the time of endotracheal 
intubation.
* - p<0.05 +-p<0.01
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7.4 DISCUSSION
The ability of magnesium ions to inhibit the release of catecholamines from both 
the adrenal gland and from peripheral adrenergic nerve terminals has been 
known for over twenty-five years (Douglas & Rubin, 1963), and is now well 
established in laboratory experiments (Lishajko, 1970; Dandavino et al., 1977; 
Kirpekar & Misu, 1967; George & Leach, 1971), but the action of increased 
serum magnesium concentrations on the output of catecholamines in vivo has 
been poorly investigated. Although Lenz et al (1987) showed a small increase 
in noradrenaline values after magnesium infusion, they attributed this rise to 
re flex ac tiva tion  of the sym pathetic nervous system by reduced arteria l 
pressure; noradrenaline levels in this study remained within normal lim its. The 
present study has shown that magnesium can significantly attenuate the output 
of catecholamines at the time of endotracheal intubation and thus reduce the 
severity of cardiovascular disturbances.
The cardiovascular effects observed in this study were particularly interesting. 
It might be expected that magnesium would produce a slowing of the atrial rate 
by inhibiting the calcium mediated depolarizing current in pacemaker tissue, 
and this effect has been demonstrated in Isolated animal hearts (Turlapaty & 
Carrier, 1973). However, in the intact animal the ability of magnesium to 
inhibit the release of acetylcholine from the vagus nerve may predominate 
(Somjen & Baskerville, 1968) and this could explain the mild increase in heart
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rate seen in this experiment. Although this result is slightly at variance with the 
earlier studies described in chapter 5, this discrepancy is small, and species 
differences may account for it. Despite this initial, small increase in heart rate, 
there  was no fu rth e r increase in heart rate fo llo w ing  in tuba tion  in the 
magnesium group. Although heart rate in the control group was significantly 
lower than that in the magnesium group prior to intubation, the post-intubation 
heart rate in the con tro l group was s ign ifican tly  h igher than that in the 
magnesium group. This was presumably due to the fact that adrenaline 
concentrations in the magnesium group did not increase above baseline values 
whereas in the control group there was a significant increase in adrenaline 
concentrations.
The vasodilator effects of magnesium have been well described (Ghonheim & 
Long, 1970; Turlapaty & Carrier, 1973; Somjen & Baskerville, 1968; Altura & 
A ltu ra , 1978a; K e lly  et a l, 1960; Farm er & C am pbe ll, 1967), and are 
characterized by a mild and transient fall in blood pressure which is associated 
w ith peripheral vasodilata tion and a consistent increase in cardiac index 
(Mroczek et al, 1977; Chapter 5, vide supra). Magnesium has also been shown 
to reduce the responsiveness of vascular smooth muscle to noradrenaline 
stimulation (Farmer & Campbell, 1967). In the present study, increases in both 
systolic and diastolic blood pressure were less in the magnesium group than 
those  seen in the co n tro l g roup. In ne ithe r g roup was the release of 
noradrenaline to ta lly prevented but the noradrenaline levels in the magnesium
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group were significantly lower than those seen in the control group. The 
improved control of blood pressure in the magnesium group was probably 
therefore due to a combination of the vasodilatory effects of the ion and the 
inhibition of catecholamine release.
This study thus provides the first evidence that elevated serum magnesium 
concentrations can inhibit the release of catecholamines during periods of 
stress. This response is almost certainly due to direct calcium antagonism at 
adrenergic nerve terminals and in the adrenal gland. It might be argued that 
magnesium is producing its effect by a central sedative mechanism but this is 
unlikely as magnesium crosses the blood-brain barrier with difficulty, and has 
little  or no central sedative effect even at much higher serum levels than those 
used in the present study (Somjen et al, 1966).
These actions of magnesium in p ro tecting  against the harmful effects of 
endotracheal intubation are probably not superior to the effects of the potent 
short-acting opiate agents, fentanyl and alfentanil. A lfentanil in particular 
shows considerable promise in this regard (Crawford & Fell, 1987). However, 
the use of opiates has been associated with muscle rigid ity, bradycardias, 
hypotension, and respiratory depression and in those circumstances in which 
these com p lica tion s  may be undesirable  magnesium could be a useful 
alternative. In the case of patients with pregnancy-associated hypertension, 
although the use of intravenous opiates has been advocated to attenuate the
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potentially life-threatening hypertensive response to intubation at the time of 
caesarean section, the use of such drugs carries obvious hazards in terms of 
foetal depression. A serum magnesium level of 2-4 mmol/l at the time of 
endotracheal in tubation may be particu la rly  valuable in the hypertensive 
pregnant patient. In a brief study, this possible protective effect of magnesium 
in patients with pregnancy-associated hypertension was confirmed (Cork et al, 
1984), w ith  no apparent de trim enta l e ffects on the foetus. Even where 
magnesium has been used to control the convulsive risk in these patients, it 
would seem sensible to confirm the serum concentration of magnesium prior to 
the induction of anaesthesia, as standard doses of MgS0 4  frequently fail to 
produced this desirable therapeutic level. A further intriguing possibility is that 
co m b in a tio ns  of s h o rt-a c tin g  op ia tes  and m agnesium  may o ffe r good 
cardiovascular control at lower doses of both agents and therefore with fewer 
side effects. This possibility remains to be evaluated.
Magnesium has also been shown to reduce fasciculations (De Vore & Asrami, 
1980) and potassium release (Aldrete et al, 1970; James et al, 1986) following 
suxamethonium and these actions combined with the cardiovascular control 
that can be achieved by the use of magnesium may be of value. Firstly, the 
reduction in fasciculations should reduce the post-operative muscle discomfort 
which commonly accompanies the use of depolarizing relaxants. Secondly, by 
reducing the incidence and severity of the fasciculations, magnesium might 
p ro te c t ag a in s t the increase  in in tra o cu la r pressure w hich  fre q u en tly
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accompanies the onset of suxamethonium paralysis and this would obviate the 
need fo r  the  p o te n tia lly  dange rous  use o f a p re tre a tm e n t dose o f a 
non-depolariz ing relaxant in patients w ith open eye in juries. Thirdly, by 
preventing the release of potassium at the time of depolarization, magnesium 
should offer protection in patients with electrolyte disturbances. None of these 
possibilities have been studied at the present time.
This study has, therefore, confirmed the in vitro work which demonstrated that 
excess magnesium can inhibit the release of catecholamines, probably by 
calcium antagonism at adrenergic nerve terminals and the adrenal gland. It has 
also shown that th is  effect occurs at c lin ica lly  adequate and safe serum 
concentrations of magnesium, similar to those advocated for the management 
of pre-eclam ptic toxaemia, and it has demonstrated that th is effect is of 
sufficient magnitude as to be of use in clinical situations. This inhibition of 
ca techo lam ine release coupled w ith the an ti-ad renerg ic  e ffects already 
demonstrated make magnesium a potentially very valuable agent in conditions 
of ca techo lam ine excess, but its role in such cond itions remains to  be
evaluated.
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8. MAGNESIUM AND THE MANAGEMENT OF 
SEVERE TETANUS
Very severe tetanus is characterized by cardiovascular instability and other 
signs of autonomic nervous system disturbances. These disturbances have 
been shown to be due mainly to over activ ity of the sympathetic nervous system 
and are associated with elevated circulating catecholamine levels (Kerr et al, 
1968; Keilty et al, 1968). Prys-Roberts and others (Prys-Roberts et al, 1969) 
used propranolol to control the characteristic tachycardias and hypertension, 
and this approach has become standard practice (Kerr, 1978). Addition of 
vasodilator drugs including phentolamine (Alfrey & Rauscher, 1979; Goldman 
et al, 1979), bethanidine (Kanarek et al, 1973) and phenoxybenzamine (Furste, 
1980) has been recommended. More recently, labetalol has been used fo r its 
added a -b lo c k in g  properties (Dundee & Morrow, 1979; Omar et al, 1979; 
Connor et al, 1979). Very heavy sedation has been claimed to reduce the 
incidence of autonomic dysfunction (Cole & Youngman, 1969; Edmondson & 
Flowers, 1979) but cardiovascular instability and elevated catecholamine levels 
may persist in severely intoxicated patients (Kerr et al., 1968; Buchanan et al, 
1979) and the use of adrenergic blocking drugs to control the peaks of pulse 
rate and blood pressure is recommended in addition to sedation (Kanarek et al,
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1973; Edmondson, 1980). It is now widely accepted practice to utilize deep 
sedation, coupled with muscle relaxants and positive pressure ventilation as the 
mainstay of treatment in an attempt to minimize input stimuli which may result 
in excessive autonomic activ ity. In some patients, however, these disturbances 
persist, despite very heavy sedation to the point of virtual anaesthesia. In this 
group of patients the m ortality has been quoted as being in excess of 50%, even 
with the addition of adrenergic blocking drugs (Wesley et al, 1983) and it has 
been suggested that p-adrenergic blockade may have contributed to the fatal 
outcome in some of these patients. The use of p-adrenergic blocking drugs is 
not w ithout hazard, as the heart may depend on p-adrenergic activ ity  to 
maintain adequate tissue perfusion (Kerr, 1979). The commonest cause of 
death in these circumstances is sudden, unexpected cardiac arrest (Kanarek et 
al, 1973; Kerr, 1979; T ru jillo  et al, 1980) and this has been associated with the 
use of p-blockers (Edmondson & Flowers, 1979; Buchanan et al, 1978). Where 
adrenergic blockers are used, it is not uncommon to be faced with the problem 
of a relative overdose of these agents when the spasm of adrenergic discharge 
a b ru p tly  te rm in a te s . If it w ere  p o s s ib le  to  p re v e n t the re le a se  of 
catecholamines, this would be an attractive alternative to trying to block their 
a c tio n s . The a n ti-a d re n e rg ic  a c t iv ity  o f m agnesium  w hich has been 
dem onstrated in previous chapters as being po ten tia lly  useful in c lin ica l 
situations suggests that this agent may have a role in the management of the 
cardiovascular disturbances associated with severe tetanus. If, in addition, 
magnesium also inhibited the release of adrenaline and noradrenaline from the 
adrenal gland and from peripheral adrenergic nerve terminals, this would add
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significantly to the ease w ith which the cardiovascular disturbances could be 
managed and should decrease both morbidity and mortality. Furthermore, the 
well-known neuromuscular blocking properties of this agent (Engbaek, 1952; 
Del Castillo & Engbaek, 1952; Jenkinson & Engbaek, 1954; Jenkinson, 1957) 
could be of value in co n tro llin g  spasms. It the re fo re  seemed w orthy of 
investigation as a potential therapeutic agent in very severe tetanus.
8.1 METHODS
All patients admitted to the intensive care unit with a diagnosis of severe tetanus 
were treated by standard methods based on neuromuscular blockade and deep 
sedation, but omitting the use of p-blockers. Sedation was gradually increased 
as indicated by the patient’s condition up to a pre-set maximum. The drugs and 
dosage schedules used are illustrated in table 8.1.
Drug
Diazepam
Morphine
Chlorpromazine
Phenobarbitone
Table 8.1
In itia l Dosage
10mg every 2 h 
5mg every 2 h 
50mg every 12 h 
50mg every 12 h
Maximum Dosage
20mg every hour 
10mg every hour 
100mg every 6 h 
100mg every 6 h
Table 8.1 Sequence and dosage in which sedative drugs were administered 
to adult patients with severe tetanus. Dosages were appropriately scaled 
down for children.
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Muscle relaxation was maintained with 10 mg of alcuronium i.v. as necessary 
to control persistent spasms. This form of therapy was followed for at least 7 
days.
At the end of seven days, the patient’s response to therapy was assessed. 
Criteria for judging current therapy as unsatisfactory were arb itrarily defined as 
follows: fluctuations of systolic arterial blood pressure of more than 40 mmHg 
per day, fluctuations of pulse rate of more than 40 beats per minute in a 24 hour 
period and frequency of spasms of more than one per hour. If all these criteria 
were met, the patient was then admitted to the trial.
At the time of admission to the tria l, all patients had an arterial line placed, 
usually in the radial artery, using a 22G teflon cannula. This was to facilitate 
blood pressure monitoring, and to provide easy access fo r the frequent blood 
samples that the study required. Where possible, a flow-directed thermodilution 
pulmonary artery catheter (Edwards 93A-131-7F) was inserted at the same time.
Magnesium sulphate in fus ions have achieved an accepted place in the 
management of pre-eclamptic toxaemia (Pritchard & Pritchard, 1975; Cavenagh 
& Knuppel, 1981) and it was decided to use therapeutic regimes borrowed from 
standard obstetric practice as the basis for the use of magnesium in tetanus. 
Accordingly, each patient was given a loading dose of 70mg/Kg of magnesium 
sulphate as an infusion over 5 minutes. This was followed by an infusion at 
whatever rate was required to maintain a steady state blood level of between
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2.5 and 4 mmol/litre. Serum magnesium levels were monitored every 4 hours, 
using a tom ic  a b so rp tio n  sp e c tropho tom e try , and serum ca lc ium  levels 
m onitored on a da ily basis along w ith all the routine daily investigations. 
Cardiac output was estimated by therm odilution using 10 ml of iced 5% dextrose 
as an indicator and a Hewlett Packard cardiac output computer (HP 78231C). 
Measurements were made prior to the start of magnesium therapy, and then 
tw ice daily for the next two days. Measurements were made at the same time of 
day, and at least two hours after any disturbing procedure such as tracheal 
suction or physiotherapy, in order to ensure that measurements were relatively 
comparable. Readings of central venous and pulmonary artery wedge pressures 
were also made, and a value for peripheral vascular resistance calculated. In 
all patients, blood pressure recordings were made on an hourly basis, but peaks 
of pulse rate and blood pressure occurring between these intervals were also 
no ted  th ro u g h o u t the cou rse  o f the illn e ss . To m in im ize  the risks  of 
catheter-related sepsis, the pulmonary artery catheter was removed after two 
days, but the arterial pressure monitoring maintained continuously over the 
next two weeks using multiple sites. Following the institution of magnesium 
therapy, other forms of sedation were gradually decreased as the patient’s 
condition allowed, commencing with the phenothiazines and benzodiazepines. 
If the patient failed to respond to magnesium therapy, provision was made in 
the protocol for additional doses of sedatives as well as allowance being made 
for the addition of a-adrenergic blockers in extreme cases. The magnesium 
infusion was gradually reduced after two weeks, or earlier if the patient’s
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condition permitted, but if cardiovascular instability recurred, the infusion was 
increased again.
8.2 RESULTS
Out of a total of twenty-one patients with tetanus admitted to the intensive care 
unit of the Paryrenyatwa Hospital, Harare, Zimbabwe, over a two year period 
from 1981 to 1983, ten patients qualified for admission to the trial. There were 
two children in the group, both under six years of age. Neonates were not 
considered for admission to the trial. Of the ten patients, eight survived. The 
cause of death in one patient was overwhelming sepsis and in the other severe 
pulmonary infection which predated her admission to the unit. Of the non-trial 
group, three patients died, two of whom had sympathetic overload, but died 
before the seven day point. One of these patients, a 70 year-old male, died 
suddenly, follow ing a sudden fall in blood pressure, and a myocardial infarction 
was suspected. The other two both had aspiration pneumonia on admission, 
and this was the probable cause of death in these cases. In the pretrial period, 
therefore, there was a tota l of 12 patients with sympathetic overload, four of 
whom died, two without receiving magnesium. The mortality in the pretrial 
group was 3 out of 11, whilst in the post-trial group, 2 patients died out of 10. 
Of the 5 deaths over this period, four of these were due to infections with 
organisms resistant to the limited range of antib iotics available in Zimbabwe at
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the time. One of the deaths in the pretrial group was probably the result of 
sympathetic overactivity. The surviving 8 patients in the non-study group were 
all easily controlled at re latively low levels of sedation and were not studied 
further.
The magnesium infusion was maintained for a mean of 22 days with a range of 
9 to 31 days. In every surviving case, it was possible to stop all sedation except 
for morphine for the last few days, and to contain stiffness and spasms with 
magnesium alone. This allowed for a comfortable, awake and co-operative 
patient.
In all but one case, sa tis fa c to ry  contro l of ca rd iovascu la r function  was 
achieved. The one case in whom control of the cardiovascular system could 
not be established was the one who died of severe sepsis. Since this patient’s 
problems were related to sepsis, additional cardiovascular agents were not 
used in this case, although deep sedation was maintained. No other case 
required modification of the protocol. Typical records are illustrated in figures 
8.1, 8.2, 8.3 and 8.4.
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Figure 8.1 Hourly heart rate and blood pressure recordings in a patient with severe 
cardiovascular disturbances at Day 7 prior to admission to the trial
24 HOUR OBSERVATION
HR — |—  BP
Figure 8.2 The same patient as in figure 8.1 at Day 9, two days after the commencement of 
magnesium therapy.
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Figure8.3 Cardiovascular disturbances in another patient on Day 12, the day of commencement 
of magnesium therapy. Between 23:00 and 24:00 the infusion was interrupted due to 
a blocked line. Note the re-appearance of instability at this time, and the drop in serum 
magnesium to below therapeutic levels.
24 HOUR OBSERVATION
HR — (—  BP
Figure 8.4 The same patient as in figure 8.3 at Day 13.
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The range of blood pressure and pulse rate encountered before and during 
magnesium therapy is illustrated in table 8.2. The maximum pulse rate was 
reduced in all but the one case, and the difference in maximum heart rate before 
and during the magnesium infusion was h ighly s ign ificant. There was no 
significant change in the minimum rate. The maximum systolic blood pressure 
was also reduced in 9 cases, the difference again being significant.
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Table 8.2
Pre-magnesium
SBP/DBP SBP/DBP Heart Rate
Max Min Max Min
160/110 60/40 165 60
240/110 90/40 160 68
160/70 110/60 130 82
150/100 90/60 160 110
160/90 80/40 150 104
170/120 130/100 164 80
176/130 60/20 140 64
142/102 80/45 152 94
150/70 90/50 150 80
130/60 60/30 146 74
Means 163.8^28 85_±_21 151.7+JO 82 4J6
Post-m agnesium
SBP/DBP SBP/DBP Heart Rate
Max Min Max Min
98/58 86/47 118 110
120/50 90/40 100 60
150/90 80/50 170 100
130/70 100/40 128 102
120/70 90/50 118 100
110/70 100/60 108 84
130/80 110/70 120 90
124/90 100/72 144 92
140/60 80/50 104 72
100/60 84/40 104 72
Means 122+.16* 91.4JJ5 121_±J20* 92.9_±_9
Table 8.2 Pulse rates and blood pressures before and after magnesium therapy. 
Pre-magnesium values represent the greatest fluctuation in a 24 hour period for 
the 2 days p rio r to  treatm ent. The post-magnesium values represent the 
greatest fluctuations during the firs t week after starting treatment.
* - p < 0.05
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Pulmonary artery catheterisation was achieved in six cases. It was decided not 
to attempt it in the case of overwhelming sepsis, due to the risks of bacterial 
endocarditis, nor was it attempted in the two children. In one other case, 
catheterisation was impossible for technical reasons. The values for cardiac 
indices obtained are illustrated in table 8.3.
Table 8.3
Pre-Magnesium Post-Magnesium
HR Cl SVI SVR HR Cl SVI SVR
130 4.12 31.4 970 116 2.79 37.9 860
106 4.46 47.4 1129 90 2.79 52.1 732
120 4.72 40.3 869 80 4.00 50.0 695
124 5.51 44.9 1067 76 5.23 68.9 636
110 5.34 48.5 1109 60 7.08 68.0 745
168 7.00 41.7 1008 72 4.29 49.9 868
Means 126 5.19 42.4 1025.3 82.3* 4.68 54.5* 757.3
SEM 9.1 0.4 2.5 44.7 7.8 0.6 4.9 37.5
Table 8.3 Cardiovascular indices in six patients prior to the start of magnesium 
therapy, and two days after magnesium therapy had been instituted.
HR - heart rate in beats per minute 
Cl - cardiac index in l/m in/m 2 body surface area 
SVI - stroke volume index in ml/beat/m2 body surface area 
SVR - systemic vascular resistance in dyne.s.cm '5 
* - p < 0.05
+ - p<0.01
Not surprisingly, all patients exhibited an elevated cardiac index which was not 
markedly reduced by the magnesium infusion. In these patients pulse rate at 
the time of doing the readings was reduced in every case and the difference in 
mean pulse rate between the pre-magnesium and post-magnesium values was
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s ta tis tica lly  sign ificant (p< 0 .05 ). There was a parallel increase in stroke 
volume in all patients (p<0.05  for the difference in means between pre- and 
post-m agnesium  groups) p robab ly  due to  a reduction  in a fte rload. The 
systemic vascular resistance was relatively low prior to the use of magnesium, 
presumably as a result of the chlorpromazine and barbiturate included in the 
sedative regime. Further significant reductions followed the use of magnesium 
(p <0.01). Pulmonary capillary wedge pressure was within the normal range 
(5-12 mmHg) in all cases both before and after the commencement of the 
magnesium infusion, and appeared to be unaffected by it. Central venous 
pressure was sim ilarly unchanged by magnesium in all cases.
In order to maintain a steady level of serum magnesium of between 2.5 and 4 
mmol/L, an infusion rate of between 1 and 3 gm per hour was required. However, 
there was wide individual variation and also considerable day-to-day variation 
w ithin each individual. No firm guide-lines could be determined for the infusion 
rate, and frequent estimation of the serum magnesium was the only safe way to 
keep control of the magnesium level. In two cases the serum magnesium rose 
to over 6 mmol/l on one occasion in each patient. These patients both exhibited 
prolongation of the PR interval with runs of nodal rhythm. The arrhythmias 
responded promptly to the infusion of calcium gluconate and reduction in the 
infusion rate of the magnesium sulphate, and did not recur. No other serious 
cardiac disturbances were noted in the series.
The commonest biochemical complication was a fall in serum calcium. This is 
not surprising, as magnesium inhibits the release of parathyroid hormone (Ebel
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& Gunther, 1980). Calcium supplements were needed frequently in order to 
maintain the serum calcium level within the normal range. In no patient was the 
serum calcium level allowed to fall below 1.7mmol/l.
Four p a tie n ts  showed s ign s  of h igh o u tp u t renal fa ilu re  p r io r  to  the 
commencement of magnesium sulphate therapy, w ith elevations of serum 
creatinine and urea, and a fall in creatinine clearance, despite adequate urine 
output in three of the four cases. One patient in this group died, this being the 
patient with severe sepsis, this patient ultimately developing oliguric renal 
failure as part of his septicaemic state.
The levels of serum magnesium used in this study (2.5-4 mmol/l) produced 
profound neuromuscular b lock in all patients. As a result, the amount of 
alcuronium required was drastically reduced from a general range of 250 - 
300mg per day (approximately one dose every 45 to 60 min.) to around 100mg 
per day (approximately 2 to 3 hours between doses).
8.4 DISCUSSION
This is not the first time that a role for magnesium in the management of tetanus 
has been suggested. Blake (1906) described two cases of severe tetanus 
treated with intrathecal magnesium sulphate. One patient with a very heavy 
bacteraemia died twelve hours after the injection, but the other received 5
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intrathecal injections of 12.5% magnesium sulphate over a ten day period and 
made a full recovery. In the same year, Meltzer described the use of magnesium 
by intravenous, intraspinal and subcutaneous routes and concluded that no 
other agent then available was as as effective in control of symptoms as was 
magnesium (Meltzer, 1906b). More recently, Natu and his colleagues described 
hypomagnesaemia in a series of 36 patients and correlated the level of serum 
magnesium with the severity of the disease (Natu et al, 1980). They suggested 
a role for magnesium infusions in the management of the condition, at least in 
those pa tien ts  in whom the serum magnesium was low. The fin d in g  of 
hypomagnesaemia was not, however, confirmed in the present study.
Although it is impossible to make any firm  statement about mortality in a small 
series like this one, the fact that no patients died from causes attributable to 
their tetanus was pleasing, particularly in view of the fact that four patients had 
episodes of high output renal failure, and only one of these died. Seedat et al. 
(1981) found that their patients with this complication of tetanus had a 65% 
mortality. The two deaths were both related to infections (one pulmonary, the 
other septicaemia of unknown source) with organism that were resistant to the 
available antibiotics. It is possible that, with a wider spectrum of antib io tics to 
call upon, these patients could also have been saved.
The control of the cardiovascular effects of severe tetanus demonstrated in this 
study are most encouraging. At the time of performing this study, facilities for 
the d ire c t measurement of catecholam ine levels were not available, and 
therefore the mode of action of magnesium in these cases remains conjectural.
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The reduction in peripheral resistance that occurred could be mediated by a 
direct effect on the blood vessels (Kelly et al, 1960; Farmer & Campbell, 1967; 
Overbeck et al, 1969; George & Leach, 1971; Altura & Altura, 1981 a, b & c, chap 
5). However, in vivo, the hypotension produced by raised serum magnesium is 
generally found to be evanescent (Pritchard & Pritchard, 1975; Maxwell et al, 
1965; Dandavino et al, 1977; Mroczek et al, 1977). One of the features of this 
study was the consistent reduction in systolic blood pressure, and the control 
obtained over the paroxysmal episodes of hypertension. Although the daily 
range of blood pressure fluctuation still exceeded the admission criteria for the 
tria l, the range of blood pressure was reduced in 8 of the 10 subjects and 
unchanged in one. The only case in which the range in blood pressure 
deteriorated was in the patient with severe progressive septicaemia. It is 
unlikely, therefore, that the control of blood pressure achieved was due solely 
to the direct vasodilator effects of magnesium. The reduction in heart rate that 
occurred is also unlikely to be due to a direct action of magnesium. The action 
of magnesium is to produce a mild slowing of heart rate in the isolated heart 
(Somjen & Baskerville, 1968), and this has also been shown to occur in the 
in tact animal (see chapter 5). However, it has also been described that 
inhibition of acetylcholine release at the vagal terminals may predominate 
resulting in a mild increase in heart rate in humans (Garb, 1951; see chapter 7). 
The observed reduction in heart rate was very much greater than that seen in 
the animal experiments at sim ilar magnesium levels, and opposite to the change 
seen in h e a lth y  human su b je c ts  w here m agnesium  was used p r io r  to 
endotrachea l in tuba tion  (chapter 7). Thus, it seems probable tha t th is
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reduction in heart rate was, at least in part, due to a lessening of sympathetic 
tone. The range of heart rate fluctuation was also reduced in every case except 
the patient with septicaemia. It is most likely, therefore that the improvement 
in cardiovascular function in these subjects was due in some degree to a 
reduction in the level of circulating catecholamines. However, although it has 
been shown that magnesium infusion can inhibit the release of catecholamines, 
this study does not allow the assumption that the beneficial effects seen were 
entirely due to this action of magnesium. Whilst there is a strong circumstantial 
case to be made for this possibility, further evidence is required before this 
claim can be made with confidence.
Contrary to the popular view (see chapter 2), magnesium is not an anaesthetic 
nor even a major central nervous system depressant, unless applied d irectly to 
the nervous tissue via the cerebrospinal flu id (Mordes & Wacker, 1978). Somjen 
et al (1966) showed th a t, p rov ided  v e n tila tio n  was m ain ta ined, serum 
magnesium levels of up to 8 mmol/L had no sedative effect in humans. Aldrete 
et al (1968) found that sim ilar levels of magnesium produced a sleep-like state 
in dogs, but not anaesthesia. They attributed the decline in conscious level to 
impaired cardiovascular function. The failure of intravenously administered 
magnesium to produce anaesthesia is largely due to the fact that the blood- 
brain barrier is relatively impervious to magnesium and even in long-standing 
deliberate hypermagnesaemia, only small increases in CSF magnesium levels 
were found (P ritchard , 1955). Central ac tions of magnesium, there fore , 
probably did not contribute significantly to the observed results of this study.
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The calcium antagonistic effects of magnesium might be expected to produce 
a reduction in myocardial contractility, and a fall in cardiac output. However, it 
has been shown that, p rovided hypocalcaem ia is avoided, the negative 
inotropic effects of magnesium are minimal (Garb, 1951; Kovacs & O'Donnell,
1975) . The preservation of card iac ou tput at elevated levels is also not 
surprising, as magnesium increases the cardiac output in baboons (chapter 5), 
particularly in the presence of catecholamines (chapter 6). It has also been 
shown that magnesium can increase the cardiac output in normal human 
subjects (Mroczek et al, 1977). Although magnesium diminishes the output of 
catecholamines, it is unlikely that total inhibition of catecholamine release can 
be achieved in the clinical situation. The hazards of p-blockade in the face of 
ct-adrenergic discharge have already been described, and magnesium may offer 
a safer means of contro lling the tachycardias. Not only does magnesium not 
depress myocardial contractility , but the ab ility  of the heart to respond to 
adrenergic stimulation is preserved (Paddle & Haugaard, 1971; Levin et al,
1976) . Indeed, it has been shown that magnesium is essential for the inotropic 
action of adrenaline (Vincent, 1982). It has been suggested that the toxic 
myocarditis occasionally described in tetanus may be merely a manifestation 
of catecholamine excess (Kerr et al, 1968), since the histological changes are 
similar to those described in myocardial damage associated with prolonged 
adrenergic stimulation (Raab, 1963). The failure of magnesium to block the 
increases in ca rd iac o u tpu t caused by adrenerg ic  s tim u la tion  m ight be 
considered a disadvantage. However, it has been shown that, although the 
con tractile  response is preserved by magnesium, the harmful biochemical
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effects of adrenergic drive, such as glycogenolysis, lactate production, and ATP 
degradation are inhibited (Paddle & Haugaard, 1971; Levin et al, 1976). It is 
tempting to speculate, therefore, that magnesium may not only protect the 
cardiovascular system by lim iting the fluctuations in catecholamine levels, but 
also may protect the myocardium from the adverse biochemical effects of 
excess adrenergic drive when it occurs.
In view of the fact that magnesium has been given intramuscularly to obstetric 
patients in whom only lim ited monitoring was used, it m ight be considered that 
it could be used in the conservative management of tetanus. However, in this 
study, magnesium sulphate infusions exerted a far more profound effect on 
neuromuscular transmission than would have been expected from experience 
gained with sim ilar serum levels in obstetrics. Serum magnesium levels of less 
than  5 m m o l/l are g e n e ra lly  rega rded  as h av ing  no more than m ild  
neurom uscular b locking properties, but in patients in th is series marked 
neuromuscular block occurred at levels between 2.5 - 4 mmol/l. This could, 
perhaps have been anticipated as tetanus toxin is known to exhibit a botulinus- 
like action at the motor end plate (Kaeser & Saner, 1970; Melianby & Green, 
1981), producing a sim ilar type of neuromuscular block to that produced by 
magnesium alone, and therefore leading to an additive effect. Whatever the 
mechanism of this enhanced neuromuscular block produced by magnesium, the 
marked neurom uscular b lockade that was found in patients in this study 
precludes recommending the agent for use outside the intensive care unit at 
the present time.
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In conclus ion , magnesium sulphate in fusions have been shown to be of 
po tentia l benefit in ass is ting  the con tro l of card iovascu la r d isturbances 
associated with severe tetanus. Further studies into the use of this agent are, 
the re fo re  ju s tif ie d  in o rder to  answer some of the rem aining questions, 
p a rtic u la r ly  those pe rta in ing  to  the use of magnesium in less severely 
intoxicated patients than those studied in this tria l. It is also necessary to 
demonstrate that catecholamine concentrations can, indeed, be reduced by 
infusions of magnesium.
8.5 MAGNESIUM AND CATECHOLAMINE RELEASE IN TETANUS
A recent case of very severe tetanus presented the opportunity for studying the 
hypothesis tha t magnesium su lphate  in fus ions cou ld  reduce c ircu la tin g  
catecholamine levels and thus improve cardiovascular function.
8.6 CASE REPORT
The patient was a 29 year old black male, previously in good health, who was 
transferred from another hospital with a diagnosis of severe tetanus. The focus 
for his Clostridium tetanii infection was a septic compound fracture of the right 
radius which he had sustained during an assault one week previously. There
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was no record of his ever being vaccinated against tetanus and the phase of 
onset of the disease was only 48 hours . At the time of his transfer, he was 
having fra n k  te ta n ic  spasm s, w ith  op is tho ton o s , risus sa rdon icus  and 
abdom inal r ig id ity  fo r w hich he had received 20mg of diazepam and 11 
ampoules of human anti-tetanus globulin (10 ampoules )Ml, and 1 ampoule 
intrathecaliy). Appropriate antib io tic therapy in the form of penicillin G 2 million 
units 2 hourly IVI had been instituted.
Physical examination findings were normal and his pulse was 130/min, blood 
pressure 150/100 and his perfusion good. However, the most minor stimulation 
provoked genera lised m uscular spasms. The pa tien t was sedated w ith 
diazepam, paralysed with alcuronium, intubated and ventilated. Tetanus toxoid 
was administered, and a thorough debridement of the arm wound performed. 
A tracheostomy was subsequently performed on day 3. In itia lly, the patient was 
controlled on intravenous infusions of alcuronium (10mg/hr), and diazepam 
(5mg/hr). As his illness progressed these doses became to ta lly inadequate as 
muscle spasms, tachycardia and severe hypertensive episodes associated with 
profuse sweating and oro-nasal secretions continued unabated. His muscle 
spasms were eventually controlled on alcuronium, at a dose of 17,5mg/hr but 
his blood pressure remained extremely labile.
Various combinations of diazepam, morphine and chlorpromazine, both as 
continuous infusions and hourly boluses, were tried. At his most unstable, he 
was rece iv ing  a diazepam  in fusion o f 80m g/hr and boluses of 40m g/hr, 
morphine boluses of 30mg approxim ately every 4 hr., and chlorprom azine
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20mg/hr. On one occasion, day 15, he was given 175mg of diazepam, plus 
10mg of morphine in one hour; 195mg of diazepam in the next hour and 115mg 
of diazepam with 25 mg of chlorpromazine in the 3rd hour; the average hourly 
sedation fo r th is day was 120 mg diazepam, 5 mg m orphine and 10 mg 
chlorpromazine. The instab ility  of the patient’s blood pressure on day 18 can 
be seen in figure 8.5, although greater fluctuations in cardiovascular status 
actually occurred than can be shown on this periodic chart.
24 HOUR OBSERVATION
HR — \— BP
Figure 8.5 Hourly heart rate and blood pressure chart on day 18. The patient was receiving an 
average of 120mg diazepam and 7.5mg morphine each hour plus chlorpromazine 60 
mg 6 hourly
On day 19, it was decided to try to stabilize the patient using large doses of 
magnesium sulphate given as a continuous infusion. The patient was being 
paralysed with alcuronium 17,5 mg per hour and the sedatives that were being 
used at that time are shown in figure 8.6.
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A loading dose of 4g magnesium sulphate IVl over 20 minutes was administered, 
followed by a continuous infusion of 1g/hr (see figure 8.6). Serum calcium and 
magnesium levels were measured every 4 hrs, calcium  supplemented as 
required, and the rate of magnesium infusion adjusted to keep the serum 
magnesium level between 2 and 4 mmol/l (see figures 8.5, 8.6, 8.7). This 
required high infusion rates and as a result adequate magnesium levels were 
not achieved until 18.00 hrs on day 20.
Following the institution of magnesium therapy, a d istinct downward trend in 
systolic and diastolic pressures, mean blood pressure and pulse rate were 
noted; and smaller doses of sedatives were required. Once the rate of MgS04 
was increased to above 2gm/hour, no systolic blood pressure of greater than 
170 mmHg was recorded despite the fact that catecholamine levels were still 
elevated at this time. Fluctuations in blood pressure were also less marked. This 
is in contrast to the state prior to the advent of magnesium therapy when 
systolic pressures of over 200 mmHg were common with a range of systolic 
pressure of 140 mmHg. Catecholamine levels were recorded before and during 
the administration of magnesium (see Appendix B). These levels are recorded 
in table 8.4. Once magnesium levels above 2 mmol/l were established (18.00 
hr. day 20) catecholamine levels returned to normal, with the exception of 
dopamine which remained marginally elevated.
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24 HOUR OBSERVATION
HR BP
Figure 8.6 Hourly heart rate and blood pressure changes on day 19 during the introduction of 
magnesium. Diazepam dosage averaged 100mg/hr until 18.00hr. and 80mg/hr 
thereafter. Morphine dosage averaged 2.5mglhr. No chlorpromazine was used.
24 HOUR OBSERVATION
HR — {—  BP
Figure 8.7 Hourly heart rate and blood pressure changes on day 20. Diazepam dosage 
averaged 80mglhr and morphine dosage averaged 5mg every 4 hours. No 
chlorpromazine was used
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24 HOUR OBSERVATION
HR — f—  BP
Figure 8.8 Hourly heart rate and blood pressure changes on day 21. No morphine or 
chlorpromazine was needed., and the diazepam infusion rate was 80mg/hr
24 HOUR OBSERVATION
HR — I—  BP
Figure 8.9 Hourly heart rate and blood pressure changes following the withdrawal of all sedation 
on day 22. Sedation was re-introduced at a rate of 80mg diazepam per hour at 18:00 
hours
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TABLE 8.4
DATE TIME NORADRENALINE ADRENALINE DOPAMINE
06/03/86 09h00 918,59 54,70 47,71
(Day 18) 13h40 747,68 78,71 22,81
16h50 820,92 57,13 40,98
07/03/86 08h30 734,53 59,85 15,78
(Day 19) 09h45 1160,72 118,90 50,34
15h30 1602,64 115,24 98,13
16h 15 1916,56 109,62 164,39
17h30 983,95 58,10 38,30
08/03/86 10h15 429,4 62,48 18,98
(Day 20)
09/03/86 12h00 178,98 21,66 22,80
(Day 21)
Table 8.4 Catecholamine levels during the initiation of magnesium therapy. 
Mg started at 12h00 on 07/03/86.
A ll above va lues  in p ico g ra m s  per ml. N orm al (p ico g ra m s  per ml) : 
Noradrenaline 250 - 400; Adrenaline 10 - 50; Dopamine 0 - 20.
On the morning of day 22, the patient seemed very stable, and the diazepam 
in fu s io n  was s to p p e d . T h is  how eve r p re c ip ita te d  a re c u rre n c e  of 
haemodynamic instability, although this was less marked than prior to the 
institution of magnesium therapy (figure 8.9). Catecholamine levels could not 
be obtained at this time. The patient became increasingly unstable on MgS04 
alone, and diazepam  boluses were re -in troduced a fte r 11 hours, which 
re-established good control. The total sedation now received by the patient 
was 80 mg/hour in addition to a magnesium infusion of 2 gm/hour. No morphine 
or chlorpromazine was needed. This partial recurrence of instability strongly 
argues against the poss ib ility  that the changes seen above were due to 
spontaneous remission of the disease.
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The patient was continued on magnesium and diazepam, and the subsequent 
course of the patient over the fo llow ing  2 weeks was that of progressive 
improvement enabling gradual weaning of all sedatives.
8.7 DISCUSSION
It is apparent from this case report that even massive doses of sedative drugs 
may be unable to prevent the release of catecholamines in large amounts. 
Magnesium has been shown in vitro  to inhib it the release of adrenaline and 
noradrenaline from both the adrenal gland and from peripheral nerve terminals, 
as well as reducing the sensitiv ity  of the a-adrenergic receptors to these 
neurotransmitters (Douglas & Rubin, 1963; Kirpekar & Misu, 1967; Lishajko, 
1970; George & Leach, 1971; Von Euler & Lishajko, 1973). It was shown in 
chapter 7 that this action of magnesium could be confirmed in normal human 
subjects submitted to the stress of endotracheal intubation. This case, however 
represents the first demonstration of the ab ility  of magnesium to reduce the 
level of circulating adrenaline and noradrenaline in the presence of elevated 
circulating catecholamine concentrations. It is of interest that magnesium 
sulphate alone was unable to control the autonomic disturbances in this patient 
once the other sedatives were stopped. Unfortunately, catecholamine levels 
were not obtainable at this time, but it seems like ly that magnesium would have 
continued to inhibit catecholamine release from the adrenal gland. The most
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likely explanation for the recurrence of cardiovascular instability at this time is 
that magnesium is a poor central sedative (Somjen et al, 1966), and that the 
lig h te n in g  level of consc iousness  of the pa tien t led to  an increase in 
sympathetic tone. It has already been shown (chapter 7) that magnesium 
appears to be more e ffective  in b locking  the release of adrenaline than 
noradrenaline. Possibly, sympathetic nerve terminals, which operate at much 
lower levels of noradrenaline than those needed to exert systemic effects 
(Cryer, 1980), are less susceptible to the effects of increased serum magnesium 
levels than are the cells of the adrenal medulla. Whatever the explanation, it is 
clear that, whilst magnesium may be a very useful adjunct in the management 
of the cardiovascular disturbances of tetanus, it is inadequate as a sole agent 
and should be used in addition to adequate sedation.
These two stud ies have dem onstrated tha t magnesium can im prove the 
cardiovascular stab ility in patients with very severe tetanus. It seems likely that 
the mechanism by which it achieves this action is a dual one involving both the 
anti-adrenergic actions of magnesium, and in addition, blocking the release of 
catecholamines from the adrenal medulla. Less sedation is required when 
magnesium is concom itantly infused. Magnesium is therefore a useful adjunct 
to sedation in the management of the cardiovascular disturbances of tetanus.
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9. Magnesium and Anaesthesia for 
Phaeochromocytoma
The a n a e s th e tic  m anagem ent o f a p h a e o ch ro m o cy to m a  p ro v id e s  a 
considerable challenge to the anaesthetist and involves careful control of every 
phase of the procedure. Although there are no controlled tria ls on the subject, 
it is generally accepted that adequate preoperative adrenergic blockade, 
particularly of a-receptors, has enhanced patient safety and improved outcome. 
Preoperative preparation, therefore, usually entails the the use of a-adrenergic 
b lockers such as phenoxybenzamine, w ith the add ition  of 13-adrenergic 
blockers, if necessary, to control tachycardias (Hull, 1986). Intraoperatively, 
the problem is approached on two fronts. Deep anaesthesia, usually with the 
generous use of opiate agonists, Is employed to minimize input stimuli which 
may trigger neurogenically mediated catecholamine release. Control of the 
effects of excess catecholamine release is usually maintained by the use of 
adrenergic blocking drugs such as phentolam ine and propranolol and/or 
vasodilators such as sodium nitroprusside; following tumour devascularization, 
vasoconstrictors may prove necessary (Hull, 1986; Roizen, 1986). Despite all 
of these therapeutic  manoeuvers, the to ta l e lim ination of card iovascular 
disturbances is seldom achieved and some fluctuation in arterial pressure often
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occurs, and a rrhythm ias are common (Roizen, 1986), due to surges of 
catecholamine release in response to minimal stimuli. None of the agents in 
common use has the ability to prevent or reduce the release of catecholamines 
other than by reducing noxious stimuli which may cause hormone release 
through stimulation of the autonomic nervous system. Magnesium, as has been 
shown in the previous chapters, can inhibit the release of catecholamines from 
both the adrenal medulla and peripheral adrenergic nerve terminals, as well as 
blocking catecholamine receptors directly. In addition, magnesium has, as has 
been discussed in previous chapters, a direct d ila tor effect on vessel walls. It 
therefore appeared worthy of a trial in phaeochromocytoma as an adjunct to 
conventional therapy.
9.1 PATIENTS AND METHODS
Over a period of 5 years, magnesium sulphate has been used as an adjunct to 
the anaesthetic management of 16 patients on 17 occasions. In the first of 
these cases, MgS04 was used, based on the rationale presented in previous 
chapters, in response to a situation in which conventional therapy appeared to 
be inadequate to meet the problems presented by the patient. The success 
achieved in the management of this case prompted the study of the remainder 
of the cases presented in this series. Relevant individual patients details are 
presented in the appendix, but the overall findings of this series, the general
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approach to preoperative preparation, and the basic anaesthetic approach 
adopted, with relevant illustrations from selected cases is outlined below.
9.1.1 Patients: The age range of the patients was from 14 years to 55 years. 
There were 5 males and 11 females in the series. Two of the patients 
were pregnant at the time of presentation. One of these was delivered 
by Caesarean section and had her tum our resected on a separate 
occasion (case 4). The other had a malignant phaeochromocytoma for 
which she had had three previous excisions (case 7). In this case, an 
elective caesarean section was performed, and she was subsequently 
managed with radioactive meta-iodobenzylguanethidine (MIBG). Of the 
remainder, two had tumours that were locally invasive, one involving the 
right diaphragm and the other invading the left renal vein and inferior 
vena cava. The first of these patients had pre-existing chronic renal 
dysfunction (preoperative creatinine clearance 42 ml/hr). Two other 
patients had evidence of target organ damage in the form of a strain 
pattern on the ECG with inverted T-waves and depressed ST segments 
in one case, and left ventricular hypertrophy in the other. The remaining 
10 patients all had uncomplicated tumours. Tumour size varied between 
3cm and 12 cm.
9.1.2 P reoperative  p re pa ra tio n : This consisted  p rim a rily  of a-adrenergic 
blockade with either phenoxybenzamine (8 cases) or prazosin (8 cases) 
in increasing dosage until adequate control of symptomatology had been 
achieved. Beta-blockade was added as indicated by the occurrence of 
ta c h y c a rd ia s  and flu id  rep lacem en t perfo rm ed as ind ica te d  by 
cardiovascular measurements. In one case in which the author was
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involved in an advisory capacity on the morning of surgery, the patient 
had been prepared primarily with B-blockade (atenolol 100mg b.d.) and 
a small dose (40mg/day) of phenoxybenzamine (case 9). Fitness for 
surgery was judged in accordance with criteria laid down by Roizen 
(1986), but in case 9 these criteria were not met and surgery probably 
should have been postponed. One case was not prepared preoperatively 
as the diagnosis was made at laparotomy.
Premedication was generally achieved with a combination of diazepam 10mg 
and promethazine 25mg administered orally the night before surgery and again 
on the morning of operation. Despite this aggressive and apparently adequate 
preoperative preparation, several of the patients arrived in the operating room 
w ith  elevated a rte ria l pressures but m inimal o ther c lin ica l evidence of 
catecholamine excess such as sweating and anxiety. This was regarded as a 
m an ifes ta tion  of the s tress of im pending surgery, and not taken as a 
c o n tra - in d ic a t io n  to  the p rocedu re . A sum m ary o f p a tie n t data and 
preoperative presentation is presented in table 9.1.
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Table 9.1
Case Age Sex Preparation D iagnosis Comments
1 14 F Phen, prop Large RA Hypertensive in Theatre
2 45 F Phen, prop Small RA Hypertensive in Theatre
3 54 M Phen, prop V.large RA Renal disease, Diaphragm
4 26 F Praz, aten Small RA Pregnant, poor control
4 26 F Praz, aten Small RA
5 48 M Phen Large LA Renal vein, IVC involved
6 22 F Praz, aten Small RA
7 24 F Phen, aten Multiple Malignant, pregnant
8 26 F Phen, aten Small RA
9 42 M Aten, phen Small LA Inadequately prepared
10 34 F Phen Small LA
11 32 F Praz, aten Small RA
12 51 F Praz, aten Large LA Hypertensive in Theatre
13 39 F Praz, aten Large RA Hypertensive in Theatre
14 28 F Praz, aten Small LA
15 55 F Nil PA Diagnosed intra-op.
16 14 M Praz, aten Large PA
Table 9.1 Summary of patient details
Phen - Phenoxybenzamine 
Praz - Prazosin 
Aten - atenolol
RA/LA - Right/left adrenal tumour 
Diaphragm - diaphragm involved 
IVC - inferior vena cava involved 
PA - Para-aortic tumour
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9.1.3 Anaesthetic technique: In most cases, patients were given a moderate
dose of 3-5 |ig/kg of fentanyl prior to induction of anaesthesia, followed 
by an intravenous infusion of magnesium sulphate (MgS04) 4 0 mg/kg if 
the arrival systolic blood pressure (SBP) was within 20mm/Hg of the 
preoperative baseline, or 60 mg/kg if the arrival SBP was above this 
range. The two pregnant patients received magnesium but no opiate. In 
two other cases who arrived in theatre well contro lled, magnesium 
sulphate was withheld until after induction of anaesthesia In order to 
allow an investigation of the separate effects of anaesthesia and MgS04 
on catecholamine levels. In all patients, arterial and central venous 
pressure monitoring lines were inserted under local anaesthetic prior to 
induction of anaesthesia. Anaesthesia was induced with thiopentone 
and muscle relaxation achieved with alcuronium except in the pregnant 
patients in whom suxamethonium was used. Whilst individual variations 
occurred, the scheme by which MgS04 was administered was as follows. 
If the arterial pressure remained elevated after induction of anaesthesia, 
a fu rthe r bolus of 40 mg/kg MgS04 was adm inistered fo llowed by 
endotracheal intubation. Anaesthesia was maintained throughout with 
nitrous oxide, oxygen and enflurane in all but the first case in which 
halothane was used as It was the only agent available at the time. A 
continuous infusion of MgS04 at between 1-2 gm/hr was started and 
maintained throughout the procedure. The rate of this infusion was 
adjusted according to the patients response. Cardiovascular control 
was aimed at keeping the systolic blood pressure within a range 30mmHg 
either side of the preoperative baseline. Peaks of arterial pressure were 
managed in itia lly with up to three further boluses injections of MgS04, 
20 mg/Kg on each occasion, but if this proved insufficient to restore SBP 
to within the stated limits, sodium nitroprusside was added. If SBP was 
controlled within the stated range by magnesium alone control was 
designated as good; if adequate control could be established by the
Phaeochromocytoma 156
addition of either nitroprusside or phentolamine or both, control was 
designated as fair, and if adequate control could not be achieved by any 
combination, control was designated as poor. Once the tumour had 
been devascularized, magnesium was discontinued, and at the end of 
surgery neuromuscular blockade was reversed in the normal manner. 
Adequate reversal of neuromuscular blockade was demonstrated by the 
use of a peripheral nerve stimulator prior to extubation. Blood samples 
for serum magnesium were taken after the initial loading doses, and at 
re g u la r in te rva ls  th ro u g h o u t the p rocedu re . Serum m agnesium  
c o n c e n tra t io n s  w ere  m easured  by a to m ic  a b s o rp tio n  
spectrophotometry. Blood gases were sampled using heparinised 2ml 
syringes at regular intervals throughout all procedures and analysed 
w ithou t tem perature  co rrec tion  on an ABL4 au tom atic  blood gas 
analyzer.
9.1.4 Catecholam ines: Catecholamine concentrations were measured using a 
radio-immune assay technique, as described in chapter 7, in five of the 
last six cases. In case 11, catecholamine concentrations were measured 
prior to induction, following tracheal intubation, and during periods of 
tumour handling. In cases 12 and 14, catecholamines were estimated 
preoperatively following the initial dose of MgSCU, after induction of 
anaesthesia and after tracheal intubation, as well as during tumour 
handling. MgS04 was withheld until after induction of anaesthesia and 
adm inistered just prio r to intubation in cases 13 and 16. In these 
pa tien ts , ca techo lam ine  co n cen tra tions  were measured p rio r to 
induction, following induction, after MgS04, after tracheal intubation, 
and during tumour handling.
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9.2 RESULTS
In the firs t case of this series, magnesium provided remarkable contro l of 
cardiovascular function p rio r to induction of anaesthesia when conventional 
methods had failed (figure 9.1). Excellent contro l was maintained during 
induction of anaesthesia and intubation (figure 9.2). The surprising feature of 
this case, was the remarkably good control of cardiovascular function which 
was maintained throughout surgery, even during periods of tumour handling 
(figure 9.3), and it was th is result which encouraged the continuation of the 
study.
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Figure 9.11nitial cardiovascular changes in response to infusion ofMgSO* in case 1 as recorded 
during the initial infusion of MgSO4. Chart speed is 0. imm/sec and one large square 
represents 50 seconds. The figures on the y-axis are in mmHg.
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Figure 9.2 Blood pressure response to insertion of a CVP line, and its control by MgSO4.
Subsequent blood pressure response to induction and intubation is also shown. Chart 
speed is 0. Immlsec and one large square represents 50 seconds. The figures on 
the y-axis are in mmHg.
TUMOUR j
Figure 9.3 Cardiovascular responses and MgSO4 administration during tumour handling. Chart 
speed is 0. Immlsec and one large square represents 50 seconds. The figures on 
the y-axis are in mmHg.
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In all but one of the remaining cases, magnesium provided satisfactory control 
of arterial blood pressure and heart rate up to the time of tumour handling. 
Where patients arrived in the operating room with elevated arterial pressures, 
the combination of magnesium and fentanyl satisfactorily controlled the arterial 
pressure in all but one patient. The only failure was the first of the pregnant 
patients (case 4, firs t anaesthetic). Only one other patient exhibited an 
increase in arterial pressure at intubation, and this was the second patient 
undergoing Caesarean section (case 7) in whom opiates were not administered 
prior to intubation. This increase was small (20 mmHg). In 11 of the 17 
anaesthetics, MgS04 alone provided good cardiovascular control throughout 
the procedure. The case record of the worst controlled patient in this group is 
shown in figure 9.4.
Figure 9.4 Systolic blood pressure in case 8 in whom control was designated as good. Events: 
1 - induction; 2 - intubation; 3 - incision; 4 - tumour handling; 5 - tumour removal.
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In four of the remaining six patients, two with locally invasive tumours, and two 
others with very large tumours, infusions of nitroprusside were required in 
addition to the MgS04 in order to control increases in arterial pressure at the 
time of tumour handling. The case record of the worst controlled patient in 
this group is shown in figure 9.5. In two of these cases (Cases 12 & 13), 
catecholamine levels were measured during tumour handling and found to be 
very high, although higher values than these have been reported in other series.
Figure 9.5 Systolic blood pressure in case 12 in whom control was designated as fair. Events: 
1 - induction; 2 - intubation; 3 - incision; 4 - tumour handling; 5 - tumour removal.
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In the firs t of the pregnant patients, MgS04 was without apparent benefit at any 
stage, but it was subsequently found that she had been grossly magnesium 
depleted, and therapeutic levels of magnesium were not approached. The 
highest serum magnesium level attained in this patient was 1.3 mmol/l (figure 
9.6). In her subsequent anaesthetic for removal of her tumour she was well 
stabilised pre-operatively, therapeutic levels of magnesium were established 
and excellent control was maintained (figure 9.7). The fact that she was no 
lon g e r p regnan t w ou ld  a lso  have co n tr ib u te d  to  her g rea te r ease of 
management.
mmHg
Figure 9.6 SBP changes during caesarean section in case 4. 
Events: 1 - induction; 2 - incision; 3 - delivery.
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Figure 9.7 SBP changes in case 4 during tumour removal.
Events: 1 - induction; 2 - incision; 3 - incision; 4 - tumour handling; 5 - tumour removal.
In the other pregnant patient, no resection of the tumour was contemplated as 
the tum our was a m a lignan t one w ith  secondaries. In th is  case, a fte r 
pre-operative control had been established in the usual manner, a routine 
Caesarean section anaesthetic was performed, w ith the sole addition of 
magnesium prior to induction and continuously throughout the procedure. 
Good ca rd io va scu la r co n tro l was m ain ta ined th ro u gh o u t the surgery. 
Withdrawal of magnesium after the procedure had ben completed resulted in a 
rapid and severe increase in blood pressure to  250/140 mmHg fo r which 
intravenous phenoxybenzamine had to be administered.
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In the remainder, serum magnesium levels in the presumed therapeutic range 
of between 2-4 mmol/l were achieved and maintained. During tumour handling, 
all patients required supplemental doses of MgS04 to control increases in 
arterial pressure, and the total dose administered was in the range of 8-16 gm 
with a surgical duration ranging between 60 and 150 min. before tumour 
devascularization. No arrhythmias occurred In any of the patients studied. 
These results are summarized in Table 9.2. In case 16, the cardiovascular 
stability which was maintained during tumour handling was such that it led to 
the e rroneous assum ption  th a t the tum our had been devascu la rized . 
Magnesium was therefore withdrawn prior to tumour removal, and this was 
followed by an immediate, steep increase in SBP which responded promptly to 
two further bolus injections of MgS04 (figure 9.8).
mmHg
Time (hours)
SBP Magnesium Infusion
Figure 9.8 SBP changes during anaesthesia and surgery in case 16. Events: 1 - induction; 2 
- intubation; 3 - incision; 4 - tumour handling; 5 - MgSO4 withdrawn; 6 - tumour removal.
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In case 15, the diagnosis was made as a result of severe hypertension and 
multifocal arrhythmias exhibited during exploration of a para-aortic abdominal 
mass. On this occasion, the administration of a 4gm bolus of MgS04 resulted 
in immediate, but short lived, reduction of blood pressure and control of 
arrhythm ias. Two further 4gm boluses and one of 2gm were required to 
establish good cardiovascular control, and tumour removal then proceeded 
uneventfully (figure 9.9).
mmHg
Figure 9.9 SBP changes in case 15 where the diagnosis was made intraoperatively. Events: 1 
- induction; 2 - intubation; 3 - incision; 4 - tumour handling; 5 - tumour removal
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Table 9.2
Case SBP1 SBP2 IO Range S tab ility Other Agents
1 195 135 120-140 Good Nil
2 220 115 110-140 Good Nil
3 215 145 95-180 Fair SNP
4a 220 150 85-220 Poor SNP. PH
4b 130 110 100-140 Good Nil
5 195 115 110-190 Fair SNP
6 130 100 100-150 Good Nil
7 170 150 120-150 Good Nil
8 186 130 105-150 Good Nil
9 205 100 100-140 Good Nil
10 140 95 95-135 Good Nil
11 150 100 95-140 Good Nil
12 240 120 100-250 Fair SNP
13 120 105 100-185 Fair SNP
14 130 100 90-145 Good Nil
15 150 175 70-260 Nil
16 130 95 90-200 Good Nil
Table 9.2. Intra-operative control of cardiovascular events.
SNP - sodium nitroprusside used in addition to MgS0 4  
PH - phentolamine used.
IO Range - intraoperative systolic blood pressure range.
SBP1 - Systolic blood pressure on arrival in the operating theatre.
SBP2 - Systolic pressure after MgS04 and induction of anaesthesia.
Note that case 16 is designated "Good" despite one episode of very high blood 
pressure as this was associated with inappropriate withdrawal of magnesium 
(see text and figure 9.8).
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Two patients in this series required post-operative ventilation. The firs t was a 
54 yr. old male with a tumour invading the diaphragm, and pre-existing renal 
dysfunction. In view of his renal disease, persistence of high levels of serum 
magnesium was antic ipated, but the nature of the surgery made elective 
post-operative ventilation the method of choice. Neuromuscular transmission 
remained depressed for 12 hours postoperatively. In the other, adequate 
neuromuscular function was restored at the end of the procedure, but in view 
of her obesity, and the fact that a sub-costal incision had been performed, it 
was decided to institute elective post-operative ventilation for the first 12 hours 
postoperative ly. In all of the other patients, neuromuscular blockade was 
reversed without d ifficulty, despite a mean serum magnesium level at the time 
of reversal of 1.9 mmol/l. In the first 3 cases, 1gm calcium gluconate was 
routinely administered prior to reversal of neuromuscular blockade, but this 
appeared unnecessary and was discontinued in the later cases. Good blood 
gases were maintained in all cases, with no acid-base disturbances seen.
Greatly increased adrenaline and noradrenaline concentrations were found on 
arrival in the operating theatre in the 5 patients in whom they were measured. 
Noradrenaline levels ranged from 1900 - 6650 pg/ml (normal range 100-600 
pg/ml) and adrenaline levels from 120-390 pg/ml (normal range 10-80 pg/ml). 
Dopamine levels were normal. Noradrenaline and adrenaline levels were 
reduced follow ing magnesium in all 5 cases, although the effect was greater on 
adrena line  than on noradrena line. Adrena line leve ls were reduced by
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magnesium to within the normal range in all 5 cases, but noradrenaline levels, 
although reduced, remained markedly elevated. In the two patients in whom 
a n ae s the s ia  was induced  p r io r  to  the  a d m in is tra tio n  of m agnesium , 
noradrenaline and adrenaline levels increased following induction, and returned 
to pre-induction values following magnesium. No increase in catecholamine 
levels occurred following intubation. During tumour handling MgS04 appeared 
to be ineffective in blocking the release of catecholamines. In two cases, 
noradrenaline levels were very high and sodium nitroprusside was required in 
addition to magnesium to control arterial pressure during tumour handling. In 
the other three magnesium alone provided adequate control, despite the fact 
that adrenaline levels were similar in all 5 cases. The changes in catecholamine
levels are illustrated in figures 9.10 and 9.11.
500 ----------------------------------------------------------------------------------------------------------
Baseline Mag/lnd Ind/Mag Intubation Tumour Handled
I Case 11 WSM,. Case 12 '/////. Case 14 MM. Case 13 Case 16
Figure 9.10 Changes in adrenaline concentrations in 5 patients. Mg/ind - induction of 
anaesthesia in cases 13 & 16; administration of MgSOA in the other 3 cases. Ind/mag 
- administration of MgSOA in cases 13 & 16; induction of anaesthesia in the other 3 
cases.
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Thousands
Baseline Mag/ind Ind/mag Post Intubation Tumour handled
I  Case 11 WM. Case 12 '////, Case 14 H H  Case 13 S88S Case 16
Figure 9.11 Changes in noradrenaline concentrations in 5 patients. Mg/ind - induction of 
anaesthesia in cases 13 & 16; administration of MgSOt, in the other 3 cases. Ind/mag 
- administration of MgSOa in cases 13 & 16; induction of anaesthesia in the other 3 
cases.
Complications: One patient developed severe hypotension following tumour 
removal and in association with massive blood loss. Blood transfusion and 
vasoconstric to rs  fa iled to  improve the arteria l pressure, and m yocardial 
depression appeared to be contribu ting  to the poor arterial pressure. An 
adrenaline infusion was required to maintain satisfactory arterial pressures 
during the remainder of the surgery and for 24 hours postoperatively. This 
patient (case 9) had been inadequately prepared for surgery, and his problem 
appeared to be principally due to an excess of B-blockade persisting after 
tumour excision. As he continued to require adrenaline long after his serum 
magnesium levels had returned to normal, it seems most unlikely that his 
cardiovascular problem was due to the magnesium, although this possibility
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cannot be ruled out completely. The only other complication was the well known 
unpleasant burning sensation produced by magnesium infusion. The only 
patient to complain of this was the second of the Caesarean section patients in 
whom MgS04 was given without the prior administration of any analgesic or 
sedative drugs. The other pregnant patient did not complain of this, but as she 
was in labour at the time this may account for her absence of symptoms. The 
concomitant use of fentanyl appeared to prevent complaint of this problem in 
the other patients.
9.3 DISCUSSION
The rationale for the use of MgS04 infusions in the anaesthetic management of 
phaeochromocytoma is based on the ability of magnesium to inhibit the release 
of catecholamines from the adrenal medulla as well as its vasodilator and 
anti-adrenergic properties which have been discussed in preceding chapters. 
The ability of magnesium infusions to control catecholamine-induced crises 
associated with severe tetanus, and reduction of catecholamine concentrations 
follow ing infusions of magnesium in a patient with this condition have been 
described in the previous chapter. The safety of MgS04 at the  serum 
concentrations used in this series is well established by the use of similar serum 
m agnesium  c o n ce n tra tio n s  in the m anagem ent o f p regnancy-induced  
hypertension (Pritchard & Pritchard, 1975; Pritchard et al, 1984).
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In the five patients in whom catecholam ine concentrations were studied, 
magnesium reduced adrenaline concentrations to within the normal range and 
also reduced noradrenaline concentrations, although not to levels approaching 
normal values. The greater effect on adrenaline could simply be due to its 
shorter half-life, and therefore a more rapid clearance follow ing the inhibition 
of release from the tumour. Although the stress of intubation is known to 
release catecholamines (Russell et al, 1981; Derbyshire et al, 1983), there was 
no increase in ca techo lam ine concen tra tions fo llow ing  in tuba tion . No 
comment can be made on the effect of magnesium on catecholamine release 
during tumour handling, as no comparisons were made with patients treated 
w ithou t magnesium. It is possible that magnesium may have had some 
inhibitory effect on catecholamine release at this time, but this possibility 
requ ires  fu r th e r s tudy. The m echanism  by w h ich  m agnesium  b locks 
catecholamine release is by competition with calcium for membrane channels 
as has been outlined previously, and it seems unlikely that this action would be 
important during physical stimulation of the tumour.
In addition to its action in blocking catecholamine release, magnesium exerts 
considerable cardiovascular effects of its own (chapter 5), all of which could 
be e xp e c te d  to  be o f b e n e fit  d u r in g  a n a e s th e s ia  in p a tie n ts  w ith  
phaeochromocytomas. The direct vasodilating properties of the agent are well 
established and as has been shown in chapter 6, magnesium infusions can
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antagonize the adverse effects of high concentrations of circulating adrenaline 
in intact animals.
The resu lts  of th is  present study are in apparent co n flic t w ith the well 
established role of magnesium in obste tric  practice in which magnesium 
appears to produce only mild hypotension, although profound hypotension 
following magnesium therapy in association with a blood volume deficit has 
been described (Bourgeois et al, 1986). There are several possible explanations 
for this discrepancy. Firstly, the dosages of magnesium generally used in 
obstetric practice frequently fail to produce the desired serum concentrations 
of magnesium (Sibai et al, 1981). In the present study, very large doses of 
m agnesium  su lpha te  were needed to  m a in ta in  the  serum m agnesium  
concentra tions w ith in  the required range. Secondly, the mild degree of 
hypotension produced by magnesium in obstetrics is generally regarded as 
indicating little  cardiovascular effect. However, magnesium has been shown to 
produce marked vasodilata tion in both experimental animals and humans 
accompanied by an increase in cardiac output (Mroczek et al, 1977; Lee et al, 
1984; see chapter 5), which largely offsets the hypotensive effect of the 
vasodilatation. In the presence of excess catecholamines, the reduction in 
peripheral resistance produced by magnesium appears to be greater than that 
p ro d u c e d  by m agnesium  unde r c o n d it io n s  in w h ich  c a te c h o la m in e  
concentrations are not elevated (chapter 6), probably because of the a-blocking 
p ro p e rtie s  o f m agnesium . F u rthe r, the re d u c tio n  of ca techo lam ine
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concentrations in patients with phaeochromocytoma will not only enhance the 
vasodilator effect but will prevent the usual increase in cardiac output, as was 
seen in the study on patients with severe tetanus (chapter 8). It is not surprising 
therefore that the cardiovascular effects of MgS04 infusion should be far more 
profound in phaeochromocytoma patients than in obstetric patients.
Magnesium is a potent anti-arrhythmic agent (Enselberg et al, 1950; Ghani & 
Rabah, 1977; Ise ri et a l, 1983) p a r t ic u la r ly  in the  p resence  of h igh 
concentrations of catecholamines (chapter 6) and no patient in this series 
deve loped  in tra -o p e ra tive  a rrhy thm ias , even when there  was massive 
catecholamine release. This was impressive, as almost all other agents used 
are associated w ith a high rate of transient in tra-operative dysrhythmias 
(Roizen, 1986). Where arrhythmias occurred prior to the use of magnesium 
these were reversed, as in the unprepared patient, whose arrhythmias were 
completely controlled by the magnesium injections.
The rarity of phaeochromocytomas makes controlled tria ls in this condition 
extremely difficu lt. Consequently, reports of the management of this condition 
tend to be collections of case reports, and the present series is no exception. 
As this series of patients was collected over a considerable period of time and 
the patients were referred by many different practitioners, using different 
methods of initial patient preparation, a controlled trial of magnesium was not
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feasible. Nevertheless, the ease of management of these cases, particularly 
during the induction and early surgical phases of the procedure, was in marked 
c o n tra s t to  the  a u th o r ’ s pe rsona l expe rience  o f 10 p rev ious  phaeo- 
chromocytomas handled by conventional means. The author’s experience with 
the use of magnesium in the cases presented here was so successful that it was 
fe lt that a personal contro lled tria l would be d ifficu lt to jus tify  on ethical 
grounds. Whilst other anti-adrenergic and vasodilatory agents are more potent 
than magnesium, the unique capacity of magnesium to inhibit the release of 
catecholamines prior to tumour handling is probably the principal reason for 
the good cardiovascular control obtained in this series.
The anaesthetic management of pregnant patients with phaeochromocytomas 
presents a major anaesthetic problem and various techniques have been 
suggested. As in other cases, a-adrenergic blockade has been the mainstay of 
perioperative blood pressure control (Burgess, 1978), but is often inadequate 
on its own during the stresses of surgery (Fox et al, 1969;Griffith et al, 1974) 
and may be accompanied by severe hypotension at the time of delivery (Galletly 
et al, 1983; Burgess et al, 1978). The use of sodium nitroprusside in pregnant 
p a tie n ts  is co n tro ve rs ia l (W illoughby, 1984) as a c id o s is  and cyanide 
accumulation occurs to a greater degree in foetal lambs than in the mother; the 
foetus may also have immature mechanism for cyanide metabolism (Naulty et 
al, 1977). In addition the drug may reduce uterine blood flow (Lieb et al, 1981). 
Regional blockade has been said to be contra-indicated (Schenker & Granat,
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1982) , a lthough there have been reports of successful management with 
epidural anaesthesia (Davies & Navaratnarajah, 1984; Stoneham & Wakefield,
1983) . It is worth noting that in the first of the two pregnant patients in this 
series epidural analgesia was totally ineffective in ameliorating cardiovascular 
disturbances. In view of these conflicts and d ifficulties in managing these rare 
but highly challenging cases, an agent with an already established place in 
obstetric practice such as magnesium sulphate may offer the anaesthetist a 
unique additional tool for the safe management of the patient. It is also worth 
noting that both of the pregnant patients in this series showed magnesium 
deficiency. This is not surprising in view of the fact that pregnancy itself is 
often associated with magnesium deficiency (Seelig, 1980), and catecholamine 
stimulation may prevent the influx of magnesium to the intracellular space 
(Maguire & Erdos, 1980; Erdos & Maguire, 1983). Such deficiency should always 
be looked for and corrected.
Magnesium appears to be a useful addition to the armamentarium available for 
the anaesthetic management of patients with phaeochromocytomas. It appears 
to  be of pa rticu la r value in con tro lling  card iovascu lar d isturbances and 
catecholamine release at the times of induction and intubation, but can also be 
of use, in conjunction with other agents, in controlling arrhythmias and blood 
pressure disturbances during tumour handling.
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10. Conclusions
The review of the biochemistry, physiology and pharmacology of magnesium 
invited speculation that magnesium infusions may have considerable benefits 
to offer in various circumstances pertaining to anaesthesia. On reviewing the 
lite ra tu re  it appeared tha t the re  were cons ide rab le  de fic ienc ies  in the 
knowledge pertaining to the cardiovascular actions of this ion.
10.1 C ard iovascu lar Effects
Investigations of the cardiovascular effects of infusions of magnesium sulphate 
in intact baboons generally confirmed existing information available regarding 
the effects of the ion on blood pressure. In addition, it confirmed some of the 
human studies which have suggested that the relative ly mild hypotensive 
effects that resulted from infusions of magnesium were the consequence of a 
combination of vasodilatation with an increased cardiac output rather than 
evidence of weak cardiovascular effects. This study also demonstrated, for the 
f irs t tim e, tha t the e ffective  range of serum magnesium concentra tions
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appeared to be between 2 and 5mmols per litre and that only at levels greater 
than 5mmols per litre were significant falls in blood pressure and heart rate 
likely to occur. Even at very high levels of serum magnesium the absence of 
significant myocardial depression was one of the most important findings of 
this study.
10.2 Anti-adrenerg ic Effects
It was also confirmed that the in vitro findings that magnesium could block 
adrenergic ac tiv ity  at the alpha receptor could be demonstrated in intact 
animals receiving an adrenaline infusion. The magnitude of this effect appeared 
to be such as to be of clinical value. It was also demonstrated, for the firs t time, 
that magnesium exerts important anti-arrhythmic effects in the presence of high 
levels of catecholamines. Finally it was demonstrated that magnesium did not 
appear to exert potentially hazardous interactions with either alpha or beta 
adrenergic blockade in animals treated with high levels of adrenaline.
The conclusions drawn from the animal experimentation section of this thesis 
were that magnesium exerted significant and potentially useful vasodilator 
e ffec ts  w h ile  at the same tim e m a in ta in ing  at least normal m yocardia l 
contractility, and, in addition, that magnesium exerted clin ica lly useful and 
apparently safe anti-adrenergic effects in animals treated with high doses of 
adrenaline. These animal studies therefore justified tria ls  of this agent in
Conclusions 177
clinical conditions in which catecholamine excess presented a therapeutic 
problem.
10.3 Clinical Studies
In the clin ical studies section of this thesis it was shown that magnesium not 
only usefully antagonised excess adrenergic activ ity  but also appeared to 
inhibit the release of catecholamines from adrenergic nerve terminals. This 
confirmed the findings of in vitro experiments in which this action of excess 
magnesium ions had been demonstrated. It can be concluded, therefore, that 
in conditions of catecholamine excess, infusions of magnesium sulphate, and 
probably of other salts of magnesium, may well provide clinicians with an 
additional tool to enable them to manage d ifficu lt clinical situations with a 
greater degree of patient safety.
10.4 Unanswered Questions
There are, however, a number of questions which remain unanswered.
10.4.1 Magnesium and inotropy. One of the in trigu ing  observations that 
emerged from both the animal work and from the clinical studies in 
tetanus, was the increase in cardiac stroke volume that was consistently
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described. This increased stroke volume is, at least superfic ia lly, 
d ifficu lt to explain in view of the fact that magnesium is theoretically a 
calcium  antagonist and, therefore, should have negative inotrop ic 
effects and that such effects have been described in isolated tissue 
experiments. There are a number of important considerations to be 
borne in mind when considering this rather surprising finding. Central 
to these arguments is the concept that magnesium is essential for energy 
metabolism and is probably essential for the action of beta adrenergic 
stimulants on the contractile state of the myocardium. In all of the 
experiments in which an increased stroke volume was found, increased 
adrenergic activity was likely to be present. Increased (3-agonist binding 
has been described as one of the actions of magnesium and it is 
the re fo re  poss ib le  tha t th is  is an exp lana tion  fo r  the ac tions  of 
magnesium in these situations. It is also possible, although less likely, 
that the experimental animals and the human subjects were marginally 
magnesium deficient at the start of the experiments. If this were the 
case, then the finding of an increased stroke volume would be less 
surprising because catecholamines require magnesium to exert their 
inotropic effects. It is also possible that these results were merely 
chance find ings as there is some evidence, a lthough none of it in 
essentially intact animal models such as those used for the present 
experiments, that magnesium may have negative inotropic effects in the 
intact animal. In general, these results were found in extensively 
instrumented animals in which rather deep anaesthesia would have been 
required, and the influence of this is unclear. It seems a safe conclusion 
to  draw that magnesium is not a negative inotrope at the c lin ica l 
concentrations used but it is d ifficu lt at this stage to be sure about what 
other effects it may have on contractility.
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10.4.2 Catecholamines and tumour handling. It has not been investigated 
whether magnesium infusions had any effect at all on the output of 
catecholamines during tumour handling in patients undergoing surgery 
fo r the removal of a phaechromocytoma. One of the surprising features 
of the phaechromocytoma studies was that, in the majority of patients, 
cardiovascular disturbance could be well controlled even during the 
pe riods  o f tum our hand ling . Only a com parative  study between 
magnesium and other forms of cardiovascular control could indicate 
whether or not magnesium was, in fact, inhibiting catecholamine release 
at this time. Unfortunately this author found the cardiovascular control 
so impressive as to make magnesium the drug of choice. Ethically, 
therefore, it would require someone else, less convinced of the benefits 
to do such a controlled study. This does, however, remain an intriguing 
possibility and worthy of further research. Whether or not this is the 
case the evidence presented here does suggest that magnesium may 
provide an extremely useful addition to the armamentarium of drugs 
available to the anaesthetist for the management of this problem.
10.4.3 Pre-eclamptic toxaemia. The role of magnesium in the management of 
p re -ec lam ptic  toxaem ia remains a controvers ia l sub ject. C lin ica l 
experience would appear to indicate that magnesium both prevents and 
controls convulsions in this potentially life-threatening condition. The 
mechanism by which it does so are, however, obscure in view of the 
apparent inability of magnesium infusions to produce significant CNS 
depression. It seems most like ly  tha t magnesium is exerting its 
anti-convulsant effects secondarily to its action on the cardiovascular 
sys tem  and the  m ost l ik e ly  m echan ism  of a c tio n  is c e re b ra l 
vasodilatation and improved cerebral oxygenation. This possibility,
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however, remains entirely speculative and the subject for much further 
research. An alternative possibility is that pre-eclampsia produces local 
areas of brain injury which act as epileptic foci. As such foci would be 
lik e ly  to  have d is ru p te d  b lood bra in  ba rrie rs  it is poss ib le  tha t 
magnesium could penetrate such areas locally and exert anti-convulsant 
effects w ithout altering CSF magnesium to any great extent.
10.5 Further studies
A fu rthe r po te n tia lly  fru itfu l area fo r magnesium research is the role of 
magnesium infusions in the protection of the stressed myocardium particularly 
during periods of actual or potential coronary ischaemia. The possibility exists 
that magnesium infusions may offer particular benefit in anaesthesia in cases 
where coronary perfusion may be at risk.
In a to ta lly  different direction, it appears that the interaction of magnesium with 
muscle relaxants has been inadequately evaluated. There are potentia lly 
exciting possibilities in the observation that magnesium appears to reduce the 
incidence in severity of suxamethonium-induced fasciculations and that it 
appears to  inh ib it the release of potassium, at least in normal subjects, 
follow ing the use of this relaxant. If these observations are confirmed, it may 
imply a role for magnesium in reducing some of the hazards associated with the
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use of depolarising muscle relaxants. It may protect against increases in intra­
ocular pressure and thus make emergency anaesthesia in the patient with an 
open eye injury considerably safer. Inhibition of potassium release may also 
enable the use of depolarising relaxants in situations such as burns where the 
rapid, com plete, and short duration paralysis produced is of benefit but 
currently prevented by the hazards of potassium induced arrhythmias.
An even more in trigu ing poss ib ility  lies in the recent confirm ation of old 
observations that magnesium may reduce bronchial tone. Given the apparently 
bene fic ia l in te rac tions  between magnesium and adrena line which were 
demonstrated in this thesis, particularly the a-blockade and anti-arrhythmic 
properties of magnesium, the possibility exists that combinations of magnesium 
and adrenaline or indeed, other p-stim ulants may not only improve the 
efficiency of bronchodilatation but may also increase the safety of p-agonists 
by suppressing the arrhythmic response. Furthermore, the possibility which 
has been suggested that magnesium may protect against the adverse metabolic 
effects of catecholamine stimulation on the myocardium further increases the 
potential benefit tha t could be gained from th is in teraction. One further 
in te resting  poss ib ility  is that if the enhancement of p-agonist binding by 
magnesium can be demonstrated in bronchial muscle it is likely that magnesium 
would have a synergistic action in asthma with the p-agonist stimulants.
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It is also possible that combinations of magnesium and adrenaline may exert 
other beneficial effects. There is currently a resurgence of interest in the use 
of adrenaline in a wide variety of clinical conditions limited predominantly by 
the a rrhy thm ic  risk  posed by in fus ions of th is  agent. C om binations of 
adrena line  and magnesium may well a llow  fu rth e r m anipu la tions of the 
cardiovascular system without the arrhythmic risk. In addition, magnesium is 
known to dilate renal blood vessels and may have a diuretic action. It is 
possible that magnesium may antagonise the adverse effects of adrenaline on 
renal blood flow and urine output. The studies reported in this thesis have 
shown th a t m agnesium  may have b e n e fic ia l e ffe c ts  in c o n d it io n s  of 
catecholamine excess. The possibility exists that these studies are only the 
beginning of a wide range of future investigations into the clinical significance 
of magnesium as a therapeutic agent.
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Appendix A
Cardiac Output Estimation by Thermodilution
The thermodilution technique for determining cardiac output utilizes the Stewart-Hamilton 
indicator dilution equation as modified for thermal indicator. The following equation is the result:
1.08 (60) CT V| (TB -T|)
C .O . =  ________________________
1.22 J  ATb (t) dt
Where:
C.O. = Cardiac output in litres/minute
p Cp (5 percent dextrose) The ratio of the density
1.08 = ____________________ times the specific heat of
p Cp (Blood) 5 percent dextrose to the density
times the specific heat of blood.
Ct = Correction factor for the injectate temperature rise through the catheter.
60 = Seconds/minute
V| = Volume of injectate in litres
TB = Initial blood temperature in °C
T| = Initial injectate temperature in 0
T f
1.22 0J A Tb (t) dt = Area under the time-temperature thermodilution curve in °C - sec
T = Time to 30% of curve peak amplitude from START
1.22 = Compensation for area lost due to 30% termination
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Basis for Modified Equation
One aspect of heat theory relates the change of heat in a substance to its mass 
and specific heat for a given change in temperature. In a static situation, if two 
substances at different temperatures are mixed, the resulting temperature of 
the mixture will fall between the original temperatures. If one of the masses is 
unknown, it can be determined by equating, at equilibrium, the change in heat 
of the two substances and calculating the unknown mass from the resulting 
equation. When applied to a system of continuous flow, as in the heart and 
vasculature, a small amount of cold indicator can be introduced into and mixed 
with the flow ing substance (blood) to determine a time-temperature curve 
d o w n s tre a m . The area under th is  cu rve  re p re se n ts  the  sum o f the 
instantaneous mixture temperature at the sensing point. When applied to the 
Stewart-Hamilton equation, the unknown flow of mass per unit time can be 
determined much as mass alone is determined in the static case.
The f irs t  fo u r term s of the m od ified  equa tion  [(1 .08 ) Ct (60) Vi] are 
pre-determined by the volume and physical properties of the injectate and the 
characteristics of the catheter. They can, therefore, be grouped and entered 
Into the computer as a preset constant called the "Computation Constant". The 
components of the fifth  term (TB - Tl) are continuously measured by the 
therm istor probe on the catheter, and the injectate temperature sensor from the 
computer. The computer electronically determines the difference between TB 
and Tl and multiplies the difference by the computation constant. The resulting 
va lue  is in te rn a lly  held fo r  la te r p ro cess in g . The te m p e ra tu re  o f the
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indicator-blood mixture is sensed by a therm istor in the catheter. The resulting 
time-temperature curve is amplified and integrated in the computer. Integration 
is automatically terminated when the curve returns to  30 percent of its peak. 
The ratio of the final value shown in the previous paragraph to this integrated 
value is the measured cardiac output. The area lost by cutting off the curve on 
the downslope at 30 percent of its peak amplitude amounts to approximately 22 
percent of the remaining area. Compensation for this lost area is accomplished 
by amplifying the dilution signal presented to the integrator by 22 percent. The 
value of 30 percent is chosen as the cut-off point because of documented 
clinical studies which relate this point to  m inimal variability.(Ref: Edwards 
Laboratories Cardiac Output Computer Manual, 1980)
Thermodilution techniques have the advantage over other methods that the 
technique is nontoxic and readily repeatable. The values obtained by this 
method correlate well with those obtained by other techniques such as the Fick 
method or the use of ind ica to r d ilu tion  curves (Keefer & Barash, 1985). 
Potential sources of error include injectate temperature changes prior to 
injection and along the catheter; incomplete mixing in low cardiac output 
states, and variations in pulmonary artery temperature with changes in the 
ve n tila to ry  cycle  (Sykes et al, 1981). In th is  thesis, all card iac output 
measurements were made using cold dextrose. The injectate, tubing and 
syringes were kept in a water bath for at least an hour prior to use, and until 
the moment of injection. The injectate temperature probe from the computer 
was placed in the water bath which wa frequently stirred to ensure an even
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temperature distribution throughout the container. Syringe handling was kept 
to a minimum by the use of insulated syringes. All in jections were made by the 
author to minimise variation induced by different injection styles. All readings 
were on animals or patients on controlled ventilation, and during readings 
ventilation was discontinued to minimise errors due to fluctuations in airway 
temperature.
C ard iovascu la r Measurements
In the cardiovascular investigations reported in chapters 5, 6 & 8 of this thesis, 
the fo llow ing direct measurements were made:
Systolic, d iastolic and mean systemic arterial blood pressure from the 
radial artery
Central venous pressure from the proximal port of the PA catheter 
Systolic, diastolic and mean pulmonary arterial pressure from the distal 
port of the PA catheter
Pulmonary capillary wedge pressure from the distal port with the balloon 
inflated
Heart Rate from the rate counter of the ECG 
Cardiac output
Mean systemic (MAP) and pulmonary (PAP) arterial pressures were determined 
by the monitoring apparatus by integration of the area under the curve of the 
a rte ria l p ressure wave. Central venous and pu lm onary  cap illa ry  wedge
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pressures were read from the recorded trace at end of expiration. 
From these measurements the following values were derived:
Stroke volume =
Cardiac Output 
Heart Rate
Systemic Vascular Resistance =
Pulmonary Vascular Resistance =
ml/beat
(MAP - CVP1 X 80 
Cardiac Output
(PAP - CVP) X 80 
Cardiac Output
dyne.sec.cm
dyne.sec.cm
Left Ventricular Stroke Work = SV X (MAP - PCWP) X 0.0136 gm.m/beat 
Right Ventricular Stroke Work = SV X (PAP - CVP) X 0.0136 gm.m/beat
In the tetanus study, body surface area (BSA) was determined for each patient 
using a nomogram relating height and weight to BSA and then cardiac index, 
stroke volume index and stroke work index derived by dividing the appropriate 
values by the body surface area. In the baboon studies this technique was not 
used since the animals were of reasonably consistent size and weight, and 
reliable BSA tables for baboons were not available.
B iochem ica l assays fo r magnesium and ca lc ium
The various methods which can be used for the estimation of the magnesium 
content of body fluids have been reviewed extensively by Wacker (1980) and 
Aikawa (1981). Earlier techniques involved the use of colorimetric methods
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inc lud ing  T itan-ye llow  and eriochrom e black, but although both of these 
methods are simple, they are generally not regarded as sufficiently accurate or 
reproducible for research purposes. In 1955, Walsh developed a hollow cathode 
discharge lamp, using magnesium metal as the hollow cathode. When excited 
by an e lectric current, such a lamp emits a stable, high-intensity light at the 
wavelength specific for the metal. This ligh t beam is focused through a flame 
which contains the unknown concentration of magnesium atoms at ground 
state. Absorption of the light beam occurs in the flame in proportion to the 
concentration of magnesium in the so lu tion. Since the mid-1960s atomic 
absorption spectrophotometry has been available in commercial devices and 
has become the standard method for magnesium analysis as this technique 
considerably improves the precision and accuracy of the determination. In all 
of the studies contained in this series atomic absorption spectrophotometry 
was the method adopted. The p rin c ip a l problem  w ith this techn ique is 
interference from phosphate, although this is a relatively minor problem with 
blood samples and only becomes a significant factor when CSF magnesium is 
estimated. In order to minimise this interference, the serum specimens studied 
were diluted 1:50 in 0.75% ethylenediaminetetra-acetic acid (EDTA). The EDTA 
has a high a ffin ity for calcium and magnesium and all of the calcium and 
magnesium in the specimen is complexed, preventing the loss of magnesium 
phosphate from the estimation. The solution is then assayed for calcium and 
magnesium content using atomic absorption using lanthanum as an internal 
s tanda rd . As ca lc ium  and m agnesium  have very d iffe re n t a b so rp tio n  
characteristics, the two substances are readily distinguished. Quality control
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was maintained using standard commercially available stock solution diluted to 
yield standard magnesium concentrations from 0.25 to 1.75 mmol/l in 0.25 
m m ol/l increm ents and from  5 to  20 m m ol/l concen tra tions in 5 m m ol/l 
increments. Similar standards were prepared using calcium standards with 
concentration of 1 to 4 mmol/l w ith increments of 0.5 mmol/l. The accuracy of 
this method is to within 0.01 mmol/l, and the between run precision of the 
method is ±_ 5%.
Catecholamine Assays
Catecholamine assays reported in this thesis were performed by Dr. Jan Esser 
of the department of Nuclear Medicine, University of the Witwatersrand.
Tubes w ith  blood samples fo r serum ca techo lam ine measurement were 
immediately placed on ice. Samples were centrifuged at 3 000 revolutions per 
minute for 10 min at 4°C. Aliquots of the serum were stored at -70°C for not 
longer than one week. Catecholam ine extraction was performed using a 
c o m m e rc ia lly  a va ila b le  k it  (C a t-A -K it, U p john  P h a rm ace u tica ls ) and 
frac tionated  serum catecholam ine concentra tions were determined using 
reversed-phase high-performance liquid chromatography with electrochemical 
detection using a Waters ECD machine. The lower lim it of sensitivity of the 
detector is 0.5 nanoamps, and the lowest accurate readings are 10 pg/ml. An
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internal standard DHBA was used for every estimation and the catecholamine 
concentration calculated is related to the recovery of DHBA.
The interassay variation is as follows:
Noradrenaline 1%
Adrenaline 2%
DHBA 4.7%
Dopamine < 1%
The mean peak height and standard deviation of each estimate calculated by 
the integrator in mm for each substance are as follows:
Noradrenaline
Adrenaline
DHBA
Dopamine
36 .9 21  i  0 .1 2 6  
17.501  _±_ 0 .3 5 8  
3 9 .6 9 0  jL  0 .9 0 9  
1 2 .0 8 3  jL 0 . 0 5 2
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APPENDIX B
CASE REPORTS.
Case 1. A 16 year old g irl presented w ith peripheral gangrene and labile 
h yp e rte n s io n . A d ia g n o s is  o f phaeoch rom ocytom a  was con firm ed  by 
angiography and by finding elevated urinary vanilmandelic acid levels. An 
initia l dose of phenoxybenzamine 50mg i.v. was infused over 2 hours followed 
by 20mg orally 8 hourly for five days days with careful i.v. fluid replacement 
m on ito red  by cen tra l venous pressure m on ito ring . The f irs t doses of 
phenoxybenzamine produced hypotension with tachycardia which responded 
well to i.v. fluid therapy. Over the next few days good cardiovascular stability 
was achieved without the need for p-adrenergic blockers. During this time, the 
supine arterial blood pressure remained within the range 110/60 - 130/80 mmHg 
and on standing this decreased to between 100/60 and 90/40 mmHg. There were 
no hypertensive episodes. The heart rate remained below 100 b.p.m. at all 
times, and there were no arrhythmias detected or ECG abnormalities noted.
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After a further three days the patient was then judged ready for surgery in 
accordance with the criteria laid down by Roizen (1987).
She was premedicated with chlorpromazine 50mg, papaveretum 15mg and 
scopolamine 0.4mg as well as being given 10mg phenoxybenzamine orally. On 
arrival in the anaesthetic room, her arterial blood pressure was 190/120 mmHg 
and her heart rate was 170 b.p.m. She was further sedated with 100p.g fentanyl 
and 10mg d ro pe rido l i.v. w ithou t bene fit to  her ca rd iovascu la r status. 
Ventilation was gently assisted and 50% nitrous oxide in oxygen inhaled. The 
patient was now well sedated, but the severe tachycardia and hypertension 
persisted, although the patient was peripherally warm and vasodilated. As the 
tachycardia appeared to be the major problem, and in view of the fact that 
several a-adrenerg ic b lockers had already been given, proprano lo l was 
administered in 2mg increments with continuous ECG monitoring, and blood 
pressure record ing using an autom atic doppler device. A fter 10 mg of 
propranolol, little  improvement had been achieved and her arterial blood 
pressure was 180/120mmHg and her heart rate 149 b.p.m. At this point, 
abandonment of the procedure was contemplated, but in view of her excellent 
preoperative status, it was felt that this was an acute response to the stress of 
coming to the operating theatre. It was, therefore, decided to make one further 
attempt to control the cardiovascular disturbances at this time and a trial of 
magnesium therapy was initiated.
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The patient was transferred to the operating theatre, an arterial line inserted 
into the left radial artery under local anaesthesia, and a magnesium sulphate 
infusion commenced at a rate of 2 gm per minute. After 1.5 min the arterial 
blood pressure had reduced to 130/90 mmHg, and the heart rate had decreased 
to 122 b.p.m. (Figure 9.1). As the central venous line had become displaced 
prior to the patient coming to theatre, a right subclavian catheter was inserted 
under local anaesthesia prior to induction of anaesthesia. This produced a 
mild increase in arterial blood pressure which responded well to infusion of an 
additional 2.5 gm magnesium sulphate. As eye lash and pharyngeal reflexes 
were still present, anaesthesia was then induced with 150 mg thiopentone i.v., 
paralysis with 15 mg alcuronium i.v., and the trachea then intubated. There was 
no cardiovascular response to endotracheal intubation and no change in heart 
rate (figure 9.2).
Surgery proceeded uneventfully under halothane, nitrous oxide and oxygen 
with controlled ventilation until mobilization of the tumour was attempted. The 
tumour was tightly adherent to the inferior vena cava, and ligation of the venous 
drainage proved to be impossible. As it was obvious that extensive tumour 
handling would be necessary to remove the mass, severe disturbances of 
cardiovascular function were anticipated. As expected, arterial blood pressure 
and heart rate began to increase, and before resorting to phentolamine and 
sodium nitroprusside as had been planned, a further infusion of magnesium 
sulphate was administered. A 2 gm infusion terminated the upward trend, and 
a further 2 gm restored the arterial pressure and heart rate to  normal levels,
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despite the fact that tumour handling was continuing throughout. Despite 
fu rth e r m anipu lation of the mass, there were no fu rther card iovascular 
disturbances (Figure 9.3). Following tumour removal, mild hypotension and 
bradycardia occurred (arterial blood pressure 8 0 / 6 0 mmHg and heart rate 64 
b.p.m.) but this responded adequately to i.v. fluid therapy alone, and inotropic 
support was not required, although 1 gm calcium gluconate was given to 
counteract any remaining magnesium effects. This produced no significant 
change in cardiovascular status. Neuromuscular blockade was reversed with
2.5 mg neostigmine and 1.2mg atropine, follow ing which good muscle tone was 
readily restored and satisfactory spontaneous ventilation established. The post 
operative course was uneventful.
Case 2. A 45 year old black female presented in itia lly  with long-standing 
hypertension and was diagnosed as having a phaeochromocytoma situated in 
the right adrenal gland. Preoperative preparation consisted of increasing 
doses of phenoxybenzamine up to a maximum dosage of 180mg per day and 
propranolol 40mg per day. She was judged as fit for anaesthesia according to 
the criteria laid down by Roizen. Premedication consisted of 10mg of diazepam 
and 25mg of phenergan both administered orally, 90 minutes preoperatively.
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On arrival in the operating theatre the patient was mildly hypertensive but 
during placement of central venous and arterial monitoring lines under local 
anaesthesia she became severely hypertensive with a systolic blood pressure 
of 220mmHg. Fentanyl 200p.g was administered i.v. followed by an infusion of 
4gm MgS0 4 . The blood pressure rapidly fell to 120mmHg and then anaesthesia 
was induced with thiopentone 300mg and muscle relaxation obtained with 15mg 
alcuronium. Endotracheal intubation was performed 3 min. after induction and 
produced no increase in blood pressure or heart rate. During the procedure a 
continuous infusion of MgS04 was administered at a rate of 2gm per hour and 
anaesthesia maintained with 50% nitrous oxide in oxygen and 1-3% enflurane. 
Excellent cardiovascular control was established and maintained throughout 
the procedure with 3 further boluses of MgS04 each of 2gm being administered 
during tumour handling. At the end of the procedure 1gm of calcium gluconate 
was given intravenously followed by reversal of the neuromuscular block with 
2.5mg neostigmine and 1.2mg atropine. Good neuromuscular transmission was 
rapidly established and the patient made an uneventful recovery.
Case 3. This patient was a 54 year old adult male who had until recently been 
an underground mineworker. He had mild restrictive lung disease as a result 
o f o ld  tu b e rc u lo s is  and had been d ia g n o se d  as hav ing  a la rg e  
phaeochromocytoma arising from the right adrenal gland as a result of recent 
onset hypertension. The patient also had reduced renal function with a 
crea tin ine  clearance of 42m l/hr. Preoperative preparation consisted of
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increasing doses of phenoxybenzamine to a maximum of 100mg per day and 
propranolol 60mg per day. Following routine oral premedication with diazepam 
and phenergan the patient arrived in the operating theatre with a systolic blood 
pressure of 215mmHg and a heart rate of 100 beats per minute. After the 
adm in is tra tion  of 200p,g fe n ta n y l a rte r ia l and cen tra l venous pressure 
monitoring lines were placed and an infusion of 4gm MgSC>4 administered. 
Systolic blood pressure reduced to 145mmHg and heart rate fell to 80 beats per 
minute. Induction of anaesthesia with thiopentone and muscle relaxation with 
alcuronium 20mg did not alter the patient’s haemodynamic status and there was 
no increase in blood pressure or heart rate follow ing intubation. At laparotomy 
the tum our was found to  be extrem ely large and attached to  the righ t 
diaphragm. Extensive tumour handling and opening of the diaphragm were 
necessary. During this time an infusion of sodium nitroprusside was necessary 
to control systolic blood pressure in addition to a continuous infusion of MgS04 
at a rate of 2gm per hour and four 2gm boluses. Inhalational anaesthesia 
consisted of 50% nitrous oxide in oxygen with 1-3% enflurane. At the end of 
the procedure the patient was transferred to a high care ward and electively 
ventilated for the next 24 hours. Serum magnesium levels of 3.7mmol/l were 
achieved intraoperatively and serum levels of greater than 2mmol/l persisted 
fo r six hours postoperatively, with evidenced of depressed neuromuscular 
transmission persisting for the next six hours. Thereafter the patient made an 
uneventful recovery.
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Case 4 . This patient was a 26-year old pregnant black woman who was 
investigated for secondary hypertension at a peripheral hospital. An elevated 
urinary vanillyl mandelic acid (VMA) level was found and she was transferred to 
a central hospital. She had had two previous uncomplicated pregnancies, the 
last in 1982.
P rom inent sym ptom s on p resenta tion  inc luded sw eating, pa lp ita tions , 
headache, dizziness and backache, which had occurred interm ittently during 
the preceding 15 months. Examination of the patient revealed a pregnancy of 
38 weeks duration in association w ith a lab ile  blood pressure (BP). No 
hypertensive ta rge t organ damage was noted. An elevated urinary VMA 
excretion was confirmed at 121 |xmol/24 hours (normal <60 p.mol/24 hours). 
The plasma adrenaline level was 2 pg/ml but the noradrenaline level was 
markedly elevated at 1164 pg/ml. Other biochemical measurements were within 
normal limits.
She was treated with prazosin 4 mg twice daily and atenolol 50 mg daily. After 
an initial hypotensive reaction, which responded to bed rest and intravenous 
fluid administration, her blood pressure stabilized at 150/100 mmHg from an 
admission level of 180/120 mmHg over the next five days, and her symptoms 
related to her catecholamine excess subsided. Foetal maturity was confirmed 
with ultrasound examination and it was decided to proceed with delivery.
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Vaginal de livery under epidural anaesthesia was chosen as the mode of 
delivery. The establishment of arterial, central venous and peripheral lines 
under local anaesthesia produced a marked hypertensive response (BP 220/110 
mmHg), and an infusion of phentolamine at a rate of 3 mg/hour was instituted 
w ith some improvement in the blood pressure. An epidural catheter was 
inserted and 10 ml 0.5% bupivicaine injected following a test dose, with no 
improvement in cardiovascular control. Membranes were ruptured to induce 
labour. These manoeuvres also produced a marked hypertensive response, 
which necessitated an increase in the rate of the phentolamine infusion to 10 
mg/hour. Shortly after labour had begun, foetal bradycardia occurred which 
made immediate operative delivery imperative.
Prior to induction of anaesthesia, a 4 gm bolus of MgSC>4 was administered 
intravenously over 15 minutes, followed by a continuous infusion of 1.5gm/hour. 
This produced little  improvement in the control of blood pressure. A sodium 
n itrop russ ide  in fus ion  was commenced at 0.27 p,g/Kg/min which almost 
immediately reduced the BP to 102/60 mmHg. This infusion was maintained 
throughout the induction sequence. Following pre-oxygenation, lignocaine 60 
mg was infused intravenously prior to induction. A standard rapid sequence 
induction and intubation was then performed using thiopentone sodium 4 
mg/Kg and suxamethonium 1 mg/kg while c rico id  pressure was applied, 
followed by a further 2 mg/Kg thiopentone just prior to intubation. Intubation 
produced a dramatic rise In BP to 265/165 mmHg which persisted for about 4 
minutes, requiring an increase in nitroprusside infusion rate to 0.8 ug/Kg/min.
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A healthy 2730 gm baby was delivered rapidly. Immediately after delivery, there 
was a precipitous fall in BP to 90 mmHg systolic which lasted for approximately 
5 minutes. This responded to temporary discontinuation of the nitroprusside 
and intravenous fluids. Thereafter she maintained a SBP in the range 180-230 
mmHg for the rest of the procedure (Figure 9.6).
Postoperatively, the patient required continuation of sodium nitroprusside 
infusion fo r the control of her persistent hypertension, until oral prazosin 
therapy could be re-established. It was subsequently found that her serum Mg 
level prior to the Induction of anaesthesia was 0.5 mmol/l and despite the fairly 
large doses of MgS04 the maximum serum Mg level achieved was 1.4 mmol/l.
Prazosin and atenolol were recommenced postoperatively in the same dosages 
as before delivery, and she was maintained on these drugs for 5 weeks while 
tu m o u r lo c a liz in g  p rocedu res  were be ing  p e rfo rm ed . She rem ained 
asymptomatic and her BP was well controlled at 130/90 mmHg. A right adrenal 
tu m o u r was found  on CT scan w h ich  had a p o s it iv e  up take  o f 131l 
m eta-iodobenzylguanidine (MIBG), and the patient agreed to surgery for 
removal of the tumour.
The night prior to surgery, the patient was sedated with diazepam 7.5 mg orally, 
and on the morning of surgery she received 5 mg prazosin orally, 100 mg 
atenolol orally, and 15 mg papaveretum i.m. In the operating theatre she was 
reasonably well sedated but placement of central venous and radial arterial
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lines under local anaesthetic produced a moderate pressor response with the 
BP rising to 160/100 mmHg.
Anaesthesia was induced with 150 p.g fentanyl followed by 250 mg thiopentone 
and a bolus of 4 gm MgS04 given over 5 minutes. This produced a reduction 
in blood pressure to 110/70 mmHg. Muscular relaxation was achieved with 20 
mg alcuronium and lignocaine 80 mg was given prior to intubation. Following 
induction, BP fell to 100 mmHg systolic, and returned to 120/80 mmHg following 
intubation. A continuous infusion of 1 gm/hour MgS04 was started. Incision 
produced an increase in blood pressure to 140 mmHg systolic which responded 
well to a further bolus of 2 gm MgS0 4 . During tumour handling, three similar 
mild increases in BP occurred, and on each occasion these responded well to 
MgS04 boluses. Throughout the procedure, anaesthesia was maintained with 
50% nitrous oxide in oxygen and 1-1.5% enflurane. No other anti-hypertensive 
m ed ica tion  was requ ired . Fo llow ing  tum our e xc is ion , the MgS04 was 
discontinued and at the end of the procedure, muscular relaxation was easily 
reversed with 5 mg neostigmine preceded by 0.4 mg glycopyrrolate (Figure 9.7). 
There were no post-operative complications. A total of 16 gm of MgSC>4 had 
been administered over a 2-hour period, and the patient's intraoperative serum 
Mg levels were found to have been in the range of 2.6-3.9 mmol/l, with the 
maximum level just prior to tumour devascularization. At the time of reversal, 
one hour later, the serum Mg level was 2.5 mmol/l.
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Case 5. A 24 year old white woman was transferred from a peripheral hospital 
because of uncontro llable blood pressure during pregnancy. She gave a 
history of having had an abdominal phaeochromocytoma removed in 1979 and 
three operations for recurrences in her neck in 1980, 1981 and 1983. She had 
had a normal vaginal delivery in 1982, and a miscarriage at 4 weeks in 1984. 
She had been well con tro lled  m ed ica lly  un til her pregnancy. She now 
com pla ined of headache, v isua l d is tu rbances and fee ling  flushed. On 
admission her arterial blood pressure was 170/110 mmHg and her heart rate 116 
beats per minute. Foetal maturity was estimated at 32 weeks and confirmed on 
u ltrasound exam ination. S ign ifican t laboratory find ings included a VMA 
excretion of 205 p.mol/24 hours and metadrenaline 42.5 n.mol/24 hours (normal 
<5.5p,mol/24 hours).
She was controlled on phenoxybenzamine 20mg 8 hourly and tenormin 50 mg 
daily. After an in itia l hypotensive episode this regime provided excellent 
control. Her progress was uneventful for the next 4 weeks, but it is of interest 
that her serum Mg level which was initia lly 0.83 mmol/l fell to 0.57 mmol/l during 
this period. On oral supplementation it improved but remained below normal 
at 0.71 mmol/l.
A fter 4 weeks of medical management, very poor foetal growth prompted 
concern. Adequate fetal m aturity was established and it was decided to 
proceed with delivery by elective caesarean section under general anaesthesia. 
Preoperatively, she was well controlled with an arterial blood pressure in the 
range 150/90 - 140/80 mmHg and no postural hypotension.
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Diazepam 10mg ora lly  was adm inistered the n ight p rio r to surgery, and 
repeated 30 minutes preoperatively, together with 10 mg metoclopramide and 
30 ml sodium citrate. Phenoxybenzamine and tenormin were given on the 
morning of surgery. On arrival in the operating room, her arteria l blood 
pressure pressure was 170/100 mmHg, and this increased during the insertion 
of arterial and central venous lines under local anesthesia to 200/120 mmHg. A 
bolus of 4 g of MgS04 was administered by slow intravenous injection, and this 
reduced the a rte ria l b lood pressure to  150/90 mmHg but produced an 
unpleasant burning sensation. Follow ing 3 m inutes of pre-oxygenation, 
anaesthesia was induced with thiopentone 4mg/Kg, and the trachea intubated 
under 100mg succinylcholine while cricoid pressure was applied. Intubation 
produced a mild increase in arterial blood pressure to 180/100 mmHg which 
responded well to a further bolus of 2 gm MgSC>4 and a continuous infusion of 
MgS04 was maintained at 2 gm/hour throughout the procedure. Anaesthesia 
was maintained with 50% oxygen in nitrous oxide with 0.75% enflurane, and 
relaxation with intermittent suxamethonium. Two further boluses of MgSC>4 
were given intraoperatively to control small increases in arterial blood pressure 
but at no time did the blood pressure exceed 170/90 mmHg after the initial 
response to  in tubation . A healthy female infant weighing 1540 gm was 
delivered. Following surgery, spontaneous ventilation was resumed readily; 
when fu lly  consc ious  she was extubated  and the MgS0 4  in fus ion  was 
d is c o n tin u e d . One hour la te r she re q u ire d  a co n tin u o u s  in fu s io n  of 
phenoxybenzamine in order to control her arterial blood pressure which had 
increased to 230/120 mmHg. The following day, she was restarted on oral
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therapy, and made a satisfactory recovery. Intraoperative Mg level was found 
to have been in the range 2.4 - 3.3 mmol/l.
Case 6. A 48 year old male was diagnosed as having a large phaeochromo- 
cytoma arising from the left adrenal gland. Good preoperative cardiovascular 
control was established with a daily dosage of 160mg phenoxybenzamine. On 
arrival in the operating theatre his blood pressure was 195mmHg which settled 
following 200p,g of fentanyl to 115 mmHg and remained stable at this level for 
the induction, intubation and initial surgery. At laparotomy the tumour was 
found to be locally invasive and extending along the renal vein and into the 
inferior vena cava. It was not therefore possible to gain control of the venous 
drainage from the tumour and during tumour manipulation MgSC>4 alone proved 
inadequate to control blood pressure. An infusion of sodium nitroprusside was 
requ ired  in a d d itio n  to  m agnesium  bo luses  and in fu s io n s  to  co n tro l 
hypertensive episodes. Once the tumour had been removed the patient’s 
condition stabilized and he made an uneventful recovery.
Case 7. This patient was a 22 year old white female who presented with 
unstable hypertension and was diagnosed as having a phaeochromocytoma 
a ris in g  from  the r igh t adrenal g land. Good p reope ra tive  co n tro l was 
established with prazosin 4mg b.d. and atenolol 100mg daily. She arrived in 
theatre well contro lled and anaesthesia was induced with fentanyl 100p,g,
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th iopentone 200mg and alcuronium 20mg follow ing pretreatment with 3gm 
MgS04. During surgery a continuous infusion of 2gm per hour Mg$ 0 4  was used 
w ith  tw o a d d itio n a l 2gm bo luses du ring  tum ou r m a n ipu la tion . Good 
cardiovascular control was maintained throughout and the patient made an 
uneventful recovery.
Case 8. A 26 year old white female presented with long-standing hypertension 
w h ich  was found  to  be a ttr ib u ta b le  to  a sm all r ig h t adrena l tum our. 
Preoperative ECG’s showed a left ventricu lar strain pattern w ith inverted 
T-waves and depressed ST segm ents. Good p reopera tive  con tro l was 
established with phenoxybenzamine 240mg per day and atenolol 50mg daily, 
and over the two week preoperative period the ECG changes resolved. The 
patient arrived in the operating theatre mildly hypertensive with a systolic blood 
pressure of 186mmHg but no tachycardia. An infusion of 4gm MgS04 resulted 
in stab iliza tion of the blood pressure at l30mmHg systolic. Induction of 
anaesthesia was performed using fentanyl 150p,g, th iopentone 300mg and 
alcuronium 15mg. A continuous infusion of MgS04 was used throughout the 
procedure at the rate of 2gm per hour and four additional 2gm boluses were 
adm in istered during tum our handling. Good card iovascular contro l was 
maintained throughout the procedure and neuromuscular blockade was readily 
reversed at the end of surgery (Figure 9.4).
Appendix B 256
Case 9. This patient was a 42 year old male with long-standing hypertension 
who had been diagnosed as having a left adrenal gland tumour. Preoperative 
preparation consisted of tenormin lOOmg b.d. and a small dose (40mg dally) of 
phenoxybenzamine. This patient did not meet the criteria for fitness for surgery 
at the time of operation. The decision to proceed with surgery had already been 
taken by the surgical team, but it was nevertheless decided to use MgS04 in 
th is  case in order to assist the cardiovascular contro l. On arrival In the 
operating theatre his systolic blood pressure was 205mmHg but this responded 
well to fentanyl 200jxg and a 4gm infusion of MgS04- Intraoperative blood 
pressure control with a continuous infusion of 2gm per hour MgS04 and three 
boluses of 2gm each was satisfactory but at the time of tumour removal there 
was a sudden haemorrhage of approximately 2 litres from a torn spleen. This 
was accom pan ied  by severe hypo tens ion  and b radyca rd ia  w hich was 
unresponsive to transfusion and vasopressor drugs. The patient required an 
ad rena line  in fu s io n  fo r 24 hours p o s to p e ra tive ly  to  susta in  adequate 
cardiovascular function. At the time of tumour excision the serum magnesium 
level was 2.8mmol/l and this had dropped to l.2m m ol/l 6 hours postoperatively. 
After 24 hours the adrenaline infusion was gradually weaned and the patient 
made a good recovery.
Case 10. Th is  p a tie n t was a 34 year o ld  b la ck  fem a le  w ith  a sm all 
phaeochromocytoma arising from the left adrenal gland. Good preoperative 
control was established on phenoxybenzamine alone and her intraoperative 
co u rse  was u n e v e n tfu l. She re ce ive d  a to ta l o f 11gm m agnesium
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intraoperatively and was well controlled throughout the procedure. There were 
no postoperative complications.
Case 11. A 32 year old black female presented with a small right adrenal tumour 
and was well controlled on prazosin 4mg b.d. and atenolol 50mg daily. Good 
Intraoperative control was maintained with magnesium infusions alone and she 
made an uneventful recovery. Catecholamine levels were measured in this 
patient prior to induction and following intubation and again during tumour 
handling. Following the initial catecholamine measurement, 4gm MgS04 were 
given followed by a thlopentone-fentanyl-alcuronium induction sequence. Both 
adrenaline and noradrenaline concentrations were markedly elevated prior to 
induction and fo llow ing intubation the levels of both hormones had been 
reduced although it is im possible to say that th is  reduction was due to 
magnesium as the other drugs used in the induction sequence may have 
contribu ted . During tum our handling both adrenaline and noradrenaline 
concentra tions increased to pre induction levels but good cardiovascular 
control was maintained despite this.
Case 12. T h is  p a tie n t was a 51 yea r o ld  fem a le  w ith  a la rge  
phaeochromocytoma arising from the left adrenal gland. Preoperative control 
was established with 4mg prazosin b.d. and 50mg atenolol daily. On arrival in 
the operating theatre this patient was markedly hypertensive (systolic blood
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pressure 240mmHg) but this responded well to the administration of 200p,g 
fentanyl and 4gm MgS04- Noradrenaline and adrenaline levels were markedly 
elevated at the tim e of a rriva l in the opera ting  theatre . Fo llow ing the 
administration of magnesium adrenaline levels fell to within the normal range 
and noradrenaline levels were reduced by 45%. Anaesthesia was induced with 
350mg thiopentone and muscle relaxation achieved with 20mg alcuronium. 
Further catecholamine estimations were performed at this point which showed 
a slight further reduction in both adrenaline and noradrenaline concentrations. 
Intubation of the trachea produced no cardiovascular disturbance and no 
increase in catecholamine levels. Extensive tumour handling was unavoidable 
in this case and this produced increases of both adrenaline and noradrenaline 
to above baseline values. An infusion of sodium nitroprusside was necessary 
in addition to a total dose of 16gm MgS04 in order to maintain adequate blood 
pressure control. Once the tumour had been removed the remaining procedure 
was uneventful and the patient made a good recovery (Figure 9.5).
Case 13. This patient, a 39 year old female, was diagnosed as having a large 
right-sided adrenal tumour. Good cardiovascular was attained with prazosin 
4mg b.d. and atenolol 100mg daily. On arrival in the operating theatre the 
patient’s blood pressure was well controlled and anaesthesia was induced with 
150p,g fentanyl, 300mg thiopentone and 15 mg alcuronium. catecholamine 
levels were estimated prior to induction and were found to be moderately
elevated with a marked increase in concentration of both adrenaline and
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noradrenaline following induction of anaesthesia. Four gm MgSC>4 were then 
administered and catecholamine levels again estimated. Both adrenaline and 
noradrenaline concentrations were decreased following the administration of 
magnesium and endotracheal intubation was accompanied by a continuing 
decline in the concentration of both catecholamines. Intraoperatively both 
noradrenaline and adrenaline levels were markedly elevated during periods of 
tum our handling and an infusion of n itroprusside was required to provide 
adequate cardiovascular control. Postoperative course was uneventful.
Case 14. This patient was a 28 year old female who had a small right-sided 
adrenal tumour. Symptoms were well controlled on prazosin and atenolol and 
she arrived in the operating theatre well controlled. Following a bolus of 4gm 
MgSC>4 preceded by 100|xg fentanyl, anaesthesia was induced with thiopentone 
250mg and alcuronium 15mg. Catecholamine levels were moderately elevated 
p r io r  to  the  a d m in is tra t io n  o f any d ru gs  and w ere reduced  by the 
m agne s iu m /fe n ta n y l tre a tm e n t. N e ithe r in d u c tio n  of anaesthes ia  nor 
e n d o tra c h e a l in tu b a tio n  p ro du ce d  any in c re a se  in ca te ch o la m in e  
concentrations and although both hormones increased in concentration during 
tumour handling good cardiovascular control was maintained throughout the 
procedure using a total of 14gm of MgS04. The patient made an uneventful
recovery.
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£a&fi_15.. A 55 year old female presented fo r a d iagnostic laparotomy to 
investigate an abdominal mass. The mass had been noted previously at 
hysterectomy 2 months previously, but although manipulation of the mass had 
produced severe intraoperative hypertension and cardiac dysrhythmias, the 
d iagnos is  of a phaeochrom ocytom a had not been made. P reoperative 
investigation had included a CT-scan of the abdomen which had shown a 
right-sided para-aortic mass. Induction of anaesthesia was performed using 
100|i,g fentanyl, 350mg thiopentone and 6mg pancuronium. Endotracheal 
intubation produced a mild increase in blood pressure followed by a drop in 
p re ssu re  a fte r  the  in tro d u c t io n  o f h a io th a n e  to  70m mHg s y s to lic .  
Commencement of surgery was accompanied by multifocal supraventricular 
and ventricular ectopic heart beats and a rapid rise in arterial blood pressure 
to  260 /140m m H g when the  tu m o u r was to u c h e d . A d ia g n o s is  of 
p h a e o ch ro m o cy to m a  was e n te rta in e d  and 4gm MgSCU adm in is te red  
intravenously. This produced a transient reduction in blood pressure and 
temporary control of the arrhythmias. Two further 4gm boluses of MgS04 and 
one of 2gm established cardiovascular contro l, at which tim e the serum 
magnesium level was 3.68mmol/l (Figure 9.9). The tumour was then removed 
and subsequently proven to be a phaeochromocytoma on histology. The 
patient made a good recovery.
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Case 16. This patient was a 14 year old black male who was diagnosed as 
having a large left-sided para-aortic phaeochromocytoma. Good preoperative 
control was established with 4mg prazosin b.d. and 50mg atenolol daily. On 
arrival in the operating theatre the patient was stable and after placement of 
m on ito ring  lines anaesthesia was induced w ith  150p.g fen tany l, 300mg 
th io p e n to n e  and 15mg a lcu ron ium . C atecho lam ine leve ls, p a rtic u la r ly  
noradrenaline, were markedly elevated prior to induction of anaesthesia and 
increased fu rthe r fo llow ing  the induction  sequence, accompanied by an 
increase in systolic blood pressure to 170 mmHg. An infusion of 4gm MgS04 
immediately reduced the arterial blood pressure to 100/60mmHg and produced 
a m arked d ro p  in n o ra d re n a lin e  c o n c e n tra t io n s  w ith  the  a d ren a lin e  
concentration being reduced to within normal values. Following intubation 
there was no increase in blood pressure and the levels of both catecholamines 
continued to decline. A continuous infusion of 2gm/hr MgS04 was maintained 
during the procedure and six 2gm boluses of MgS04 were administered during 
the course of the procedure. The tumour was adherent to the inferior vena cava 
and to  bow el bu t d e s p ite  c o n s id e ra b le  tu m o u r h a n d lin g  ve ry  l i t t le  
c a rd io v a s c u la r d is tu rb a n ce  o ccu rre d . This p rom pted  the e rroneous 
assumption that the tumour had been devascularized prior to its removal and 
magnesium was withdrawn. Within a few minutes the blood pressure rapidly 
rose to 200/1 lOmmHg but the administration of bolus doses of 3gm and 2gm 
MgSC>4 regained control within a few minutes. At the time of tumour excision 
serum magnesium levels were 3.8mmol/l. Neuromuscular blockade was readily 
reversed and the patient made an uneventful recovery (Figure 9.8).
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Appendix C
Glossary of Abbreviations
ABP Arterial blood pressure
AP Arterial pressure
ASA l-ll American Society of Anesthesiologists patient fitness criteria, 
indicates minimal intercurrent disease.
ATP Adenosine triphosphate
BP Blood pressure
Cl Cardiac index
CNS Central nervous system
CO Cardiac output
C 02 Carbon dioxide
CSF Cerebrospinal fluid
CT Computerised tomography
CVP Central venous pressure
DBP Diastolic blood pressure
DNA Deoxyribose nucleic acid
ECG Electrocardiograph
Mg Magnesium
MgS04 Magnesium sulphate
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MIBG Meta-iodobenzylguanethidine
PA Pulmonary artery
PCWP Pulmonary capillary wedge pressure
p g e 2 Prostaglandin E2
PGI2 Prostaglandin I2
PVR Pulmonary vascular resistance
RNA Ribose nucleic acid
QTc QT interval corrected for heart rate
SA node Sino-atrial node
SBP Systolic blood pressure
SEM Standard error of the mean
SeMg Serum magnesium
SPSS Statistical package for the Social Sciences
SV Stroke volume
SVI Stroke volume index
SVR Systemic vascular resistance
SW Stroke work
